id	sid	tid	token	lemma	pos
cord-354168-omen8vvq	1	1	key	key	NN
cord-354168-omen8vvq	1	2	:	:	:
cord-354168-omen8vvq	2	1	cord-354168-omen8vvq	cord-354168-omen8vvq	NNP
cord-354168-omen8vvq	2	2	authors	author	NNS
cord-354168-omen8vvq	2	3	:	:	:
cord-354168-omen8vvq	2	4	Al	Al	NNP
cord-354168-omen8vvq	2	5	Saleh	Saleh	NNP
cord-354168-omen8vvq	2	6	,	,	,
cord-354168-omen8vvq	2	7	Abdullah	Abdullah	NNP
cord-354168-omen8vvq	2	8	S.	S.	NNP
cord-354168-omen8vvq	2	9	;	;	:
cord-354168-omen8vvq	2	10	Sher	Sher	NNP
cord-354168-omen8vvq	2	11	,	,	,
cord-354168-omen8vvq	2	12	Taimur	Taimur	NNP
cord-354168-omen8vvq	2	13	;	;	:
cord-354168-omen8vvq	2	14	Gertz	Gertz	NNP
cord-354168-omen8vvq	2	15	,	,	,
cord-354168-omen8vvq	2	16	Morie	Morie	NNP
cord-354168-omen8vvq	2	17	A.	a.	NN
cord-354168-omen8vvq	2	18	title	title	NN
cord-354168-omen8vvq	2	19	:	:	:
cord-354168-omen8vvq	2	20	Multiple	multiple	JJ
cord-354168-omen8vvq	2	21	Myeloma	Myeloma	NNP
cord-354168-omen8vvq	2	22	in	in	IN
cord-354168-omen8vvq	2	23	the	the	DT
cord-354168-omen8vvq	2	24	Time	Time	NNP
cord-354168-omen8vvq	2	25	of	of	IN
cord-354168-omen8vvq	2	26	COVID-19	COVID-19	NNP
cord-354168-omen8vvq	2	27	date	date	NN
cord-354168-omen8vvq	2	28	:	:	:
cord-354168-omen8vvq	2	29	2020	2020	CD
cord-354168-omen8vvq	2	30	-	-	HYPH
cord-354168-omen8vvq	2	31	04	04	CD
cord-354168-omen8vvq	2	32	-	-	SYM
cord-354168-omen8vvq	2	33	17	17	CD
cord-354168-omen8vvq	2	34	journal	journal	NN
cord-354168-omen8vvq	2	35	:	:	:
cord-354168-omen8vvq	2	36	Acta	Acta	NNP
cord-354168-omen8vvq	2	37	Haematol	Haematol	NNP
cord-354168-omen8vvq	2	38	DOI	DOI	NNP
cord-354168-omen8vvq	2	39	:	:	:
cord-354168-omen8vvq	2	40	10.1159/000507690	10.1159/000507690	CD
cord-354168-omen8vvq	2	41	sha	sha	NNP
cord-354168-omen8vvq	2	42	:	:	:
cord-354168-omen8vvq	3	1	b868b97fd167fb8c771dc669e1a0de86d546209d	b868b97fd167fb8c771dc669e1a0de86d546209d	NNP
cord-354168-omen8vvq	3	2	doc_id	doc_id	NNP
cord-354168-omen8vvq	3	3	:	:	:
cord-354168-omen8vvq	3	4	354168	354168	CD
cord-354168-omen8vvq	3	5	cord_uid	cord_uid	NNS
cord-354168-omen8vvq	3	6	:	:	:
cord-354168-omen8vvq	4	1	omen8vvq	omen8vvq	NNP
cord-354168-omen8vvq	5	1	We	-PRON-	PRP
cord-354168-omen8vvq	5	2	provide	provide	VBP
cord-354168-omen8vvq	5	3	our	-PRON-	PRP$
cord-354168-omen8vvq	5	4	recommendations	recommendation	NNS
cord-354168-omen8vvq	5	5	(	(	-LRB-
cord-354168-omen8vvq	5	6	not	not	RB
cord-354168-omen8vvq	5	7	evidence	evidence	NN
cord-354168-omen8vvq	5	8	based	base	VBN
cord-354168-omen8vvq	5	9	)	)	-RRB-
cord-354168-omen8vvq	5	10	for	for	IN
cord-354168-omen8vvq	5	11	managing	manage	VBG
cord-354168-omen8vvq	5	12	multiple	multiple	JJ
cord-354168-omen8vvq	5	13	myeloma	myeloma	NN
cord-354168-omen8vvq	5	14	patients	patient	NNS
cord-354168-omen8vvq	5	15	during	during	IN
cord-354168-omen8vvq	5	16	the	the	DT
cord-354168-omen8vvq	5	17	pandemic	pandemic	NN
cord-354168-omen8vvq	5	18	of	of	IN
cord-354168-omen8vvq	5	19	COVID-19	COVID-19	NNP
cord-354168-omen8vvq	5	20	.	.	.
cord-354168-omen8vvq	6	1	We	-PRON-	PRP
cord-354168-omen8vvq	6	2	do	do	VBP
cord-354168-omen8vvq	6	3	not	not	RB
cord-354168-omen8vvq	6	4	recommend	recommend	VB
cord-354168-omen8vvq	6	5	therapy	therapy	NN
cord-354168-omen8vvq	6	6	for	for	IN
cord-354168-omen8vvq	6	7	smoldering	smolder	VBG
cord-354168-omen8vvq	6	8	myeloma	myeloma	NN
cord-354168-omen8vvq	6	9	patients	patient	NNS
cord-354168-omen8vvq	6	10	(	(	-LRB-
cord-354168-omen8vvq	6	11	standard	standard	JJ
cord-354168-omen8vvq	6	12	or	or	CC
cord-354168-omen8vvq	6	13	high	high	JJ
cord-354168-omen8vvq	6	14	risk	risk	NN
cord-354168-omen8vvq	6	15	)	)	-RRB-
cord-354168-omen8vvq	6	16	.	.	.
cord-354168-omen8vvq	7	1	Screening	screen	VBG
cord-354168-omen8vvq	7	2	for	for	IN
cord-354168-omen8vvq	7	3	COVID-19	COVID-19	NNP
cord-354168-omen8vvq	7	4	should	should	MD
cord-354168-omen8vvq	7	5	be	be	VB
cord-354168-omen8vvq	7	6	done	do	VBN
cord-354168-omen8vvq	7	7	in	in	IN
cord-354168-omen8vvq	7	8	all	all	DT
cord-354168-omen8vvq	7	9	patients	patient	NNS
cord-354168-omen8vvq	7	10	before	before	IN
cord-354168-omen8vvq	7	11	therapy	therapy	NN
cord-354168-omen8vvq	7	12	.	.	.
cord-354168-omen8vvq	8	1	For	for	IN
cord-354168-omen8vvq	8	2	standard	standard	JJ
cord-354168-omen8vvq	8	3	-	-	HYPH
cord-354168-omen8vvq	8	4	risk	risk	NN
cord-354168-omen8vvq	8	5	patients	patient	NNS
cord-354168-omen8vvq	8	6	,	,	,
cord-354168-omen8vvq	8	7	we	-PRON-	PRP
cord-354168-omen8vvq	8	8	recommend	recommend	VBP
cord-354168-omen8vvq	8	9	the	the	DT
cord-354168-omen8vvq	8	10	following	follow	VBG
cord-354168-omen8vvq	8	11	:	:	:
cord-354168-omen8vvq	8	12	ixazomib	ixazomib	NNP
cord-354168-omen8vvq	8	13	,	,	,
cord-354168-omen8vvq	8	14	lenalidomide	lenalidomide	NN
cord-354168-omen8vvq	8	15	,	,	,
cord-354168-omen8vvq	8	16	and	and	CC
cord-354168-omen8vvq	8	17	dexamethasone	dexamethasone	NN
cord-354168-omen8vvq	8	18	(	(	-LRB-
cord-354168-omen8vvq	8	19	IRd	IRd	NNP
cord-354168-omen8vvq	8	20	)	)	-RRB-
cord-354168-omen8vvq	8	21	(	(	-LRB-
cord-354168-omen8vvq	8	22	preferred	prefer	VBN
cord-354168-omen8vvq	8	23	)	)	-RRB-
cord-354168-omen8vvq	8	24	,	,	,
cord-354168-omen8vvq	8	25	cyclophosphamide	cyclophosphamide	IN
cord-354168-omen8vvq	8	26	lenalidomide	lenalidomide	NN
cord-354168-omen8vvq	8	27	and	and	CC
cord-354168-omen8vvq	8	28	dexamethasone	dexamethasone	NN
cord-354168-omen8vvq	8	29	(	(	-LRB-
cord-354168-omen8vvq	8	30	CRd	CRd	NNP
cord-354168-omen8vvq	8	31	)	)	-RRB-
cord-354168-omen8vvq	8	32	,	,	,
cord-354168-omen8vvq	8	33	daratumumab	daratumumab	VBD
cord-354168-omen8vvq	8	34	lenalidomide	lenalidomide	NN
cord-354168-omen8vvq	8	35	and	and	CC
cord-354168-omen8vvq	8	36	dexamethasone	dexamethasone	NN
cord-354168-omen8vvq	8	37	(	(	-LRB-
cord-354168-omen8vvq	8	38	DRd	DRd	NNS
cord-354168-omen8vvq	8	39	)	)	-RRB-
cord-354168-omen8vvq	8	40	,	,	,
cord-354168-omen8vvq	8	41	lenalidomide	lenalidomide	NN
cord-354168-omen8vvq	8	42	,	,	,
cord-354168-omen8vvq	8	43	bortezomib	bortezomib	NNP
cord-354168-omen8vvq	8	44	,	,	,
cord-354168-omen8vvq	8	45	and	and	CC
cord-354168-omen8vvq	8	46	dexamethasone	dexamethasone	NN
cord-354168-omen8vvq	8	47	(	(	-LRB-
cord-354168-omen8vvq	8	48	RVd	rvd	NN
cord-354168-omen8vvq	8	49	)	)	-RRB-
cord-354168-omen8vvq	8	50	,	,	,
cord-354168-omen8vvq	8	51	or	or	CC
cord-354168-omen8vvq	8	52	cyclophosphamide	cyclophosphamide	NN
cord-354168-omen8vvq	8	53	,	,	,
cord-354168-omen8vvq	8	54	bortezomib	bortezomib	NNP
cord-354168-omen8vvq	8	55	,	,	,
cord-354168-omen8vvq	8	56	and	and	CC
cord-354168-omen8vvq	8	57	dexamethasone	dexamethasone	NN
cord-354168-omen8vvq	8	58	(	(	-LRB-
cord-354168-omen8vvq	8	59	CyBorD	CyBorD	NNP
cord-354168-omen8vvq	8	60	)	)	-RRB-
cord-354168-omen8vvq	8	61	.	.	.
cord-354168-omen8vvq	9	1	For	for	IN
cord-354168-omen8vvq	9	2	high	high	JJ
cord-354168-omen8vvq	9	3	-	-	HYPH
cord-354168-omen8vvq	9	4	risk	risk	NN
cord-354168-omen8vvq	9	5	patients	patient	NNS
cord-354168-omen8vvq	9	6	we	-PRON-	PRP
cord-354168-omen8vvq	9	7	recommend	recommend	VBP
cord-354168-omen8vvq	9	8	carfilzomib	carfilzomib	NNP
cord-354168-omen8vvq	9	9	,	,	,
cord-354168-omen8vvq	9	10	lenalidomide	lenalidomide	NN
cord-354168-omen8vvq	9	11	,	,	,
cord-354168-omen8vvq	9	12	and	and	CC
cord-354168-omen8vvq	9	13	dexamethasone	dexamethasone	NN
cord-354168-omen8vvq	9	14	(	(	-LRB-
cord-354168-omen8vvq	9	15	KRd	KRd	NNS
cord-354168-omen8vvq	9	16	)	)	-RRB-
cord-354168-omen8vvq	9	17	(	(	-LRB-
cord-354168-omen8vvq	9	18	preferred	prefer	VBN
cord-354168-omen8vvq	9	19	)	)	-RRB-
cord-354168-omen8vvq	9	20	or	or	CC
cord-354168-omen8vvq	9	21	RVd	rvd	NN
cord-354168-omen8vvq	9	22	.	.	.
cord-354168-omen8vvq	10	1	Decreasing	decrease	VBG
cord-354168-omen8vvq	10	2	the	the	DT
cord-354168-omen8vvq	10	3	dose	dose	NN
cord-354168-omen8vvq	10	4	of	of	IN
cord-354168-omen8vvq	10	5	dexamethasone	dexamethasone	NN
cord-354168-omen8vvq	10	6	to	to	IN
cord-354168-omen8vvq	10	7	20	20	CD
cord-354168-omen8vvq	10	8	mg	mg	NN
cord-354168-omen8vvq	10	9	and	and	CC
cord-354168-omen8vvq	10	10	giving	give	VBG
cord-354168-omen8vvq	10	11	bortezomib	bortezomib	NNP
cord-354168-omen8vvq	10	12	subcutaneously	subcutaneously	RB
cord-354168-omen8vvq	10	13	once	once	RB
cord-354168-omen8vvq	10	14	a	a	DT
cord-354168-omen8vvq	10	15	week	week	NN
cord-354168-omen8vvq	10	16	is	be	VBZ
cord-354168-omen8vvq	10	17	recommended	recommend	VBN
cord-354168-omen8vvq	10	18	.	.	.
cord-354168-omen8vvq	11	1	We	-PRON-	PRP
cord-354168-omen8vvq	11	2	recommend	recommend	VBP
cord-354168-omen8vvq	11	3	delaying	delay	VBG
cord-354168-omen8vvq	11	4	autologous	autologous	JJ
cord-354168-omen8vvq	11	5	stem	stem	NN
cord-354168-omen8vvq	11	6	cell	cell	NN
cord-354168-omen8vvq	11	7	transplant	transplant	NN
cord-354168-omen8vvq	11	8	(	(	-LRB-
cord-354168-omen8vvq	11	9	ASCT	ASCT	NNP
cord-354168-omen8vvq	11	10	)	)	-RRB-
cord-354168-omen8vvq	11	11	,	,	,
cord-354168-omen8vvq	11	12	unless	unless	IN
cord-354168-omen8vvq	11	13	the	the	DT
cord-354168-omen8vvq	11	14	patient	patient	NN
cord-354168-omen8vvq	11	15	has	have	VBZ
cord-354168-omen8vvq	11	16	high	high	JJ
cord-354168-omen8vvq	11	17	-	-	HYPH
cord-354168-omen8vvq	11	18	risk	risk	NN
cord-354168-omen8vvq	11	19	disease	disease	NN
cord-354168-omen8vvq	11	20	that	that	WDT
cord-354168-omen8vvq	11	21	is	be	VBZ
cord-354168-omen8vvq	11	22	not	not	RB
cord-354168-omen8vvq	11	23	responding	respond	VBG
cord-354168-omen8vvq	11	24	well	well	RB
cord-354168-omen8vvq	11	25	,	,	,
cord-354168-omen8vvq	11	26	or	or	CC
cord-354168-omen8vvq	11	27	if	if	IN
cord-354168-omen8vvq	11	28	the	the	DT
cord-354168-omen8vvq	11	29	patient	patient	NN
cord-354168-omen8vvq	11	30	has	have	VBZ
cord-354168-omen8vvq	11	31	plasma	plasma	NN
cord-354168-omen8vvq	11	32	cell	cell	NN
cord-354168-omen8vvq	11	33	leukemia	leukemia	NN
cord-354168-omen8vvq	11	34	(	(	-LRB-
cord-354168-omen8vvq	11	35	PCL	PCL	NNP
cord-354168-omen8vvq	11	36	)	)	-RRB-
cord-354168-omen8vvq	11	37	.	.	.
cord-354168-omen8vvq	12	1	Testing	test	VBG
cord-354168-omen8vvq	12	2	for	for	IN
cord-354168-omen8vvq	12	3	COVID-19	COVID-19	NNP
cord-354168-omen8vvq	12	4	should	should	MD
cord-354168-omen8vvq	12	5	be	be	VB
cord-354168-omen8vvq	12	6	done	do	VBN
cord-354168-omen8vvq	12	7	before	before	IN
cord-354168-omen8vvq	12	8	ASCT	ASCT	NNP
cord-354168-omen8vvq	12	9	.	.	.
cord-354168-omen8vvq	13	1	If	if	IN
cord-354168-omen8vvq	13	2	a	a	DT
cord-354168-omen8vvq	13	3	patient	patient	NN
cord-354168-omen8vvq	13	4	achieves	achieve	VBZ
cord-354168-omen8vvq	13	5	a	a	DT
cord-354168-omen8vvq	13	6	very	very	RB
cord-354168-omen8vvq	13	7	good	good	JJ
cord-354168-omen8vvq	13	8	partial	partial	JJ
cord-354168-omen8vvq	13	9	response	response	NN
cord-354168-omen8vvq	13	10	or	or	CC
cord-354168-omen8vvq	13	11	better	well	JJR
cord-354168-omen8vvq	13	12	,	,	,
cord-354168-omen8vvq	13	13	doses	dose	NNS
cord-354168-omen8vvq	13	14	and	and	CC
cord-354168-omen8vvq	13	15	frequency	frequency	NN
cord-354168-omen8vvq	13	16	of	of	IN
cord-354168-omen8vvq	13	17	drug	drug	NN
cord-354168-omen8vvq	13	18	administration	administration	NN
cord-354168-omen8vvq	13	19	can	can	MD
cord-354168-omen8vvq	13	20	be	be	VB
cord-354168-omen8vvq	13	21	modified	modify	VBN
cord-354168-omen8vvq	13	22	.	.	.
cord-354168-omen8vvq	14	1	After	after	IN
cord-354168-omen8vvq	14	2	10–12	10–12	JJ
cord-354168-omen8vvq	14	3	cycles	cycle	NNS
cord-354168-omen8vvq	14	4	,	,	,
cord-354168-omen8vvq	14	5	lenalidomide	lenalidomide	JJ
cord-354168-omen8vvq	14	6	maintenance	maintenance	NN
cord-354168-omen8vvq	14	7	is	be	VBZ
cord-354168-omen8vvq	14	8	recommended	recommend	VBN
cord-354168-omen8vvq	14	9	for	for	IN
cord-354168-omen8vvq	14	10	standard	standard	JJ
cord-354168-omen8vvq	14	11	-	-	HYPH
cord-354168-omen8vvq	14	12	risk	risk	NN
cord-354168-omen8vvq	14	13	patients	patient	NNS
cord-354168-omen8vvq	14	14	and	and	CC
cord-354168-omen8vvq	14	15	bortezomib	bortezomib	NNP
cord-354168-omen8vvq	14	16	or	or	CC
cord-354168-omen8vvq	14	17	ixazomib	ixazomib	NNP
cord-354168-omen8vvq	14	18	are	be	VBP
cord-354168-omen8vvq	14	19	recommended	recommend	VBN
cord-354168-omen8vvq	14	20	for	for	IN
cord-354168-omen8vvq	14	21	high	high	JJ
cord-354168-omen8vvq	14	22	-	-	HYPH
cord-354168-omen8vvq	14	23	risk	risk	NN
cord-354168-omen8vvq	14	24	patients	patient	NNS
cord-354168-omen8vvq	14	25	.	.	.
cord-354168-omen8vvq	15	1	Daratumumab	Daratumumab	NNP
cord-354168-omen8vvq	15	2	-	-	HYPH
cord-354168-omen8vvq	15	3	based	base	VBN
cord-354168-omen8vvq	15	4	regimens	regimen	NNS
cord-354168-omen8vvq	15	5	are	be	VBP
cord-354168-omen8vvq	15	6	recommended	recommend	VBN
cord-354168-omen8vvq	15	7	for	for	IN
cord-354168-omen8vvq	15	8	relapsed	relapsed	JJ
cord-354168-omen8vvq	15	9	patients	patient	NNS
cord-354168-omen8vvq	15	10	.	.	.
cord-354168-omen8vvq	16	1	Routine	routine	JJ
cord-354168-omen8vvq	16	2	ASCT	ASCT	NNP
cord-354168-omen8vvq	16	3	is	be	VBZ
cord-354168-omen8vvq	16	4	not	not	RB
cord-354168-omen8vvq	16	5	recommended	recommend	VBN
cord-354168-omen8vvq	16	6	for	for	IN
cord-354168-omen8vvq	16	7	relapse	relapse	NN
cord-354168-omen8vvq	16	8	during	during	IN
cord-354168-omen8vvq	16	9	the	the	DT
cord-354168-omen8vvq	16	10	epidemic	epidemic	NN
cord-354168-omen8vvq	16	11	unless	unless	IN
cord-354168-omen8vvq	16	12	the	the	DT
cord-354168-omen8vvq	16	13	patient	patient	NN
cord-354168-omen8vvq	16	14	has	have	VBZ
cord-354168-omen8vvq	16	15	an	an	DT
cord-354168-omen8vvq	16	16	aggressive	aggressive	JJ
cord-354168-omen8vvq	16	17	relapse	relapse	NN
cord-354168-omen8vvq	16	18	or	or	CC
cord-354168-omen8vvq	16	19	secondary	secondary	JJ
cord-354168-omen8vvq	16	20	PCL	PCL	NNP
cord-354168-omen8vvq	16	21	.	.	.
cord-354168-omen8vvq	17	1	Patients	patient	NNS
cord-354168-omen8vvq	17	2	on	on	IN
cord-354168-omen8vvq	17	3	current	current	JJ
cord-354168-omen8vvq	17	4	maintenance	maintenance	NN
cord-354168-omen8vvq	17	5	should	should	MD
cord-354168-omen8vvq	17	6	continue	continue	VB
cord-354168-omen8vvq	17	7	their	-PRON-	PRP$
cord-354168-omen8vvq	17	8	therapy	therapy	NN
cord-354168-omen8vvq	17	9	.	.	.
cord-354168-omen8vvq	18	1	The	the	DT
cord-354168-omen8vvq	18	2	management	management	NN
cord-354168-omen8vvq	18	3	of	of	IN
cord-354168-omen8vvq	18	4	patients	patient	NNS
cord-354168-omen8vvq	18	5	with	with	IN
cord-354168-omen8vvq	18	6	cancer	cancer	NN
cord-354168-omen8vvq	18	7	during	during	IN
cord-354168-omen8vvq	18	8	the	the	DT
cord-354168-omen8vvq	18	9	current	current	JJ
cord-354168-omen8vvq	18	10	pandemic	pandemic	NN
cord-354168-omen8vvq	18	11	of	of	IN
cord-354168-omen8vvq	18	12	COVID-19	COVID-19	NNP
cord-354168-omen8vvq	18	13	is	be	VBZ
cord-354168-omen8vvq	18	14	challenging	challenging	JJ
cord-354168-omen8vvq	18	15	.	.	.
cord-354168-omen8vvq	19	1	As	as	IN
cord-354168-omen8vvq	19	2	of	of	IN
cord-354168-omen8vvq	19	3	March	March	NNP
cord-354168-omen8vvq	19	4	30	30	CD
cord-354168-omen8vvq	19	5	,	,	,
cord-354168-omen8vvq	19	6	2020	2020	CD
cord-354168-omen8vvq	19	7	,	,	,
cord-354168-omen8vvq	19	8	more	more	JJR
cord-354168-omen8vvq	19	9	than	than	IN
cord-354168-omen8vvq	19	10	690,000	690,000	CD
cord-354168-omen8vvq	19	11	confirmed	confirm	VBN
cord-354168-omen8vvq	19	12	cases	case	NNS
cord-354168-omen8vvq	19	13	and	and	CC
cord-354168-omen8vvq	19	14	more	more	JJR
cord-354168-omen8vvq	19	15	than	than	IN
cord-354168-omen8vvq	19	16	33,000	33,000	CD
cord-354168-omen8vvq	19	17	deaths	death	NNS
cord-354168-omen8vvq	19	18	have	have	VBP
cord-354168-omen8vvq	19	19	been	be	VBN
cord-354168-omen8vvq	19	20	documented	document	VBN
cord-354168-omen8vvq	19	21	worldwide	worldwide	RB
cord-354168-omen8vvq	19	22	[	[	-LRB-
cord-354168-omen8vvq	19	23	1	1	CD
cord-354168-omen8vvq	19	24	]	]	-RRB-
cord-354168-omen8vvq	19	25	.	.	.
cord-354168-omen8vvq	20	1	Cancer	cancer	NN
cord-354168-omen8vvq	20	2	patients	patient	NNS
cord-354168-omen8vvq	20	3	require	require	VBP
cord-354168-omen8vvq	20	4	special	special	JJ
cord-354168-omen8vvq	20	5	attention	attention	NN
cord-354168-omen8vvq	20	6	,	,	,
cord-354168-omen8vvq	20	7	as	as	IN
cord-354168-omen8vvq	20	8	decisions	decision	NNS
cord-354168-omen8vvq	20	9	regarding	regard	VBG
cord-354168-omen8vvq	20	10	treatment	treatment	NN
cord-354168-omen8vvq	20	11	during	during	IN
cord-354168-omen8vvq	20	12	the	the	DT
cord-354168-omen8vvq	20	13	current	current	JJ
cord-354168-omen8vvq	20	14	pandemic	pandemic	NN
cord-354168-omen8vvq	20	15	require	require	VB
cord-354168-omen8vvq	20	16	specialized	specialized	JJ
cord-354168-omen8vvq	20	17	consideration	consideration	NN
cord-354168-omen8vvq	20	18	.	.	.
cord-354168-omen8vvq	21	1	The	the	DT
cord-354168-omen8vvq	21	2	quality	quality	NN
cord-354168-omen8vvq	21	3	of	of	IN
cord-354168-omen8vvq	21	4	care	care	NN
cord-354168-omen8vvq	21	5	for	for	IN
cord-354168-omen8vvq	21	6	cancer	cancer	NN
cord-354168-omen8vvq	21	7	patients	patient	NNS
cord-354168-omen8vvq	21	8	has	have	VBZ
cord-354168-omen8vvq	21	9	been	be	VBN
cord-354168-omen8vvq	21	10	affected	affect	VBN
cord-354168-omen8vvq	21	11	during	during	IN
cord-354168-omen8vvq	21	12	this	this	DT
cord-354168-omen8vvq	21	13	pandemic	pandemic	NN
cord-354168-omen8vvq	21	14	[	[	-LRB-
cord-354168-omen8vvq	21	15	2	2	CD
cord-354168-omen8vvq	21	16	]	]	-RRB-
cord-354168-omen8vvq	21	17	[	[	-LRB-
cord-354168-omen8vvq	21	18	3	3	CD
cord-354168-omen8vvq	21	19	]	]	-RRB-
cord-354168-omen8vvq	21	20	[	[	-LRB-
cord-354168-omen8vvq	21	21	4	4	CD
cord-354168-omen8vvq	21	22	]	]	-RRB-
cord-354168-omen8vvq	22	1	[	[	-LRB-
cord-354168-omen8vvq	22	2	5	5	CD
cord-354168-omen8vvq	22	3	]	]	-RRB-
cord-354168-omen8vvq	22	4	and	and	CC
cord-354168-omen8vvq	22	5	strategies	strategy	NNS
cord-354168-omen8vvq	22	6	are	be	VBP
cord-354168-omen8vvq	22	7	required	require	VBN
cord-354168-omen8vvq	22	8	to	to	TO
cord-354168-omen8vvq	22	9	deliver	deliver	VB
cord-354168-omen8vvq	22	10	the	the	DT
cord-354168-omen8vvq	22	11	best	good	JJS
cord-354168-omen8vvq	22	12	care	care	NN
cord-354168-omen8vvq	22	13	.	.	.
cord-354168-omen8vvq	23	1	From	from	IN
cord-354168-omen8vvq	23	2	a	a	DT
cord-354168-omen8vvq	23	3	nationwide	nationwide	JJ
cord-354168-omen8vvq	23	4	analysis	analysis	NN
cord-354168-omen8vvq	23	5	in	in	IN
cord-354168-omen8vvq	23	6	China	China	NNP
cord-354168-omen8vvq	23	7	,	,	,
cord-354168-omen8vvq	23	8	18	18	CD
cord-354168-omen8vvq	23	9	(	(	-LRB-
cord-354168-omen8vvq	23	10	1	1	CD
cord-354168-omen8vvq	23	11	%	%	NN
cord-354168-omen8vvq	23	12	)	)	-RRB-
cord-354168-omen8vvq	23	13	out	out	IN
cord-354168-omen8vvq	23	14	of	of	IN
cord-354168-omen8vvq	23	15	1,590	1,590	CD
cord-354168-omen8vvq	23	16	COVID-19	covid-19	CD
cord-354168-omen8vvq	23	17	cases	case	NNS
cord-354168-omen8vvq	23	18	had	have	VBD
cord-354168-omen8vvq	23	19	a	a	DT
cord-354168-omen8vvq	23	20	history	history	NN
cord-354168-omen8vvq	23	21	of	of	IN
cord-354168-omen8vvq	23	22	cancer	cancer	NN
cord-354168-omen8vvq	23	23	[	[	-LRB-
cord-354168-omen8vvq	23	24	6	6	CD
cord-354168-omen8vvq	23	25	]	]	-RRB-
cord-354168-omen8vvq	23	26	.	.	.
cord-354168-omen8vvq	24	1	Patients	patient	NNS
cord-354168-omen8vvq	24	2	with	with	IN
cord-354168-omen8vvq	24	3	cancer	cancer	NN
cord-354168-omen8vvq	24	4	were	be	VBD
cord-354168-omen8vvq	24	5	more	more	RBR
cord-354168-omen8vvq	24	6	likely	likely	JJ
cord-354168-omen8vvq	24	7	to	to	TO
cord-354168-omen8vvq	24	8	be	be	VB
cord-354168-omen8vvq	24	9	older	old	JJR
cord-354168-omen8vvq	24	10	and	and	CC
cord-354168-omen8vvq	24	11	had	have	VBD
cord-354168-omen8vvq	24	12	more	more	RBR
cord-354168-omen8vvq	24	13	frequently	frequently	RB
cord-354168-omen8vvq	24	14	abnormal	abnormal	JJ
cord-354168-omen8vvq	24	15	computed	compute	VBN
cord-354168-omen8vvq	24	16	tomography	tomography	NN
cord-354168-omen8vvq	24	17	(	(	-LRB-
cord-354168-omen8vvq	24	18	CT	CT	NNP
cord-354168-omen8vvq	24	19	)	)	-RRB-
cord-354168-omen8vvq	24	20	scans	scan	NNS
cord-354168-omen8vvq	24	21	.	.	.
cord-354168-omen8vvq	25	1	More	more	RBR
cord-354168-omen8vvq	25	2	significantly	significantly	RB
cord-354168-omen8vvq	25	3	,	,	,
cord-354168-omen8vvq	25	4	patients	patient	NNS
cord-354168-omen8vvq	25	5	with	with	IN
cord-354168-omen8vvq	25	6	cancer	cancer	NN
cord-354168-omen8vvq	25	7	infected	infect	VBN
cord-354168-omen8vvq	25	8	with	with	IN
cord-354168-omen8vvq	25	9	coronavirus	coronavirus	NN
cord-354168-omen8vvq	25	10	were	be	VBD
cord-354168-omen8vvq	25	11	more	more	RBR
cord-354168-omen8vvq	25	12	likely	likely	JJ
cord-354168-omen8vvq	25	13	to	to	TO
cord-354168-omen8vvq	25	14	have	have	VB
cord-354168-omen8vvq	25	15	an	an	DT
cord-354168-omen8vvq	25	16	adverse	adverse	JJ
cord-354168-omen8vvq	25	17	event	event	NN
cord-354168-omen8vvq	25	18	defined	define	VBN
cord-354168-omen8vvq	25	19	as	as	IN
cord-354168-omen8vvq	25	20	admission	admission	NN
cord-354168-omen8vvq	25	21	to	to	IN
cord-354168-omen8vvq	25	22	the	the	DT
cord-354168-omen8vvq	25	23	intensive	intensive	JJ
cord-354168-omen8vvq	25	24	care	care	NN
cord-354168-omen8vvq	25	25	unit	unit	NN
cord-354168-omen8vvq	25	26	requiring	require	VBG
cord-354168-omen8vvq	25	27	ventilation	ventilation	NN
cord-354168-omen8vvq	25	28	or	or	CC
cord-354168-omen8vvq	25	29	death	death	NN
cord-354168-omen8vvq	25	30	(	(	-LRB-
cord-354168-omen8vvq	25	31	39	39	CD
cord-354168-omen8vvq	25	32	vs.	vs.	CC
cord-354168-omen8vvq	25	33	8	8	CD
cord-354168-omen8vvq	25	34	%	%	NN
cord-354168-omen8vvq	25	35	,	,	,
cord-354168-omen8vvq	25	36	p	p	NN
cord-354168-omen8vvq	25	37	=	=	SYM
cord-354168-omen8vvq	25	38	0.0003	0.0003	CD
cord-354168-omen8vvq	25	39	)	)	-RRB-
cord-354168-omen8vvq	25	40	.	.	.
cord-354168-omen8vvq	26	1	Cancer	cancer	NN
cord-354168-omen8vvq	26	2	patients	patient	NNS
cord-354168-omen8vvq	26	3	also	also	RB
cord-354168-omen8vvq	26	4	had	have	VBD
cord-354168-omen8vvq	26	5	a	a	DT
cord-354168-omen8vvq	26	6	shorter	short	JJR
cord-354168-omen8vvq	26	7	median	median	JJ
cord-354168-omen8vvq	26	8	time	time	NN
cord-354168-omen8vvq	26	9	to	to	IN
cord-354168-omen8vvq	26	10	severe	severe	JJ
cord-354168-omen8vvq	26	11	events	event	NNS
cord-354168-omen8vvq	26	12	(	(	-LRB-
cord-354168-omen8vvq	26	13	13	13	CD
cord-354168-omen8vvq	26	14	vs	vs	IN
cord-354168-omen8vvq	26	15	.	.	.
cord-354168-omen8vvq	27	1	43	43	CD
cord-354168-omen8vvq	27	2	days	day	NNS
cord-354168-omen8vvq	27	3	,	,	,
cord-354168-omen8vvq	27	4	p	p	NN
cord-354168-omen8vvq	27	5	<	<	XX
cord-354168-omen8vvq	27	6	0.0001	0.0001	CD
cord-354168-omen8vvq	27	7	)	)	-RRB-
cord-354168-omen8vvq	27	8	.	.	.
cord-354168-omen8vvq	28	1	Cancer	cancer	NN
cord-354168-omen8vvq	28	2	,	,	,
cord-354168-omen8vvq	28	3	as	as	IN
cord-354168-omen8vvq	28	4	a	a	DT
cord-354168-omen8vvq	28	5	variable	variable	NN
cord-354168-omen8vvq	28	6	,	,	,
cord-354168-omen8vvq	28	7	had	have	VBD
cord-354168-omen8vvq	28	8	the	the	DT
cord-354168-omen8vvq	28	9	highest	high	JJS
cord-354168-omen8vvq	28	10	odds	odd	NNS
cord-354168-omen8vvq	28	11	ratio	ratio	NN
cord-354168-omen8vvq	28	12	[	[	-LRB-
cord-354168-omen8vvq	28	13	5	5	CD
cord-354168-omen8vvq	28	14	,	,	,
cord-354168-omen8vvq	28	15	3	3	CD
cord-354168-omen8vvq	28	16	]	]	-RRB-
cord-354168-omen8vvq	28	17	for	for	IN
cord-354168-omen8vvq	28	18	having	have	VBG
cord-354168-omen8vvq	28	19	adverse	adverse	JJ
cord-354168-omen8vvq	28	20	events	event	NNS
cord-354168-omen8vvq	28	21	.	.	.
cord-354168-omen8vvq	29	1	Despite	despite	IN
cord-354168-omen8vvq	29	2	the	the	DT
cord-354168-omen8vvq	29	3	limitation	limitation	NN
cord-354168-omen8vvq	29	4	of	of	IN
cord-354168-omen8vvq	29	5	a	a	DT
cord-354168-omen8vvq	29	6	small	small	JJ
cord-354168-omen8vvq	29	7	sample	sample	NN
cord-354168-omen8vvq	29	8	size	size	NN
cord-354168-omen8vvq	29	9	and	and	CC
cord-354168-omen8vvq	29	10	the	the	DT
cord-354168-omen8vvq	29	11	heterogeneity	heterogeneity	NN
cord-354168-omen8vvq	29	12	of	of	IN
cord-354168-omen8vvq	29	13	cancer	cancer	NN
cord-354168-omen8vvq	29	14	patients	patient	NNS
cord-354168-omen8vvq	29	15	,	,	,
cord-354168-omen8vvq	29	16	these	these	DT
cord-354168-omen8vvq	29	17	results	result	NNS
cord-354168-omen8vvq	29	18	are	be	VBP
cord-354168-omen8vvq	29	19	concerning	concern	VBG
cord-354168-omen8vvq	29	20	.	.	.
cord-354168-omen8vvq	30	1	Cancers	cancer	NNS
cord-354168-omen8vvq	30	2	differ	differ	VBP
cord-354168-omen8vvq	30	3	in	in	IN
cord-354168-omen8vvq	30	4	their	-PRON-	PRP$
cord-354168-omen8vvq	30	5	pathogenesis	pathogenesis	NN
cord-354168-omen8vvq	30	6	and	and	CC
cord-354168-omen8vvq	30	7	the	the	DT
cord-354168-omen8vvq	30	8	urgency	urgency	NN
cord-354168-omen8vvq	30	9	of	of	IN
cord-354168-omen8vvq	30	10	starting	start	VBG
cord-354168-omen8vvq	30	11	treatment	treatment	NN
cord-354168-omen8vvq	30	12	is	be	VBZ
cord-354168-omen8vvq	30	13	not	not	RB
cord-354168-omen8vvq	30	14	the	the	DT
cord-354168-omen8vvq	30	15	same	same	JJ
cord-354168-omen8vvq	30	16	for	for	IN
cord-354168-omen8vvq	30	17	all	all	DT
cord-354168-omen8vvq	30	18	cancers	cancer	NNS
cord-354168-omen8vvq	30	19	.	.	.
cord-354168-omen8vvq	31	1	We	-PRON-	PRP
cord-354168-omen8vvq	31	2	report	report	VBP
cord-354168-omen8vvq	31	3	our	-PRON-	PRP$
cord-354168-omen8vvq	31	4	personal	personal	JJ
cord-354168-omen8vvq	31	5	opinions	opinion	NNS
cord-354168-omen8vvq	31	6	regarding	regard	VBG
cord-354168-omen8vvq	31	7	the	the	DT
cord-354168-omen8vvq	31	8	management	management	NN
cord-354168-omen8vvq	31	9	of	of	IN
cord-354168-omen8vvq	31	10	patients	patient	NNS
cord-354168-omen8vvq	31	11	with	with	IN
cord-354168-omen8vvq	31	12	multiple	multiple	JJ
cord-354168-omen8vvq	31	13	myeloma	myeloma	NN
cord-354168-omen8vvq	31	14	(	(	-LRB-
cord-354168-omen8vvq	31	15	MM	MM	NNP
cord-354168-omen8vvq	31	16	)	)	-RRB-
cord-354168-omen8vvq	31	17	during	during	IN
cord-354168-omen8vvq	31	18	this	this	DT
cord-354168-omen8vvq	31	19	challenging	challenging	JJ
cord-354168-omen8vvq	31	20	time	time	NN
cord-354168-omen8vvq	31	21	.	.	.
cord-354168-omen8vvq	32	1	The	the	DT
cord-354168-omen8vvq	32	2	reader	reader	NN
cord-354168-omen8vvq	32	3	is	be	VBZ
cord-354168-omen8vvq	32	4	advised	advise	VBN
cord-354168-omen8vvq	32	5	that	that	IN
cord-354168-omen8vvq	32	6	these	these	DT
cord-354168-omen8vvq	32	7	recommendations	recommendation	NNS
cord-354168-omen8vvq	32	8	are	be	VBP
cord-354168-omen8vvq	32	9	based	base	VBN
cord-354168-omen8vvq	32	10	on	on	IN
cord-354168-omen8vvq	32	11	experience	experience	NN
cord-354168-omen8vvq	32	12	and	and	CC
cord-354168-omen8vvq	32	13	are	be	VBP
cord-354168-omen8vvq	32	14	not	not	RB
cord-354168-omen8vvq	32	15	evidence	evidence	NN
cord-354168-omen8vvq	32	16	based	base	VBN
cord-354168-omen8vvq	32	17	.	.	.
cord-354168-omen8vvq	33	1	What	what	WP
cord-354168-omen8vvq	33	2	Is	be	VBZ
cord-354168-omen8vvq	33	3	Special	special	JJ
cord-354168-omen8vvq	33	4	about	about	IN
cord-354168-omen8vvq	33	5	MM	MM	NNP
cord-354168-omen8vvq	33	6	Patients	patient	NNS
cord-354168-omen8vvq	33	7	?	?	.
cord-354168-omen8vvq	34	1	The	the	DT
cord-354168-omen8vvq	34	2	immune	immune	JJ
cord-354168-omen8vvq	34	3	system	system	NN
cord-354168-omen8vvq	34	4	in	in	IN
cord-354168-omen8vvq	34	5	patients	patient	NNS
cord-354168-omen8vvq	34	6	with	with	IN
cord-354168-omen8vvq	34	7	MM	MM	NNP
cord-354168-omen8vvq	34	8	is	be	VBZ
cord-354168-omen8vvq	34	9	compromised	compromise	VBN
cord-354168-omen8vvq	34	10	by	by	IN
cord-354168-omen8vvq	34	11	many	many	JJ
cord-354168-omen8vvq	34	12	different	different	JJ
cord-354168-omen8vvq	34	13	factors	factor	NNS
cord-354168-omen8vvq	34	14	and	and	CC
cord-354168-omen8vvq	34	15	patients	patient	NNS
cord-354168-omen8vvq	34	16	with	with	IN
cord-354168-omen8vvq	34	17	MM	MM	NNP
cord-354168-omen8vvq	34	18	are	be	VBP
cord-354168-omen8vvq	34	19	at	at	IN
cord-354168-omen8vvq	34	20	increased	increase	VBN
cord-354168-omen8vvq	34	21	risk	risk	NN
cord-354168-omen8vvq	34	22	of	of	IN
cord-354168-omen8vvq	34	23	infection	infection	NN
cord-354168-omen8vvq	34	24	[	[	-LRB-
cord-354168-omen8vvq	34	25	7	7	CD
cord-354168-omen8vvq	34	26	]	]	-RRB-
cord-354168-omen8vvq	34	27	.	.	.
cord-354168-omen8vvq	35	1	The	the	DT
cord-354168-omen8vvq	35	2	mean	mean	JJ
cord-354168-omen8vvq	35	3	age	age	NN
cord-354168-omen8vvq	35	4	at	at	IN
cord-354168-omen8vvq	35	5	diagnosis	diagnosis	NN
cord-354168-omen8vvq	35	6	for	for	IN
cord-354168-omen8vvq	35	7	myeloma	myeloma	NN
cord-354168-omen8vvq	35	8	is	be	VBZ
cord-354168-omen8vvq	35	9	approximately	approximately	RB
cord-354168-omen8vvq	35	10	65	65	CD
cord-354168-omen8vvq	35	11	and	and	CC
cord-354168-omen8vvq	35	12	elderly	elderly	JJ
cord-354168-omen8vvq	35	13	patients	patient	NNS
cord-354168-omen8vvq	35	14	are	be	VBP
cord-354168-omen8vvq	35	15	more	more	RBR
cord-354168-omen8vvq	35	16	likely	likely	JJ
cord-354168-omen8vvq	35	17	to	to	TO
cord-354168-omen8vvq	35	18	have	have	VB
cord-354168-omen8vvq	35	19	comorbidities	comorbiditie	NNS
cord-354168-omen8vvq	35	20	compromising	compromise	VBG
cord-354168-omen8vvq	35	21	the	the	DT
cord-354168-omen8vvq	35	22	immune	immune	JJ
cord-354168-omen8vvq	35	23	system	system	NN
cord-354168-omen8vvq	35	24	.	.	.
cord-354168-omen8vvq	36	1	Lymphopenia	Lymphopenia	NNP
cord-354168-omen8vvq	36	2	at	at	IN
cord-354168-omen8vvq	36	3	diagnosis	diagnosis	NN
cord-354168-omen8vvq	36	4	is	be	VBZ
cord-354168-omen8vvq	36	5	a	a	DT
cord-354168-omen8vvq	36	6	well	well	RB
cord-354168-omen8vvq	36	7	-	-	HYPH
cord-354168-omen8vvq	36	8	known	know	VBN
cord-354168-omen8vvq	36	9	risk	risk	NN
cord-354168-omen8vvq	36	10	factor	factor	NN
cord-354168-omen8vvq	36	11	for	for	IN
cord-354168-omen8vvq	36	12	developing	develop	VBG
cord-354168-omen8vvq	36	13	infections	infection	NNS
cord-354168-omen8vvq	36	14	[	[	-LRB-
cord-354168-omen8vvq	36	15	8	8	CD
cord-354168-omen8vvq	36	16	]	]	-RRB-
cord-354168-omen8vvq	36	17	[	[	-LRB-
cord-354168-omen8vvq	36	18	9	9	CD
cord-354168-omen8vvq	36	19	]	]	-RRB-
cord-354168-omen8vvq	36	20	[	[	-LRB-
cord-354168-omen8vvq	36	21	10	10	CD
cord-354168-omen8vvq	36	22	]	]	-RRB-
cord-354168-omen8vvq	36	23	.	.	.
cord-354168-omen8vvq	37	1	This	this	DT
cord-354168-omen8vvq	37	2	is	be	VBZ
cord-354168-omen8vvq	37	3	a	a	DT
cord-354168-omen8vvq	37	4	result	result	NN
cord-354168-omen8vvq	37	5	of	of	IN
cord-354168-omen8vvq	37	6	the	the	DT
cord-354168-omen8vvq	37	7	myeloma	myeloma	NN
cord-354168-omen8vvq	37	8	clone	clone	NN
cord-354168-omen8vvq	37	9	suppressing	suppress	VBG
cord-354168-omen8vvq	37	10	normal	normal	JJ
cord-354168-omen8vvq	37	11	B	b	NN
cord-354168-omen8vvq	37	12	-	-	HYPH
cord-354168-omen8vvq	37	13	cell	cell	NN
cord-354168-omen8vvq	37	14	development	development	NN
cord-354168-omen8vvq	37	15	and	and	CC
cord-354168-omen8vvq	37	16	function	function	NN
cord-354168-omen8vvq	37	17	.	.	.
cord-354168-omen8vvq	38	1	A	a	DT
cord-354168-omen8vvq	38	2	loss	loss	NN
cord-354168-omen8vvq	38	3	of	of	IN
cord-354168-omen8vvq	38	4	functional	functional	JJ
cord-354168-omen8vvq	38	5	immunoglobulins	immunoglobulin	NNS
cord-354168-omen8vvq	38	6	seen	see	VBN
cord-354168-omen8vvq	38	7	in	in	IN
cord-354168-omen8vvq	38	8	most	most	JJS
cord-354168-omen8vvq	38	9	myeloma	myeloma	NN
cord-354168-omen8vvq	38	10	patients	patient	NNS
cord-354168-omen8vvq	38	11	can	can	MD
cord-354168-omen8vvq	38	12	also	also	RB
cord-354168-omen8vvq	38	13	contribute	contribute	VB
cord-354168-omen8vvq	38	14	to	to	IN
cord-354168-omen8vvq	38	15	the	the	DT
cord-354168-omen8vvq	38	16	increased	increase	VBN
cord-354168-omen8vvq	38	17	risk	risk	NN
cord-354168-omen8vvq	38	18	of	of	IN
cord-354168-omen8vvq	38	19	infection	infection	NN
cord-354168-omen8vvq	38	20	.	.	.
cord-354168-omen8vvq	39	1	Decreased	decrease	VBN
cord-354168-omen8vvq	40	1	CD+4	CD+4	NNP
cord-354168-omen8vvq	40	2	T	t	NN
cord-354168-omen8vvq	40	3	-	-	HYPH
cord-354168-omen8vvq	40	4	cell	cell	NN
cord-354168-omen8vvq	40	5	count	count	NN
cord-354168-omen8vvq	40	6	at	at	IN
cord-354168-omen8vvq	40	7	diagnosis	diagnosis	NN
cord-354168-omen8vvq	40	8	is	be	VBZ
cord-354168-omen8vvq	40	9	also	also	RB
cord-354168-omen8vvq	40	10	associated	associate	VBN
cord-354168-omen8vvq	40	11	with	with	IN
cord-354168-omen8vvq	40	12	increased	increase	VBN
cord-354168-omen8vvq	40	13	infections	infection	NNS
cord-354168-omen8vvq	40	14	[	[	-LRB-
cord-354168-omen8vvq	40	15	11	11	CD
cord-354168-omen8vvq	40	16	,	,	,
cord-354168-omen8vvq	40	17	12	12	CD
cord-354168-omen8vvq	40	18	]	]	-RRB-
cord-354168-omen8vvq	40	19	.	.	.
cord-354168-omen8vvq	41	1	Patients	patient	NNS
cord-354168-omen8vvq	41	2	with	with	IN
cord-354168-omen8vvq	41	3	MM	MM	NNP
cord-354168-omen8vvq	41	4	receive	receive	VBP
cord-354168-omen8vvq	41	5	treatment	treatment	NN
cord-354168-omen8vvq	41	6	that	that	WDT
cord-354168-omen8vvq	41	7	causes	cause	VBZ
cord-354168-omen8vvq	41	8	more	more	JJR
cord-354168-omen8vvq	41	9	immunosuppression	immunosuppression	NN
cord-354168-omen8vvq	41	10	and	and	CC
cord-354168-omen8vvq	41	11	increases	increase	VBZ
cord-354168-omen8vvq	41	12	the	the	DT
cord-354168-omen8vvq	41	13	risk	risk	NN
cord-354168-omen8vvq	41	14	of	of	IN
cord-354168-omen8vvq	41	15	infection	infection	NN
cord-354168-omen8vvq	41	16	[	[	-LRB-
cord-354168-omen8vvq	41	17	13	13	CD
cord-354168-omen8vvq	41	18	]	]	-RRB-
cord-354168-omen8vvq	41	19	.	.	.
cord-354168-omen8vvq	42	1	Lymphopenia	Lymphopenia	NNP
cord-354168-omen8vvq	42	2	worsens	worsen	VBZ
cord-354168-omen8vvq	42	3	after	after	IN
cord-354168-omen8vvq	42	4	starting	start	VBG
cord-354168-omen8vvq	42	5	therapy	therapy	NN
cord-354168-omen8vvq	42	6	for	for	IN
cord-354168-omen8vvq	42	7	MM	MM	NNP
cord-354168-omen8vvq	42	8	[	[	-LRB-
cord-354168-omen8vvq	42	9	10	10	CD
cord-354168-omen8vvq	42	10	]	]	-RRB-
cord-354168-omen8vvq	42	11	and	and	CC
cord-354168-omen8vvq	42	12	CD4	CD4	NNP
cord-354168-omen8vvq	42	13	counts	count	VBZ
cord-354168-omen8vvq	42	14	decrease	decrease	NN
cord-354168-omen8vvq	42	15	with	with	IN
cord-354168-omen8vvq	42	16	proteasome	proteasome	VBN
cord-354168-omen8vvq	42	17	inhibitor	inhibitor	NN
cord-354168-omen8vvq	42	18	(	(	-LRB-
cord-354168-omen8vvq	42	19	PI	pi	NN
cord-354168-omen8vvq	42	20	)	)	-RRB-
cord-354168-omen8vvq	42	21	therapy	therapy	NN
cord-354168-omen8vvq	42	22	[	[	-LRB-
cord-354168-omen8vvq	42	23	14	14	CD
cord-354168-omen8vvq	42	24	]	]	-RRB-
cord-354168-omen8vvq	42	25	,	,	,
cord-354168-omen8vvq	42	26	and	and	CC
cord-354168-omen8vvq	42	27	the	the	DT
cord-354168-omen8vvq	42	28	risk	risk	NN
cord-354168-omen8vvq	42	29	of	of	IN
cord-354168-omen8vvq	42	30	zoster	zoster	NN
cord-354168-omen8vvq	42	31	reactivation	reactivation	NN
cord-354168-omen8vvq	42	32	is	be	VBZ
cord-354168-omen8vvq	42	33	up	up	IN
cord-354168-omen8vvq	42	34	to	to	TO
cord-354168-omen8vvq	42	35	13	13	CD
cord-354168-omen8vvq	42	36	%	%	NN
cord-354168-omen8vvq	42	37	without	without	IN
cord-354168-omen8vvq	42	38	prophylaxis	prophylaxis	NN
cord-354168-omen8vvq	42	39	[	[	-LRB-
cord-354168-omen8vvq	42	40	15	15	CD
cord-354168-omen8vvq	42	41	]	]	-RRB-
cord-354168-omen8vvq	42	42	.	.	.
cord-354168-omen8vvq	43	1	Immunomodulatory	immunomodulatory	JJ
cord-354168-omen8vvq	43	2	drugs	drug	NNS
cord-354168-omen8vvq	44	1	(	(	-LRB-
cord-354168-omen8vvq	44	2	IMiDs	imids	NN
cord-354168-omen8vvq	44	3	)	)	-RRB-
cord-354168-omen8vvq	44	4	cause	cause	NN
cord-354168-omen8vvq	44	5	neutropenia	neutropenia	NN
cord-354168-omen8vvq	44	6	,	,	,
cord-354168-omen8vvq	44	7	which	which	WDT
cord-354168-omen8vvq	44	8	increases	increase	VBZ
cord-354168-omen8vvq	44	9	the	the	DT
cord-354168-omen8vvq	44	10	infection	infection	NN
cord-354168-omen8vvq	44	11	risk	risk	NN
cord-354168-omen8vvq	44	12	.	.	.
cord-354168-omen8vvq	45	1	Steroids	steroid	NNS
cord-354168-omen8vvq	45	2	are	be	VBP
cord-354168-omen8vvq	45	3	well	well	RB
cord-354168-omen8vvq	45	4	known	know	VBN
cord-354168-omen8vvq	45	5	to	to	TO
cord-354168-omen8vvq	45	6	increase	increase	VB
cord-354168-omen8vvq	45	7	the	the	DT
cord-354168-omen8vvq	45	8	risk	risk	NN
cord-354168-omen8vvq	45	9	of	of	IN
cord-354168-omen8vvq	45	10	infections	infection	NNS
cord-354168-omen8vvq	45	11	(	(	-LRB-
cord-354168-omen8vvq	45	12	including	include	VBG
cord-354168-omen8vvq	45	13	pneumocystis	pneumocystis	NN
cord-354168-omen8vvq	45	14	and	and	CC
cord-354168-omen8vvq	45	15	fungus	fungus	NN
cord-354168-omen8vvq	45	16	)	)	-RRB-
cord-354168-omen8vvq	45	17	and	and	CC
cord-354168-omen8vvq	45	18	the	the	DT
cord-354168-omen8vvq	45	19	combination	combination	NN
cord-354168-omen8vvq	45	20	with	with	IN
cord-354168-omen8vvq	45	21	IMiDs	imids	NN
cord-354168-omen8vvq	45	22	and	and	CC
cord-354168-omen8vvq	45	23	PIs	pis	NN
cord-354168-omen8vvq	45	24	increases	increase	VBZ
cord-354168-omen8vvq	45	25	this	this	DT
cord-354168-omen8vvq	45	26	further	further	RB
cord-354168-omen8vvq	45	27	.	.	.
cord-354168-omen8vvq	46	1	The	the	DT
cord-354168-omen8vvq	46	2	infection	infection	NN
cord-354168-omen8vvq	46	3	risk	risk	NN
cord-354168-omen8vvq	46	4	is	be	VBZ
cord-354168-omen8vvq	46	5	highest	high	JJS
cord-354168-omen8vvq	46	6	during	during	IN
cord-354168-omen8vvq	46	7	the	the	DT
cord-354168-omen8vvq	46	8	first	first	JJ
cord-354168-omen8vvq	46	9	3	3	CD
cord-354168-omen8vvq	46	10	-	-	SYM
cord-354168-omen8vvq	46	11	4	4	CD
cord-354168-omen8vvq	46	12	months	month	NNS
cord-354168-omen8vvq	46	13	of	of	IN
cord-354168-omen8vvq	46	14	therapy	therapy	NN
cord-354168-omen8vvq	46	15	.	.	.
cord-354168-omen8vvq	47	1	Prophylactic	prophylactic	JJ
cord-354168-omen8vvq	47	2	levofloxacin	levofloxacin	NNS
cord-354168-omen8vvq	47	3	for	for	IN
cord-354168-omen8vvq	47	4	12	12	CD
cord-354168-omen8vvq	47	5	weeks	week	NNS
cord-354168-omen8vvq	47	6	in	in	IN
cord-354168-omen8vvq	47	7	newly	newly	RB
cord-354168-omen8vvq	47	8	diagnosed	diagnose	VBN
cord-354168-omen8vvq	47	9	myeloma	myeloma	NN
cord-354168-omen8vvq	47	10	has	have	VBZ
cord-354168-omen8vvq	47	11	been	be	VBN
cord-354168-omen8vvq	47	12	shown	show	VBN
cord-354168-omen8vvq	47	13	to	to	TO
cord-354168-omen8vvq	47	14	reduce	reduce	VB
cord-354168-omen8vvq	47	15	deaths	death	NNS
cord-354168-omen8vvq	47	16	significantly	significantly	RB
cord-354168-omen8vvq	47	17	[	[	-LRB-
cord-354168-omen8vvq	47	18	16	16	CD
cord-354168-omen8vvq	47	19	]	]	-RRB-
cord-354168-omen8vvq	47	20	.	.	.
cord-354168-omen8vvq	48	1	All	all	DT
cord-354168-omen8vvq	48	2	of	of	IN
cord-354168-omen8vvq	48	3	the	the	DT
cord-354168-omen8vvq	48	4	previous	previous	JJ
cord-354168-omen8vvq	48	5	factors	factor	NNS
cord-354168-omen8vvq	48	6	make	make	VBP
cord-354168-omen8vvq	48	7	MM	MM	NNP
cord-354168-omen8vvq	48	8	patients	patient	NNS
cord-354168-omen8vvq	48	9	more	more	RBR
cord-354168-omen8vvq	48	10	susceptible	susceptible	JJ
cord-354168-omen8vvq	48	11	to	to	IN
cord-354168-omen8vvq	48	12	the	the	DT
cord-354168-omen8vvq	48	13	serious	serious	JJ
cord-354168-omen8vvq	48	14	adverse	adverse	JJ
cord-354168-omen8vvq	48	15	events	event	NNS
cord-354168-omen8vvq	48	16	that	that	WDT
cord-354168-omen8vvq	48	17	could	could	MD
cord-354168-omen8vvq	48	18	arise	arise	VB
cord-354168-omen8vvq	48	19	with	with	IN
cord-354168-omen8vvq	48	20	COVID-19	covid-19	JJ
cord-354168-omen8vvq	48	21	infection	infection	NN
cord-354168-omen8vvq	48	22	.	.	.
cord-354168-omen8vvq	49	1	COVID-19	COVID-19	NNP
cord-354168-omen8vvq	49	2	can	can	MD
cord-354168-omen8vvq	49	3	intensify	intensify	VB
cord-354168-omen8vvq	49	4	neutropenia	neutropenia	NN
cord-354168-omen8vvq	49	5	[	[	-LRB-
cord-354168-omen8vvq	49	6	17	17	CD
cord-354168-omen8vvq	49	7	]	]	-RRB-
cord-354168-omen8vvq	49	8	.	.	.
cord-354168-omen8vvq	50	1	There	there	EX
cord-354168-omen8vvq	50	2	is	be	VBZ
cord-354168-omen8vvq	50	3	no	no	DT
cord-354168-omen8vvq	50	4	disagreement	disagreement	NN
cord-354168-omen8vvq	50	5	regarding	regard	VBG
cord-354168-omen8vvq	50	6	the	the	DT
cord-354168-omen8vvq	50	7	management	management	NN
cord-354168-omen8vvq	50	8	of	of	IN
cord-354168-omen8vvq	50	9	standard	standard	JJ
cord-354168-omen8vvq	50	10	-	-	HYPH
cord-354168-omen8vvq	50	11	risk	risk	NN
cord-354168-omen8vvq	50	12	smoldering	smolder	VBG
cord-354168-omen8vvq	50	13	MM	MM	NNP
cord-354168-omen8vvq	50	14	(	(	-LRB-
cord-354168-omen8vvq	50	15	SMM	SMM	NNP
cord-354168-omen8vvq	50	16	)	)	-RRB-
cord-354168-omen8vvq	50	17	patients	patient	NNS
cord-354168-omen8vvq	50	18	.	.	.
cord-354168-omen8vvq	51	1	These	these	DT
cord-354168-omen8vvq	51	2	patients	patient	NNS
cord-354168-omen8vvq	51	3	should	should	MD
cord-354168-omen8vvq	51	4	be	be	VB
cord-354168-omen8vvq	51	5	monitored	monitor	VBN
cord-354168-omen8vvq	51	6	with	with	IN
cord-354168-omen8vvq	51	7	no	no	DT
cord-354168-omen8vvq	51	8	active	active	JJ
cord-354168-omen8vvq	51	9	intervention	intervention	NN
cord-354168-omen8vvq	51	10	.	.	.
cord-354168-omen8vvq	52	1	For	for	IN
cord-354168-omen8vvq	52	2	high	high	JJ
cord-354168-omen8vvq	52	3	-	-	HYPH
cord-354168-omen8vvq	52	4	risk	risk	NN
cord-354168-omen8vvq	52	5	SMM	SMM	NNP
cord-354168-omen8vvq	52	6	based	base	VBN
cord-354168-omen8vvq	52	7	on	on	IN
cord-354168-omen8vvq	52	8	the	the	DT
cord-354168-omen8vvq	52	9	Mayo	Mayo	NNP
cord-354168-omen8vvq	52	10	2018	2018	CD
cord-354168-omen8vvq	52	11	risk	risk	NN
cord-354168-omen8vvq	52	12	stratification	stratification	NN
cord-354168-omen8vvq	52	13	[	[	-LRB-
cord-354168-omen8vvq	52	14	18	18	CD
cord-354168-omen8vvq	52	15	]	]	-RRB-
cord-354168-omen8vvq	52	16	,	,	,
cord-354168-omen8vvq	52	17	experts	expert	NNS
cord-354168-omen8vvq	52	18	differ	differ	VBP
cord-354168-omen8vvq	52	19	in	in	IN
cord-354168-omen8vvq	52	20	their	-PRON-	PRP$
cord-354168-omen8vvq	52	21	approach	approach	NN
cord-354168-omen8vvq	52	22	.	.	.
cord-354168-omen8vvq	53	1	Two	two	CD
cord-354168-omen8vvq	53	2	phase	phase	NN
cord-354168-omen8vvq	53	3	III	iii	CD
cord-354168-omen8vvq	53	4	randomized	randomized	JJ
cord-354168-omen8vvq	53	5	trials	trial	NNS
cord-354168-omen8vvq	53	6	evaluated	evaluate	VBD
cord-354168-omen8vvq	53	7	the	the	DT
cord-354168-omen8vvq	53	8	use	use	NN
cord-354168-omen8vvq	53	9	of	of	IN
cord-354168-omen8vvq	53	10	active	active	JJ
cord-354168-omen8vvq	53	11	therapy	therapy	NN
cord-354168-omen8vvq	53	12	for	for	IN
cord-354168-omen8vvq	53	13	SMM	SMM	NNP
cord-354168-omen8vvq	53	14	,	,	,
cord-354168-omen8vvq	53	15	one	one	CD
cord-354168-omen8vvq	53	16	with	with	IN
cord-354168-omen8vvq	53	17	lenalidomide	lenalidomide	NN
cord-354168-omen8vvq	53	18	and	and	CC
cord-354168-omen8vvq	53	19	dexamethasone	dexamethasone	NN
cord-354168-omen8vvq	53	20	[	[	-LRB-
cord-354168-omen8vvq	53	21	19	19	CD
cord-354168-omen8vvq	53	22	]	]	-RRB-
cord-354168-omen8vvq	53	23	and	and	CC
cord-354168-omen8vvq	53	24	the	the	DT
cord-354168-omen8vvq	53	25	other	other	JJ
cord-354168-omen8vvq	53	26	with	with	IN
cord-354168-omen8vvq	53	27	lenalidomide	lenalidomide	NN
cord-354168-omen8vvq	53	28	alone	alone	RB
cord-354168-omen8vvq	53	29	[	[	-LRB-
cord-354168-omen8vvq	53	30	20	20	CD
cord-354168-omen8vvq	53	31	]	]	-RRB-
cord-354168-omen8vvq	53	32	.	.	.
cord-354168-omen8vvq	54	1	There	there	EX
cord-354168-omen8vvq	54	2	was	be	VBD
cord-354168-omen8vvq	54	3	improvement	improvement	NN
cord-354168-omen8vvq	54	4	in	in	IN
cord-354168-omen8vvq	54	5	progression	progression	NN
cord-354168-omen8vvq	54	6	-	-	HYPH
cord-354168-omen8vvq	54	7	free	free	JJ
cord-354168-omen8vvq	54	8	survival	survival	NN
cord-354168-omen8vvq	54	9	(	(	-LRB-
cord-354168-omen8vvq	54	10	PFS	PFS	NNP
cord-354168-omen8vvq	54	11	)	)	-RRB-
cord-354168-omen8vvq	54	12	in	in	IN
cord-354168-omen8vvq	54	13	2	2	CD
cord-354168-omen8vvq	54	14	trials	trial	NNS
cord-354168-omen8vvq	54	15	[	[	-LRB-
cord-354168-omen8vvq	54	16	19	19	CD
cord-354168-omen8vvq	54	17	,	,	,
cord-354168-omen8vvq	54	18	20	20	CD
cord-354168-omen8vvq	54	19	]	]	-RRB-
cord-354168-omen8vvq	54	20	and	and	CC
cord-354168-omen8vvq	54	21	overall	overall	JJ
cord-354168-omen8vvq	54	22	survival	survival	NN
cord-354168-omen8vvq	54	23	(	(	-LRB-
cord-354168-omen8vvq	54	24	OS	OS	NNP
cord-354168-omen8vvq	54	25	)	)	-RRB-
cord-354168-omen8vvq	54	26	in	in	IN
cord-354168-omen8vvq	54	27	1	1	CD
cord-354168-omen8vvq	54	28	trial	trial	NN
cord-354168-omen8vvq	54	29	[	[	-LRB-
cord-354168-omen8vvq	54	30	19	19	CD
cord-354168-omen8vvq	54	31	]	]	-RRB-
cord-354168-omen8vvq	54	32	.	.	.
cord-354168-omen8vvq	55	1	However	however	RB
cord-354168-omen8vvq	55	2	,	,	,
cord-354168-omen8vvq	55	3	both	both	DT
cord-354168-omen8vvq	55	4	trials	trial	NNS
cord-354168-omen8vvq	55	5	had	have	VBD
cord-354168-omen8vvq	55	6	several	several	JJ
cord-354168-omen8vvq	55	7	limitations	limitation	NNS
cord-354168-omen8vvq	55	8	.	.	.
cord-354168-omen8vvq	56	1	In	in	IN
cord-354168-omen8vvq	56	2	both	both	DT
cord-354168-omen8vvq	56	3	trials	trial	NNS
cord-354168-omen8vvq	56	4	,	,	,
cord-354168-omen8vvq	56	5	the	the	DT
cord-354168-omen8vvq	56	6	sample	sample	NN
cord-354168-omen8vvq	56	7	size	size	NN
cord-354168-omen8vvq	56	8	was	be	VBD
cord-354168-omen8vvq	56	9	less	less	JJR
cord-354168-omen8vvq	56	10	than	than	IN
cord-354168-omen8vvq	56	11	100	100	CD
cord-354168-omen8vvq	56	12	patients	patient	NNS
cord-354168-omen8vvq	56	13	in	in	IN
cord-354168-omen8vvq	56	14	each	each	DT
cord-354168-omen8vvq	56	15	arm	arm	NN
cord-354168-omen8vvq	56	16	.	.	.
cord-354168-omen8vvq	57	1	In	in	IN
cord-354168-omen8vvq	57	2	the	the	DT
cord-354168-omen8vvq	57	3	Spanish	spanish	JJ
cord-354168-omen8vvq	57	4	myeloma	myeloma	NN
cord-354168-omen8vvq	57	5	group	group	NN
cord-354168-omen8vvq	57	6	trial	trial	NN
cord-354168-omen8vvq	57	7	[	[	-LRB-
cord-354168-omen8vvq	57	8	19	19	CD
cord-354168-omen8vvq	57	9	]	]	-RRB-
cord-354168-omen8vvq	57	10	,	,	,
cord-354168-omen8vvq	57	11	imaging	imaging	NN
cord-354168-omen8vvq	57	12	was	be	VBD
cord-354168-omen8vvq	57	13	done	do	VBN
cord-354168-omen8vvq	57	14	using	use	VBG
cord-354168-omen8vvq	57	15	X	x	NN
cord-354168-omen8vvq	57	16	-	-	NN
cord-354168-omen8vvq	57	17	ray	ray	NN
cord-354168-omen8vvq	57	18	,	,	,
cord-354168-omen8vvq	57	19	which	which	WDT
cord-354168-omen8vvq	57	20	is	be	VBZ
cord-354168-omen8vvq	57	21	less	less	RBR
cord-354168-omen8vvq	57	22	sensitive	sensitive	JJ
cord-354168-omen8vvq	57	23	than	than	IN
cord-354168-omen8vvq	57	24	current	current	JJ
cord-354168-omen8vvq	57	25	diagnostic	diagnostic	JJ
cord-354168-omen8vvq	57	26	modalities	modality	NNS
cord-354168-omen8vvq	57	27	(	(	-LRB-
cord-354168-omen8vvq	57	28	including	include	VBG
cord-354168-omen8vvq	57	29	low	low	JJ
cord-354168-omen8vvq	57	30	-	-	HYPH
cord-354168-omen8vvq	57	31	dose	dose	NN
cord-354168-omen8vvq	57	32	CT	CT	NNP
cord-354168-omen8vvq	57	33	skeletal	skeletal	JJ
cord-354168-omen8vvq	57	34	survey	survey	NN
cord-354168-omen8vvq	57	35	and	and	CC
cord-354168-omen8vvq	57	36	PET	pet	NN
cord-354168-omen8vvq	57	37	scans	scan	NNS
cord-354168-omen8vvq	57	38	)	)	-RRB-
cord-354168-omen8vvq	57	39	,	,	,
cord-354168-omen8vvq	57	40	and	and	CC
cord-354168-omen8vvq	57	41	the	the	DT
cord-354168-omen8vvq	57	42	benefit	benefit	NN
cord-354168-omen8vvq	57	43	of	of	IN
cord-354168-omen8vvq	57	44	survival	survival	NN
cord-354168-omen8vvq	57	45	in	in	IN
cord-354168-omen8vvq	57	46	some	some	DT
cord-354168-omen8vvq	57	47	patients	patient	NNS
cord-354168-omen8vvq	57	48	could	could	MD
cord-354168-omen8vvq	57	49	have	have	VB
cord-354168-omen8vvq	57	50	been	be	VBN
cord-354168-omen8vvq	57	51	due	due	JJ
cord-354168-omen8vvq	57	52	to	to	IN
cord-354168-omen8vvq	57	53	treating	treat	VBG
cord-354168-omen8vvq	57	54	active	active	JJ
cord-354168-omen8vvq	57	55	MM	MM	NNP
cord-354168-omen8vvq	57	56	(	(	-LRB-
cord-354168-omen8vvq	57	57	normal	normal	JJ
cord-354168-omen8vvq	57	58	radiographs	radiograph	NNS
cord-354168-omen8vvq	57	59	but	but	CC
cord-354168-omen8vvq	57	60	abnormal	abnormal	JJ
cord-354168-omen8vvq	57	61	PET	pet	NN
cord-354168-omen8vvq	57	62	or	or	CC
cord-354168-omen8vvq	57	63	MRI	MRI	NNP
cord-354168-omen8vvq	57	64	)	)	-RRB-
cord-354168-omen8vvq	57	65	,	,	,
cord-354168-omen8vvq	57	66	rather	rather	RB
cord-354168-omen8vvq	57	67	than	than	IN
cord-354168-omen8vvq	57	68	SMM	SMM	NNP
cord-354168-omen8vvq	57	69	.	.	.
cord-354168-omen8vvq	58	1	In	in	IN
cord-354168-omen8vvq	58	2	the	the	DT
cord-354168-omen8vvq	58	3	second	second	JJ
cord-354168-omen8vvq	58	4	trial	trial	NN
cord-354168-omen8vvq	58	5	,	,	,
cord-354168-omen8vvq	58	6	there	there	EX
cord-354168-omen8vvq	58	7	is	be	VBZ
cord-354168-omen8vvq	58	8	no	no	DT
cord-354168-omen8vvq	58	9	OS	OS	NNP
cord-354168-omen8vvq	58	10	benefit	benefit	NN
cord-354168-omen8vvq	58	11	to	to	IN
cord-354168-omen8vvq	58	12	date	date	NN
cord-354168-omen8vvq	58	13	and	and	CC
cord-354168-omen8vvq	58	14	only	only	RB
cord-354168-omen8vvq	58	15	30	30	CD
cord-354168-omen8vvq	58	16	%	%	NN
cord-354168-omen8vvq	58	17	were	be	VBD
cord-354168-omen8vvq	58	18	high	high	JJ
cord-354168-omen8vvq	58	19	risk	risk	NN
cord-354168-omen8vvq	58	20	according	accord	VBG
cord-354168-omen8vvq	58	21	to	to	IN
cord-354168-omen8vvq	58	22	the	the	DT
cord-354168-omen8vvq	58	23	Mayo	Mayo	NNP
cord-354168-omen8vvq	58	24	2018	2018	CD
cord-354168-omen8vvq	58	25	risk	risk	NN
cord-354168-omen8vvq	58	26	stratification	stratification	NN
cord-354168-omen8vvq	58	27	[	[	-LRB-
cord-354168-omen8vvq	58	28	20	20	CD
cord-354168-omen8vvq	58	29	]	]	-RRB-
cord-354168-omen8vvq	58	30	.	.	.
cord-354168-omen8vvq	59	1	Also	also	RB
cord-354168-omen8vvq	59	2	,	,	,
cord-354168-omen8vvq	59	3	3.3	3.3	CD
cord-354168-omen8vvq	59	4	%	%	NN
cord-354168-omen8vvq	59	5	of	of	IN
cord-354168-omen8vvq	59	6	patients	patient	NNS
cord-354168-omen8vvq	59	7	had	have	VBD
cord-354168-omen8vvq	59	8	bone	bone	NN
cord-354168-omen8vvq	59	9	marrow	marrow	NN
cord-354168-omen8vvq	59	10	plasma	plasma	NN
cord-354168-omen8vvq	59	11	cells	cell	NNS
cord-354168-omen8vvq	59	12	≥60	≥60	VBP
cord-354168-omen8vvq	59	13	and	and	CC
cord-354168-omen8vvq	59	14	8.2	8.2	CD
cord-354168-omen8vvq	59	15	%	%	NN
cord-354168-omen8vvq	59	16	had	have	VBD
cord-354168-omen8vvq	59	17	serum	serum	NN
cord-354168-omen8vvq	59	18	-	-	HYPH
cord-354168-omen8vvq	59	19	free	free	JJ
cord-354168-omen8vvq	59	20	light	light	JJ
cord-354168-omen8vvq	59	21	chains	chain	NNS
cord-354168-omen8vvq	59	22	>	>	XX
cord-354168-omen8vvq	60	1	100	100	CD
cord-354168-omen8vvq	60	2	mg	mg	NNP
cord-354168-omen8vvq	60	3	/	/	SYM
cord-354168-omen8vvq	60	4	dL	dl	NN
cord-354168-omen8vvq	60	5	which	which	WDT
cord-354168-omen8vvq	60	6	are	be	VBP
cord-354168-omen8vvq	60	7	MM	MM	NNP
cord-354168-omen8vvq	60	8	defining	define	VBG
cord-354168-omen8vvq	60	9	events	event	NNS
cord-354168-omen8vvq	60	10	by	by	IN
cord-354168-omen8vvq	60	11	definition	definition	NN
cord-354168-omen8vvq	60	12	[	[	-LRB-
cord-354168-omen8vvq	60	13	20	20	CD
cord-354168-omen8vvq	60	14	]	]	-RRB-
cord-354168-omen8vvq	60	15	and	and	CC
cord-354168-omen8vvq	60	16	these	these	DT
cord-354168-omen8vvq	60	17	patients	patient	NNS
cord-354168-omen8vvq	60	18	may	may	MD
cord-354168-omen8vvq	60	19	have	have	VB
cord-354168-omen8vvq	60	20	been	be	VBN
cord-354168-omen8vvq	60	21	randomized	randomize	VBN
cord-354168-omen8vvq	60	22	to	to	IN
cord-354168-omen8vvq	60	23	no	no	DT
cord-354168-omen8vvq	60	24	therapy	therapy	NN
cord-354168-omen8vvq	60	25	.	.	.
cord-354168-omen8vvq	61	1	We	-PRON-	PRP
cord-354168-omen8vvq	61	2	currently	currently	RB
cord-354168-omen8vvq	61	3	believe	believe	VBP
cord-354168-omen8vvq	61	4	that	that	IN
cord-354168-omen8vvq	61	5	involving	involve	VBG
cord-354168-omen8vvq	61	6	patients	patient	NNS
cord-354168-omen8vvq	61	7	in	in	IN
cord-354168-omen8vvq	61	8	a	a	DT
cord-354168-omen8vvq	61	9	clinical	clinical	JJ
cord-354168-omen8vvq	61	10	trial	trial	NN
cord-354168-omen8vvq	61	11	is	be	VBZ
cord-354168-omen8vvq	61	12	the	the	DT
cord-354168-omen8vvq	61	13	best	good	JJS
cord-354168-omen8vvq	61	14	strategy	strategy	NN
cord-354168-omen8vvq	61	15	for	for	IN
cord-354168-omen8vvq	61	16	high	high	JJ
cord-354168-omen8vvq	61	17	-	-	HYPH
cord-354168-omen8vvq	61	18	risk	risk	NN
cord-354168-omen8vvq	61	19	SMM	SMM	NNP
cord-354168-omen8vvq	61	20	patients	patient	NNS
cord-354168-omen8vvq	61	21	.	.	.
cord-354168-omen8vvq	62	1	However	however	RB
cord-354168-omen8vvq	62	2	,	,	,
cord-354168-omen8vvq	62	3	with	with	IN
cord-354168-omen8vvq	62	4	the	the	DT
cord-354168-omen8vvq	62	5	current	current	JJ
cord-354168-omen8vvq	62	6	COVID-19	COVID-19	NNP
cord-354168-omen8vvq	62	7	pandemic	pandemic	NN
cord-354168-omen8vvq	62	8	,	,	,
cord-354168-omen8vvq	62	9	many	many	JJ
cord-354168-omen8vvq	62	10	trials	trial	NNS
cord-354168-omen8vvq	62	11	are	be	VBP
cord-354168-omen8vvq	62	12	not	not	RB
cord-354168-omen8vvq	62	13	accepting	accept	VBG
cord-354168-omen8vvq	62	14	new	new	JJ
cord-354168-omen8vvq	62	15	patients	patient	NNS
cord-354168-omen8vvq	62	16	and	and	CC
cord-354168-omen8vvq	62	17	we	-PRON-	PRP
cord-354168-omen8vvq	62	18	would	would	MD
cord-354168-omen8vvq	62	19	advise	advise	VB
cord-354168-omen8vvq	62	20	close	close	JJ
cord-354168-omen8vvq	62	21	monitoring	monitoring	NN
cord-354168-omen8vvq	62	22	and	and	CC
cord-354168-omen8vvq	62	23	observation	observation	NN
cord-354168-omen8vvq	62	24	for	for	IN
cord-354168-omen8vvq	62	25	these	these	DT
cord-354168-omen8vvq	62	26	patients	patient	NNS
cord-354168-omen8vvq	62	27	.	.	.
cord-354168-omen8vvq	63	1	Risk	risk	NN
cord-354168-omen8vvq	63	2	Stratification	stratification	NN
cord-354168-omen8vvq	63	3	MM	MM	NNP
cord-354168-omen8vvq	63	4	is	be	VBZ
cord-354168-omen8vvq	63	5	a	a	DT
cord-354168-omen8vvq	63	6	heterogeneous	heterogeneous	JJ
cord-354168-omen8vvq	63	7	malignancy	malignancy	NN
cord-354168-omen8vvq	63	8	and	and	CC
cord-354168-omen8vvq	63	9	patients	patient	NNS
cord-354168-omen8vvq	63	10	behave	behave	VBP
cord-354168-omen8vvq	63	11	differently	differently	RB
cord-354168-omen8vvq	63	12	.	.	.
cord-354168-omen8vvq	64	1	Risk	risk	NN
cord-354168-omen8vvq	64	2	stratification	stratification	NN
cord-354168-omen8vvq	64	3	is	be	VBZ
cord-354168-omen8vvq	64	4	critical	critical	JJ
cord-354168-omen8vvq	64	5	,	,	,
cord-354168-omen8vvq	64	6	especially	especially	RB
cord-354168-omen8vvq	64	7	during	during	IN
cord-354168-omen8vvq	64	8	the	the	DT
cord-354168-omen8vvq	64	9	current	current	JJ
cord-354168-omen8vvq	64	10	COVID-19	covid-19	JJ
cord-354168-omen8vvq	64	11	situation	situation	NN
cord-354168-omen8vvq	64	12	.	.	.
cord-354168-omen8vvq	65	1	In	in	IN
cord-354168-omen8vvq	65	2	general	general	JJ
cord-354168-omen8vvq	65	3	,	,	,
cord-354168-omen8vvq	65	4	patients	patient	NNS
cord-354168-omen8vvq	65	5	with	with	IN
cord-354168-omen8vvq	65	6	trisomies	trisomy	NNS
cord-354168-omen8vvq	65	7	,	,	,
cord-354168-omen8vvq	65	8	t(11	t(11	XX
cord-354168-omen8vvq	65	9	;	;	:
cord-354168-omen8vvq	65	10	14	14	CD
cord-354168-omen8vvq	65	11	)	)	-RRB-
cord-354168-omen8vvq	65	12	,	,	,
cord-354168-omen8vvq	65	13	or	or	CC
cord-354168-omen8vvq	65	14	t(6	t(6	NN
cord-354168-omen8vvq	65	15	;	;	:
cord-354168-omen8vvq	65	16	14	14	CD
cord-354168-omen8vvq	65	17	)	)	-RRB-
cord-354168-omen8vvq	65	18	are	be	VBP
cord-354168-omen8vvq	65	19	considered	consider	VBN
cord-354168-omen8vvq	65	20	standard	standard	JJ
cord-354168-omen8vvq	65	21	risk	risk	NN
cord-354168-omen8vvq	65	22	.	.	.
cord-354168-omen8vvq	66	1	High	high	JJ
cord-354168-omen8vvq	66	2	-	-	HYPH
cord-354168-omen8vvq	66	3	risk	risk	NN
cord-354168-omen8vvq	66	4	genetic	genetic	JJ
cord-354168-omen8vvq	66	5	abnormalities	abnormality	NNS
cord-354168-omen8vvq	66	6	include	include	VBP
cord-354168-omen8vvq	66	7	t(4	t(4	NNP
cord-354168-omen8vvq	66	8	;	;	:
cord-354168-omen8vvq	66	9	14	14	CD
cord-354168-omen8vvq	66	10	)	)	-RRB-
cord-354168-omen8vvq	66	11	,	,	,
cord-354168-omen8vvq	66	12	t(14	t(14	CD
cord-354168-omen8vvq	66	13	;	;	:
cord-354168-omen8vvq	66	14	16	16	CD
cord-354168-omen8vvq	66	15	)	)	-RRB-
cord-354168-omen8vvq	66	16	,	,	,
cord-354168-omen8vvq	66	17	t(14	t(14	XX
cord-354168-omen8vvq	66	18	;	;	:
cord-354168-omen8vvq	66	19	20	20	CD
cord-354168-omen8vvq	66	20	)	)	-RRB-
cord-354168-omen8vvq	66	21	,	,	,
cord-354168-omen8vvq	66	22	17p	17p	NNP
cord-354168-omen8vvq	66	23	del	del	NNP
cord-354168-omen8vvq	66	24	,	,	,
cord-354168-omen8vvq	66	25	1q+	1q+	CD
cord-354168-omen8vvq	66	26	and	and	CC
cord-354168-omen8vvq	66	27	p53	p53	NN
cord-354168-omen8vvq	66	28	mutations	mutation	NNS
cord-354168-omen8vvq	66	29	.	.	.
cord-354168-omen8vvq	67	1	The	the	DT
cord-354168-omen8vvq	67	2	Revised	revise	VBN
cord-354168-omen8vvq	67	3	International	International	NNP
cord-354168-omen8vvq	67	4	Staging	Staging	NNP
cord-354168-omen8vvq	67	5	System	System	NNP
cord-354168-omen8vvq	67	6	(	(	-LRB-
cord-354168-omen8vvq	67	7	R	R	NNP
cord-354168-omen8vvq	67	8	-	-	HYPH
cord-354168-omen8vvq	67	9	ISS	ISS	NNP
cord-354168-omen8vvq	67	10	)	)	-RRB-
cord-354168-omen8vvq	68	1	Acta	Acta	NNP
cord-354168-omen8vvq	68	2	Haematol	Haematol	NNP
cord-354168-omen8vvq	68	3	DOI	DOI	NNP
cord-354168-omen8vvq	68	4	:	:	:
cord-354168-omen8vvq	68	5	10.1159/000507690	10.1159/000507690	CD
cord-354168-omen8vvq	68	6	[	[	-LRB-
cord-354168-omen8vvq	68	7	21	21	CD
cord-354168-omen8vvq	68	8	]	]	-RRB-
cord-354168-omen8vvq	68	9	defines	define	VBZ
cord-354168-omen8vvq	68	10	patients	patient	NNS
cord-354168-omen8vvq	68	11	with	with	IN
cord-354168-omen8vvq	68	12	stage	stage	NN
cord-354168-omen8vvq	68	13	III	III	NNP
cord-354168-omen8vvq	68	14	as	as	IN
cord-354168-omen8vvq	68	15	high	high	JJ
cord-354168-omen8vvq	68	16	risk	risk	NN
cord-354168-omen8vvq	68	17	.	.	.
cord-354168-omen8vvq	69	1	Patients	patient	NNS
cord-354168-omen8vvq	69	2	with	with	IN
cord-354168-omen8vvq	69	3	extramedullary	extramedullary	JJ
cord-354168-omen8vvq	69	4	disease	disease	NN
cord-354168-omen8vvq	69	5	are	be	VBP
cord-354168-omen8vvq	69	6	also	also	RB
cord-354168-omen8vvq	69	7	considered	consider	VBN
cord-354168-omen8vvq	69	8	high	high	JJ
cord-354168-omen8vvq	69	9	risk	risk	NN
cord-354168-omen8vvq	69	10	.	.	.
cord-354168-omen8vvq	70	1	We	-PRON-	PRP
cord-354168-omen8vvq	70	2	consider	consider	VBP
cord-354168-omen8vvq	70	3	patients	patient	NNS
cord-354168-omen8vvq	70	4	with	with	IN
cord-354168-omen8vvq	70	5	plasma	plasma	NN
cord-354168-omen8vvq	70	6	cell	cell	NN
cord-354168-omen8vvq	70	7	leukemia	leukemia	NN
cord-354168-omen8vvq	70	8	(	(	-LRB-
cord-354168-omen8vvq	70	9	PCL	PCL	NNP
cord-354168-omen8vvq	70	10	)	)	-RRB-
cord-354168-omen8vvq	70	11	as	as	IN
cord-354168-omen8vvq	70	12	ultra	ultra	JJ
cord-354168-omen8vvq	70	13	-	-	JJ
cord-354168-omen8vvq	70	14	high	high	JJ
cord-354168-omen8vvq	70	15	risk	risk	NN
cord-354168-omen8vvq	70	16	.	.	.
cord-354168-omen8vvq	71	1	We	-PRON-	PRP
cord-354168-omen8vvq	71	2	recommend	recommend	VBP
cord-354168-omen8vvq	71	3	screening	screen	VBG
cord-354168-omen8vvq	71	4	all	all	DT
cord-354168-omen8vvq	71	5	patients	patient	NNS
cord-354168-omen8vvq	71	6	with	with	IN
cord-354168-omen8vvq	71	7	newly	newly	RB
cord-354168-omen8vvq	71	8	diagnosed	diagnose	VBN
cord-354168-omen8vvq	71	9	MM	MM	NNP
cord-354168-omen8vvq	71	10	for	for	IN
cord-354168-omen8vvq	71	11	COVID-19	COVID-19	NNP
cord-354168-omen8vvq	71	12	before	before	IN
cord-354168-omen8vvq	71	13	starting	start	VBG
cord-354168-omen8vvq	71	14	therapy	therapy	NN
cord-354168-omen8vvq	71	15	,	,	,
cord-354168-omen8vvq	71	16	as	as	IN
cord-354168-omen8vvq	71	17	treatment	treatment	NN
cord-354168-omen8vvq	71	18	for	for	IN
cord-354168-omen8vvq	71	19	MM	MM	NNP
cord-354168-omen8vvq	71	20	can	can	MD
cord-354168-omen8vvq	71	21	aggravate	aggravate	VB
cord-354168-omen8vvq	71	22	the	the	DT
cord-354168-omen8vvq	71	23	adverse	adverse	JJ
cord-354168-omen8vvq	71	24	events	event	NNS
cord-354168-omen8vvq	71	25	of	of	IN
cord-354168-omen8vvq	71	26	an	an	DT
cord-354168-omen8vvq	71	27	active	active	JJ
cord-354168-omen8vvq	71	28	COVID-19	covid-19	CD
cord-354168-omen8vvq	71	29	infection	infection	NN
cord-354168-omen8vvq	71	30	.	.	.
cord-354168-omen8vvq	72	1	Screening	screening	NN
cord-354168-omen8vvq	72	2	should	should	MD
cord-354168-omen8vvq	72	3	be	be	VB
cord-354168-omen8vvq	72	4	done	do	VBN
cord-354168-omen8vvq	72	5	for	for	IN
cord-354168-omen8vvq	72	6	outpatients	outpatient	NNS
cord-354168-omen8vvq	72	7	as	as	RB
cord-354168-omen8vvq	72	8	well	well	RB
cord-354168-omen8vvq	72	9	as	as	IN
cord-354168-omen8vvq	72	10	inpatients	inpatient	NNS
cord-354168-omen8vvq	72	11	initiating	initiate	VBG
cord-354168-omen8vvq	72	12	therapy	therapy	NN
cord-354168-omen8vvq	72	13	.	.	.
cord-354168-omen8vvq	73	1	For	for	IN
cord-354168-omen8vvq	73	2	patients	patient	NNS
cord-354168-omen8vvq	73	3	testing	test	VBG
cord-354168-omen8vvq	73	4	positive	positive	JJ
cord-354168-omen8vvq	73	5	for	for	IN
cord-354168-omen8vvq	73	6	COVID-19	covid-19	NN
cord-354168-omen8vvq	73	7	we	-PRON-	PRP
cord-354168-omen8vvq	73	8	recommend	recommend	VBP
cord-354168-omen8vvq	73	9	holding	hold	VBG
cord-354168-omen8vvq	73	10	treatment	treatment	NN
cord-354168-omen8vvq	73	11	until	until	IN
cord-354168-omen8vvq	73	12	they	-PRON-	PRP
cord-354168-omen8vvq	73	13	have	have	VBP
cord-354168-omen8vvq	73	14	convalesced	convalesce	VBN
cord-354168-omen8vvq	73	15	from	from	IN
cord-354168-omen8vvq	73	16	acute	acute	JJ
cord-354168-omen8vvq	73	17	illness	illness	NN
cord-354168-omen8vvq	73	18	.	.	.
cord-354168-omen8vvq	74	1	Metabolic	metabolic	JJ
cord-354168-omen8vvq	74	2	and	and	CC
cord-354168-omen8vvq	74	3	bone	bone	NN
cord-354168-omen8vvq	74	4	-	-	HYPH
cord-354168-omen8vvq	74	5	related	relate	VBN
cord-354168-omen8vvq	74	6	acute	acute	JJ
cord-354168-omen8vvq	74	7	complications	complication	NNS
cord-354168-omen8vvq	74	8	can	can	MD
cord-354168-omen8vvq	74	9	be	be	VB
cord-354168-omen8vvq	74	10	best	well	RBS
cord-354168-omen8vvq	74	11	managed	manage	VBN
cord-354168-omen8vvq	74	12	with	with	IN
cord-354168-omen8vvq	74	13	supportive	supportive	JJ
cord-354168-omen8vvq	74	14	care	care	NN
cord-354168-omen8vvq	74	15	.	.	.
cord-354168-omen8vvq	75	1	Prevention	prevention	NN
cord-354168-omen8vvq	75	2	is	be	VBZ
cord-354168-omen8vvq	75	3	the	the	DT
cord-354168-omen8vvq	75	4	best	good	JJS
cord-354168-omen8vvq	75	5	cure	cure	NN
cord-354168-omen8vvq	75	6	.	.	.
cord-354168-omen8vvq	76	1	We	-PRON-	PRP
cord-354168-omen8vvq	76	2	stress	stress	VBP
cord-354168-omen8vvq	76	3	educating	educate	VBG
cord-354168-omen8vvq	76	4	the	the	DT
cord-354168-omen8vvq	76	5	patient	patient	NN
cord-354168-omen8vvq	76	6	about	about	IN
cord-354168-omen8vvq	76	7	the	the	DT
cord-354168-omen8vvq	76	8	impact	impact	NN
cord-354168-omen8vvq	76	9	of	of	IN
cord-354168-omen8vvq	76	10	COVID-19	COVID-19	NNP
cord-354168-omen8vvq	76	11	on	on	IN
cord-354168-omen8vvq	76	12	their	-PRON-	PRP$
cord-354168-omen8vvq	76	13	health	health	NN
cord-354168-omen8vvq	76	14	,	,	,
cord-354168-omen8vvq	76	15	emphasizing	emphasize	VBG
cord-354168-omen8vvq	76	16	the	the	DT
cord-354168-omen8vvq	76	17	weak	weak	JJ
cord-354168-omen8vvq	76	18	immune	immune	JJ
cord-354168-omen8vvq	76	19	system	system	NN
cord-354168-omen8vvq	76	20	in	in	IN
cord-354168-omen8vvq	76	21	patients	patient	NNS
cord-354168-omen8vvq	76	22	with	with	IN
cord-354168-omen8vvq	76	23	MM	MM	NNP
cord-354168-omen8vvq	76	24	.	.	.
cord-354168-omen8vvq	77	1	Social	social	JJ
cord-354168-omen8vvq	77	2	distancing	distancing	NN
cord-354168-omen8vvq	77	3	,	,	,
cord-354168-omen8vvq	77	4	staying	stay	VBG
cord-354168-omen8vvq	77	5	home	home	RB
cord-354168-omen8vvq	77	6	(	(	-LRB-
cord-354168-omen8vvq	77	7	except	except	IN
cord-354168-omen8vvq	77	8	for	for	IN
cord-354168-omen8vvq	77	9	treatment	treatment	NN
cord-354168-omen8vvq	77	10	)	)	-RRB-
cord-354168-omen8vvq	77	11	,	,	,
cord-354168-omen8vvq	77	12	washing	wash	VBG
cord-354168-omen8vvq	77	13	hands	hand	NNS
cord-354168-omen8vvq	77	14	frequently	frequently	RB
cord-354168-omen8vvq	77	15	with	with	IN
cord-354168-omen8vvq	77	16	soap	soap	NN
cord-354168-omen8vvq	77	17	(	(	-LRB-
cord-354168-omen8vvq	77	18	for	for	IN
cord-354168-omen8vvq	77	19	at	at	RB
cord-354168-omen8vvq	77	20	least	least	JJS
cord-354168-omen8vvq	77	21	20	20	CD
cord-354168-omen8vvq	77	22	s	s	NNS
cord-354168-omen8vvq	77	23	)	)	-RRB-
cord-354168-omen8vvq	77	24	,	,	,
cord-354168-omen8vvq	77	25	covering	cover	VBG
cord-354168-omen8vvq	77	26	coughs	cough	NNS
cord-354168-omen8vvq	77	27	and	and	CC
cord-354168-omen8vvq	77	28	sneezes	sneeze	VBZ
cord-354168-omen8vvq	77	29	with	with	IN
cord-354168-omen8vvq	77	30	tissue	tissue	NN
cord-354168-omen8vvq	77	31	or	or	CC
cord-354168-omen8vvq	77	32	using	use	VBG
cord-354168-omen8vvq	77	33	the	the	DT
cord-354168-omen8vvq	77	34	elbow	elbow	NN
cord-354168-omen8vvq	77	35	,	,	,
cord-354168-omen8vvq	77	36	and	and	CC
cord-354168-omen8vvq	77	37	cleaning	clean	VBG
cord-354168-omen8vvq	77	38	frequently	frequently	RB
cord-354168-omen8vvq	77	39	touched	touch	VBN
cord-354168-omen8vvq	77	40	surfaces	surface	NNS
cord-354168-omen8vvq	77	41	are	be	VBP
cord-354168-omen8vvq	77	42	recommended	recommend	VBN
cord-354168-omen8vvq	77	43	[	[	-LRB-
cord-354168-omen8vvq	77	44	22	22	CD
cord-354168-omen8vvq	77	45	]	]	-RRB-
cord-354168-omen8vvq	77	46	.	.	.
cord-354168-omen8vvq	78	1	Family	family	NN
cord-354168-omen8vvq	78	2	members	member	NNS
cord-354168-omen8vvq	78	3	are	be	VBP
cord-354168-omen8vvq	78	4	critical	critical	JJ
cord-354168-omen8vvq	78	5	for	for	IN
cord-354168-omen8vvq	78	6	patient	patient	JJ
cord-354168-omen8vvq	78	7	care	care	NN
cord-354168-omen8vvq	78	8	and	and	CC
cord-354168-omen8vvq	78	9	their	-PRON-	PRP$
cord-354168-omen8vvq	78	10	mental	mental	JJ
cord-354168-omen8vvq	78	11	health	health	NN
cord-354168-omen8vvq	78	12	is	be	VBZ
cord-354168-omen8vvq	78	13	important	important	JJ
cord-354168-omen8vvq	78	14	.	.	.
cord-354168-omen8vvq	79	1	Social	social	JJ
cord-354168-omen8vvq	79	2	support	support	NN
cord-354168-omen8vvq	79	3	including	include	VBG
cord-354168-omen8vvq	79	4	tips	tip	NNS
cord-354168-omen8vvq	79	5	for	for	IN
cord-354168-omen8vvq	79	6	coping	cope	VBG
cord-354168-omen8vvq	79	7	with	with	IN
cord-354168-omen8vvq	79	8	stress	stress	NN
cord-354168-omen8vvq	79	9	should	should	MD
cord-354168-omen8vvq	79	10	be	be	VB
cord-354168-omen8vvq	79	11	provided	provide	VBN
cord-354168-omen8vvq	79	12	to	to	IN
cord-354168-omen8vvq	79	13	the	the	DT
cord-354168-omen8vvq	79	14	patient	patient	NN
cord-354168-omen8vvq	79	15	and	and	CC
cord-354168-omen8vvq	79	16	their	-PRON-	PRP$
cord-354168-omen8vvq	79	17	family	family	NN
cord-354168-omen8vvq	79	18	members	member	NNS
cord-354168-omen8vvq	79	19	.	.	.
cord-354168-omen8vvq	80	1	We	-PRON-	PRP
cord-354168-omen8vvq	80	2	find	find	VBP
cord-354168-omen8vvq	80	3	the	the	DT
cord-354168-omen8vvq	80	4	following	follow	VBG
cord-354168-omen8vvq	80	5	website	website	NN
cord-354168-omen8vvq	80	6	(	(	-LRB-
cord-354168-omen8vvq	80	7	https://suicidepreventionlifeline.org/current-events/	https://suicidepreventionlifeline.org/current-events/	NN
cord-354168-omen8vvq	80	8	supporting	support	VBG
cord-354168-omen8vvq	80	9	-	-	HYPH
cord-354168-omen8vvq	80	10	your	-PRON-	PRP$
cord-354168-omen8vvq	80	11	-	-	HYPH
cord-354168-omen8vvq	80	12	emotional	emotional	JJ
cord-354168-omen8vvq	80	13	-	-	HYPH
cord-354168-omen8vvq	80	14	well	well	RB
cord-354168-omen8vvq	80	15	-	-	HYPH
cord-354168-omen8vvq	80	16	being	be	VBG
cord-354168-omen8vvq	80	17	-	-	HYPH
cord-354168-omen8vvq	80	18	during	during	IN
cord-354168-omen8vvq	80	19	-	-	HYPH
cord-354168-omen8vvq	80	20	the	the	DT
cord-354168-omen8vvq	80	21	-	-	HYPH
cord-354168-omen8vvq	80	22	covid-19-outbreak/	covid-19-outbreak/	NN
cord-354168-omen8vvq	80	23	)	)	-RRB-
cord-354168-omen8vvq	80	24	useful	useful	JJ
cord-354168-omen8vvq	80	25	in	in	IN
cord-354168-omen8vvq	80	26	providing	provide	VBG
cord-354168-omen8vvq	80	27	recommendations	recommendation	NNS
cord-354168-omen8vvq	80	28	regarding	regard	VBG
cord-354168-omen8vvq	80	29	coping	cope	VBG
cord-354168-omen8vvq	80	30	with	with	IN
cord-354168-omen8vvq	80	31	the	the	DT
cord-354168-omen8vvq	80	32	current	current	JJ
cord-354168-omen8vvq	80	33	pandemic	pandemic	NN
cord-354168-omen8vvq	80	34	[	[	-LRB-
cord-354168-omen8vvq	80	35	23	23	CD
cord-354168-omen8vvq	80	36	]	]	-RRB-
cord-354168-omen8vvq	80	37	.	.	.
cord-354168-omen8vvq	81	1	For	for	IN
cord-354168-omen8vvq	81	2	Standard	standard	JJ
cord-354168-omen8vvq	81	3	-	-	HYPH
cord-354168-omen8vvq	81	4	Risk	risk	NN
cord-354168-omen8vvq	81	5	Patients	patient	NNS
cord-354168-omen8vvq	81	6	We	-PRON-	PRP
cord-354168-omen8vvq	81	7	believe	believe	VBP
cord-354168-omen8vvq	81	8	that	that	IN
cord-354168-omen8vvq	81	9	these	these	DT
cord-354168-omen8vvq	81	10	patients	patient	NNS
cord-354168-omen8vvq	81	11	could	could	MD
cord-354168-omen8vvq	81	12	be	be	VB
cord-354168-omen8vvq	81	13	managed	manage	VBN
cord-354168-omen8vvq	81	14	using	use	VBG
cord-354168-omen8vvq	81	15	oral	oral	JJ
cord-354168-omen8vvq	81	16	drugs	drug	NNS
cord-354168-omen8vvq	81	17	to	to	TO
cord-354168-omen8vvq	81	18	decrease	decrease	VB
cord-354168-omen8vvq	81	19	the	the	DT
cord-354168-omen8vvq	81	20	risk	risk	NN
cord-354168-omen8vvq	81	21	of	of	IN
cord-354168-omen8vvq	81	22	weekly	weekly	JJ
cord-354168-omen8vvq	81	23	hospital	hospital	NN
cord-354168-omen8vvq	81	24	visits	visit	NNS
cord-354168-omen8vvq	81	25	and	and	CC
cord-354168-omen8vvq	81	26	exposures	exposure	NNS
cord-354168-omen8vvq	81	27	.	.	.
cord-354168-omen8vvq	82	1	We	-PRON-	PRP
cord-354168-omen8vvq	82	2	recommend	recommend	VBP
cord-354168-omen8vvq	82	3	ixazomib	ixazomib	JJ
cord-354168-omen8vvq	82	4	,	,	,
cord-354168-omen8vvq	82	5	lenalidomide	lenalidomide	NN
cord-354168-omen8vvq	82	6	,	,	,
cord-354168-omen8vvq	82	7	and	and	CC
cord-354168-omen8vvq	82	8	dexamethasone	dexamethasone	NN
cord-354168-omen8vvq	82	9	(	(	-LRB-
cord-354168-omen8vvq	82	10	IRd	IRd	NNP
cord-354168-omen8vvq	82	11	)	)	-RRB-
cord-354168-omen8vvq	82	12	given	give	VBN
cord-354168-omen8vvq	82	13	over	over	RP
cord-354168-omen8vvq	82	14	a	a	DT
cord-354168-omen8vvq	82	15	28-day	28-day	CD
cord-354168-omen8vvq	82	16	cycle	cycle	NN
cord-354168-omen8vvq	82	17	.	.	.
cord-354168-omen8vvq	83	1	Lenalidomide	Lenalidomide	NNP
cord-354168-omen8vvq	83	2	should	should	MD
cord-354168-omen8vvq	83	3	be	be	VB
cord-354168-omen8vvq	83	4	given	give	VBN
cord-354168-omen8vvq	83	5	at	at	IN
cord-354168-omen8vvq	83	6	a	a	DT
cord-354168-omen8vvq	83	7	dose	dose	NN
cord-354168-omen8vvq	83	8	of	of	IN
cord-354168-omen8vvq	83	9	25	25	CD
cord-354168-omen8vvq	83	10	mg	mg	NNP
cord-354168-omen8vvq	83	11	p.o	p.o	NNP
cord-354168-omen8vvq	83	12	.	.	NNP
cord-354168-omen8vvq	83	13	daily	daily	RB
cord-354168-omen8vvq	83	14	on	on	IN
cord-354168-omen8vvq	83	15	days	day	NNS
cord-354168-omen8vvq	83	16	1	1	CD
cord-354168-omen8vvq	83	17	-	-	SYM
cord-354168-omen8vvq	83	18	21	21	CD
cord-354168-omen8vvq	83	19	and	and	CC
cord-354168-omen8vvq	83	20	ixazomib	ixazomib	NNP
cord-354168-omen8vvq	83	21	at	at	IN
cord-354168-omen8vvq	83	22	a	a	DT
cord-354168-omen8vvq	83	23	dose	dose	NN
cord-354168-omen8vvq	83	24	of	of	IN
cord-354168-omen8vvq	83	25	4	4	CD
cord-354168-omen8vvq	83	26	mg	mg	NNP
cord-354168-omen8vvq	83	27	p.o	p.o	NNP
cord-354168-omen8vvq	83	28	.	.	.
cord-354168-omen8vvq	84	1	on	on	IN
cord-354168-omen8vvq	84	2	days	day	NNS
cord-354168-omen8vvq	84	3	1	1	CD
cord-354168-omen8vvq	84	4	,	,	,
cord-354168-omen8vvq	84	5	8	8	CD
cord-354168-omen8vvq	84	6	,	,	,
cord-354168-omen8vvq	84	7	and	and	CC
cord-354168-omen8vvq	84	8	15	15	CD
cord-354168-omen8vvq	84	9	.	.	.
cord-354168-omen8vvq	85	1	We	-PRON-	PRP
cord-354168-omen8vvq	85	2	recommend	recommend	VBP
cord-354168-omen8vvq	85	3	decreasing	decrease	VBG
cord-354168-omen8vvq	85	4	the	the	DT
cord-354168-omen8vvq	85	5	dose	dose	NN
cord-354168-omen8vvq	85	6	of	of	IN
cord-354168-omen8vvq	85	7	dexamethasone	dexamethasone	NN
cord-354168-omen8vvq	85	8	to	to	IN
cord-354168-omen8vvq	85	9	20	20	CD
cord-354168-omen8vvq	85	10	mg	mg	NNP
cord-354168-omen8vvq	85	11	p.o	p.o	NNP
cord-354168-omen8vvq	85	12	.	.	NNP
cord-354168-omen8vvq	85	13	weekly	weekly	NNP
cord-354168-omen8vvq	85	14	to	to	TO
cord-354168-omen8vvq	85	15	decrease	decrease	VB
cord-354168-omen8vvq	85	16	the	the	DT
cord-354168-omen8vvq	85	17	risk	risk	NN
cord-354168-omen8vvq	85	18	of	of	IN
cord-354168-omen8vvq	85	19	infection	infection	NN
cord-354168-omen8vvq	85	20	.	.	.
cord-354168-omen8vvq	86	1	We	-PRON-	PRP
cord-354168-omen8vvq	86	2	understand	understand	VBP
cord-354168-omen8vvq	86	3	that	that	IN
cord-354168-omen8vvq	86	4	the	the	DT
cord-354168-omen8vvq	86	5	IRd	IRd	NNP
cord-354168-omen8vvq	86	6	regimen	regimen	NN
cord-354168-omen8vvq	86	7	has	have	VBZ
cord-354168-omen8vvq	86	8	not	not	RB
cord-354168-omen8vvq	86	9	been	be	VBN
cord-354168-omen8vvq	86	10	compared	compare	VBN
cord-354168-omen8vvq	86	11	head	head	NN
cord-354168-omen8vvq	86	12	to	to	TO
cord-354168-omen8vvq	86	13	head	head	VB
cord-354168-omen8vvq	86	14	with	with	IN
cord-354168-omen8vvq	86	15	known	know	VBN
cord-354168-omen8vvq	86	16	standard	standard	JJ
cord-354168-omen8vvq	86	17	therapy	therapy	NN
cord-354168-omen8vvq	86	18	,	,	,
cord-354168-omen8vvq	86	19	but	but	CC
cord-354168-omen8vvq	86	20	the	the	DT
cord-354168-omen8vvq	86	21	response	response	NN
cord-354168-omen8vvq	86	22	rate	rate	NN
cord-354168-omen8vvq	86	23	from	from	IN
cord-354168-omen8vvq	86	24	the	the	DT
cord-354168-omen8vvq	86	25	phase	phase	NN
cord-354168-omen8vvq	86	26	1/2	1/2	CD
cord-354168-omen8vvq	86	27	trial	trial	NN
cord-354168-omen8vvq	86	28	is	be	VBZ
cord-354168-omen8vvq	86	29	comparable	comparable	JJ
cord-354168-omen8vvq	86	30	[	[	-LRB-
cord-354168-omen8vvq	86	31	24	24	CD
cord-354168-omen8vvq	86	32	]	]	-RRB-
cord-354168-omen8vvq	86	33	and	and	CC
cord-354168-omen8vvq	86	34	in	in	IN
cord-354168-omen8vvq	86	35	our	-PRON-	PRP$
cord-354168-omen8vvq	86	36	opinion	opinion	NN
cord-354168-omen8vvq	86	37	using	use	VBG
cord-354168-omen8vvq	86	38	an	an	DT
cord-354168-omen8vvq	86	39	oral	oral	JJ
cord-354168-omen8vvq	86	40	regimen	regimen	NN
cord-354168-omen8vvq	86	41	will	will	MD
cord-354168-omen8vvq	86	42	help	help	VB
cord-354168-omen8vvq	86	43	in	in	IN
cord-354168-omen8vvq	86	44	decreasing	decrease	VBG
cord-354168-omen8vvq	86	45	the	the	DT
cord-354168-omen8vvq	86	46	exposure	exposure	NN
cord-354168-omen8vvq	86	47	to	to	IN
cord-354168-omen8vvq	86	48	and	and	CC
cord-354168-omen8vvq	86	49	infection	infection	NN
cord-354168-omen8vvq	86	50	with	with	IN
cord-354168-omen8vvq	86	51	CO	co	NN
cord-354168-omen8vvq	86	52	-	-	NN
cord-354168-omen8vvq	86	53	VID-19	VID-19	NNP
cord-354168-omen8vvq	86	54	.	.	.
cord-354168-omen8vvq	87	1	Another	another	DT
cord-354168-omen8vvq	87	2	possible	possible	JJ
cord-354168-omen8vvq	87	3	combination	combination	NN
cord-354168-omen8vvq	87	4	is	be	VBZ
cord-354168-omen8vvq	87	5	cyclophosphamide	cyclophosphamide	JJ
cord-354168-omen8vvq	87	6	lenalidomide	lenalidomide	NN
cord-354168-omen8vvq	87	7	and	and	CC
cord-354168-omen8vvq	87	8	dexamethasone	dexamethasone	NN
cord-354168-omen8vvq	87	9	(	(	-LRB-
cord-354168-omen8vvq	87	10	CRd	CRd	NNP
cord-354168-omen8vvq	87	11	)	)	-RRB-
cord-354168-omen8vvq	87	12	given	give	VBN
cord-354168-omen8vvq	87	13	over	over	IN
cord-354168-omen8vvq	87	14	a	a	DT
cord-354168-omen8vvq	87	15	28day	28day	NN
cord-354168-omen8vvq	87	16	cycle	cycle	NN
cord-354168-omen8vvq	87	17	[	[	-LRB-
cord-354168-omen8vvq	87	18	25	25	CD
cord-354168-omen8vvq	87	19	]	]	-RRB-
cord-354168-omen8vvq	87	20	with	with	IN
cord-354168-omen8vvq	87	21	cyclophosphamide	cyclophosphamide	NN
cord-354168-omen8vvq	87	22	(	(	-LRB-
cord-354168-omen8vvq	87	23	300	300	CD
cord-354168-omen8vvq	87	24	mg	mg	NNP
cord-354168-omen8vvq	87	25	/	/	SYM
cord-354168-omen8vvq	87	26	m	m	NNP
cord-354168-omen8vvq	87	27	2	2	CD
cord-354168-omen8vvq	87	28	p.o	p.o	NNP
cord-354168-omen8vvq	87	29	.	.	.
cord-354168-omen8vvq	88	1	on	on	IN
cord-354168-omen8vvq	88	2	days	day	NNS
cord-354168-omen8vvq	88	3	1	1	CD
cord-354168-omen8vvq	88	4	,	,	,
cord-354168-omen8vvq	88	5	8	8	CD
cord-354168-omen8vvq	88	6	,	,	,
cord-354168-omen8vvq	88	7	and	and	CC
cord-354168-omen8vvq	88	8	15	15	CD
cord-354168-omen8vvq	88	9	)	)	-RRB-
cord-354168-omen8vvq	88	10	,	,	,
cord-354168-omen8vvq	88	11	lenalidomide	lenalidomide	NNP
cord-354168-omen8vvq	88	12	(	(	-LRB-
cord-354168-omen8vvq	88	13	25	25	CD
cord-354168-omen8vvq	88	14	mg	mg	NNP
cord-354168-omen8vvq	88	15	p.o	p.o	NNP
cord-354168-omen8vvq	88	16	.	.	.
cord-354168-omen8vvq	89	1	on	on	IN
cord-354168-omen8vvq	89	2	days	day	NNS
cord-354168-omen8vvq	89	3	,	,	,
cord-354168-omen8vvq	89	4	and	and	CC
cord-354168-omen8vvq	89	5	dexamethasone	dexamethasone	NN
cord-354168-omen8vvq	89	6	(	(	-LRB-
cord-354168-omen8vvq	89	7	20	20	CD
cord-354168-omen8vvq	89	8	mg	mg	NNP
cord-354168-omen8vvq	89	9	p.o	p.o	NNP
cord-354168-omen8vvq	89	10	.	.	NNP
cord-354168-omen8vvq	89	11	daily	daily	RB
cord-354168-omen8vvq	89	12	once	once	RB
cord-354168-omen8vvq	89	13	weekly	weekly	RB
cord-354168-omen8vvq	89	14	)	)	-RRB-
cord-354168-omen8vvq	89	15	.	.	.
cord-354168-omen8vvq	90	1	A	a	DT
cord-354168-omen8vvq	90	2	third	third	JJ
cord-354168-omen8vvq	90	3	alternative	alternative	NN
cord-354168-omen8vvq	90	4	is	be	VBZ
cord-354168-omen8vvq	90	5	daratumumab	daratumumab	VBN
cord-354168-omen8vvq	90	6	lenalidomide	lenalidomide	NN
cord-354168-omen8vvq	90	7	and	and	CC
cord-354168-omen8vvq	90	8	dexamethasone	dexamethasone	NN
cord-354168-omen8vvq	90	9	(	(	-LRB-
cord-354168-omen8vvq	90	10	DRd	DRd	NNS
cord-354168-omen8vvq	90	11	)	)	-RRB-
cord-354168-omen8vvq	90	12	given	give	VBN
cord-354168-omen8vvq	90	13	over	over	RP
cord-354168-omen8vvq	90	14	a	a	DT
cord-354168-omen8vvq	90	15	28-day	28-day	CD
cord-354168-omen8vvq	90	16	cycle	cycle	NN
cord-354168-omen8vvq	90	17	[	[	-LRB-
cord-354168-omen8vvq	90	18	26	26	CD
cord-354168-omen8vvq	90	19	]	]	-RRB-
cord-354168-omen8vvq	90	20	.	.	.
cord-354168-omen8vvq	91	1	Full	full	JJ
cord-354168-omen8vvq	91	2	doses	dose	NNS
cord-354168-omen8vvq	91	3	of	of	IN
cord-354168-omen8vvq	91	4	daratumumab	daratumumab	NNP
cord-354168-omen8vvq	91	5	and	and	CC
cord-354168-omen8vvq	91	6	lenalidomide	lenalidomide	NN
cord-354168-omen8vvq	91	7	should	should	MD
cord-354168-omen8vvq	91	8	be	be	VB
cord-354168-omen8vvq	91	9	given	give	VBN
cord-354168-omen8vvq	91	10	.	.	.
cord-354168-omen8vvq	92	1	We	-PRON-	PRP
cord-354168-omen8vvq	92	2	would	would	MD
cord-354168-omen8vvq	92	3	recommend	recommend	VB
cord-354168-omen8vvq	92	4	that	that	IN
cord-354168-omen8vvq	92	5	the	the	DT
cord-354168-omen8vvq	92	6	first	first	JJ
cord-354168-omen8vvq	92	7	dose	dose	NN
cord-354168-omen8vvq	92	8	of	of	IN
cord-354168-omen8vvq	92	9	dexamethasone	dexamethasone	NN
cord-354168-omen8vvq	92	10	is	be	VBZ
cord-354168-omen8vvq	92	11	40	40	CD
cord-354168-omen8vvq	92	12	mg	mg	NNP
cord-354168-omen8vvq	92	13	p.o	p.o	NNP
cord-354168-omen8vvq	92	14	.	.	NNP
cord-354168-omen8vvq	92	15	to	to	TO
cord-354168-omen8vvq	92	16	decrease	decrease	VB
cord-354168-omen8vvq	92	17	the	the	DT
cord-354168-omen8vvq	92	18	risk	risk	NN
cord-354168-omen8vvq	92	19	of	of	IN
cord-354168-omen8vvq	92	20	infusionrelated	infusionrelated	JJ
cord-354168-omen8vvq	92	21	reaction	reaction	NN
cord-354168-omen8vvq	92	22	to	to	IN
cord-354168-omen8vvq	92	23	daratumumab	daratumumab	NNP
cord-354168-omen8vvq	92	24	.	.	.
cord-354168-omen8vvq	93	1	We	-PRON-	PRP
cord-354168-omen8vvq	93	2	would	would	MD
cord-354168-omen8vvq	93	3	recommend	recommend	VB
cord-354168-omen8vvq	93	4	giving	give	VBG
cord-354168-omen8vvq	93	5	dexamethasone	dexamethasone	NN
cord-354168-omen8vvq	93	6	orally	orally	RB
cord-354168-omen8vvq	93	7	,	,	,
cord-354168-omen8vvq	93	8	rather	rather	RB
cord-354168-omen8vvq	93	9	than	than	IN
cord-354168-omen8vvq	93	10	intravenously	intravenously	RB
cord-354168-omen8vvq	93	11	,	,	,
cord-354168-omen8vvq	93	12	to	to	TO
cord-354168-omen8vvq	93	13	decrease	decrease	VB
cord-354168-omen8vvq	93	14	the	the	DT
cord-354168-omen8vvq	93	15	total	total	JJ
cord-354168-omen8vvq	93	16	time	time	NN
cord-354168-omen8vvq	93	17	in	in	IN
cord-354168-omen8vvq	93	18	the	the	DT
cord-354168-omen8vvq	93	19	chemotherapy	chemotherapy	NN
cord-354168-omen8vvq	93	20	unit	unit	NN
cord-354168-omen8vvq	93	21	for	for	IN
cord-354168-omen8vvq	93	22	the	the	DT
cord-354168-omen8vvq	93	23	patient	patient	NN
cord-354168-omen8vvq	93	24	.	.	.
cord-354168-omen8vvq	94	1	The	the	DT
cord-354168-omen8vvq	94	2	dose	dose	NN
cord-354168-omen8vvq	94	3	of	of	IN
cord-354168-omen8vvq	94	4	dexamethasone	dexamethasone	NN
cord-354168-omen8vvq	94	5	can	can	MD
cord-354168-omen8vvq	94	6	be	be	VB
cord-354168-omen8vvq	94	7	decreased	decrease	VBN
cord-354168-omen8vvq	94	8	during	during	IN
cord-354168-omen8vvq	94	9	subsequent	subsequent	JJ
cord-354168-omen8vvq	94	10	cycles	cycle	NNS
cord-354168-omen8vvq	94	11	,	,	,
cord-354168-omen8vvq	94	12	if	if	IN
cord-354168-omen8vvq	94	13	no	no	DT
cord-354168-omen8vvq	94	14	infusion	infusion	NN
cord-354168-omen8vvq	94	15	reaction	reaction	NN
cord-354168-omen8vvq	94	16	is	be	VBZ
cord-354168-omen8vvq	94	17	documented	document	VBN
cord-354168-omen8vvq	94	18	.	.	.
cord-354168-omen8vvq	95	1	If	if	IN
cord-354168-omen8vvq	95	2	no	no	DT
cord-354168-omen8vvq	95	3	infusion	infusion	NN
cord-354168-omen8vvq	95	4	reactions	reaction	NNS
cord-354168-omen8vvq	95	5	occur	occur	VBP
cord-354168-omen8vvq	95	6	,	,	,
cord-354168-omen8vvq	95	7	the	the	DT
cord-354168-omen8vvq	95	8	interval	interval	NN
cord-354168-omen8vvq	95	9	for	for	IN
cord-354168-omen8vvq	95	10	daratumumab	daratumumab	NNP
cord-354168-omen8vvq	95	11	infusion	infusion	NN
cord-354168-omen8vvq	95	12	can	can	MD
cord-354168-omen8vvq	95	13	be	be	VB
cord-354168-omen8vvq	95	14	decreased	decrease	VBN
cord-354168-omen8vvq	95	15	to	to	IN
cord-354168-omen8vvq	95	16	90	90	CD
cord-354168-omen8vvq	95	17	min	min	NN
cord-354168-omen8vvq	95	18	.	.	.
cord-354168-omen8vvq	96	1	We	-PRON-	PRP
cord-354168-omen8vvq	96	2	understand	understand	VBP
cord-354168-omen8vvq	96	3	that	that	IN
cord-354168-omen8vvq	96	4	not	not	RB
cord-354168-omen8vvq	96	5	all	all	DT
cord-354168-omen8vvq	96	6	patients	patient	NNS
cord-354168-omen8vvq	96	7	can	can	MD
cord-354168-omen8vvq	96	8	access	access	VB
cord-354168-omen8vvq	96	9	these	these	DT
cord-354168-omen8vvq	96	10	medications	medication	NNS
cord-354168-omen8vvq	96	11	.	.	.
cord-354168-omen8vvq	97	1	In	in	IN
cord-354168-omen8vvq	97	2	that	that	DT
cord-354168-omen8vvq	97	3	case	case	NN
cord-354168-omen8vvq	97	4	,	,	,
cord-354168-omen8vvq	97	5	standard	standard	NN
cord-354168-omen8vvq	97	6	of	of	IN
cord-354168-omen8vvq	97	7	care	care	NN
cord-354168-omen8vvq	97	8	therapy	therapy	NN
cord-354168-omen8vvq	97	9	using	use	VBG
cord-354168-omen8vvq	97	10	lenalidomide	lenalidomide	NN
cord-354168-omen8vvq	97	11	,	,	,
cord-354168-omen8vvq	97	12	bortezomib	bortezomib	NNP
cord-354168-omen8vvq	97	13	,	,	,
cord-354168-omen8vvq	97	14	and	and	CC
cord-354168-omen8vvq	97	15	dexamethasone	dexamethasone	NN
cord-354168-omen8vvq	97	16	(	(	-LRB-
cord-354168-omen8vvq	97	17	RVd	rvd	NN
cord-354168-omen8vvq	97	18	)	)	-RRB-
cord-354168-omen8vvq	97	19	should	should	MD
cord-354168-omen8vvq	97	20	be	be	VB
cord-354168-omen8vvq	97	21	considered	consider	VBN
cord-354168-omen8vvq	97	22	.	.	.
cord-354168-omen8vvq	98	1	We	-PRON-	PRP
cord-354168-omen8vvq	98	2	would	would	MD
cord-354168-omen8vvq	98	3	recommend	recommend	VB
cord-354168-omen8vvq	98	4	RVd	rvd	WDT
cord-354168-omen8vvq	98	5	over	over	IN
cord-354168-omen8vvq	98	6	28	28	CD
cord-354168-omen8vvq	98	7	days	day	NNS
cord-354168-omen8vvq	98	8	with	with	IN
cord-354168-omen8vvq	98	9	lenalidomide	lenalidomide	NN
cord-354168-omen8vvq	98	10	(	(	-LRB-
cord-354168-omen8vvq	98	11	25	25	CD
cord-354168-omen8vvq	98	12	mg	mg	NNP
cord-354168-omen8vvq	98	13	p.o	p.o	NNP
cord-354168-omen8vvq	98	14	.	.	.
cord-354168-omen8vvq	99	1	on	on	IN
cord-354168-omen8vvq	99	2	days	day	NNS
cord-354168-omen8vvq	99	3	1	1	CD
cord-354168-omen8vvq	99	4	-	-	SYM
cord-354168-omen8vvq	99	5	21	21	CD
cord-354168-omen8vvq	99	6	)	)	-RRB-
cord-354168-omen8vvq	99	7	,	,	,
cord-354168-omen8vvq	99	8	bortezomib	bortezomib	NNP
cord-354168-omen8vvq	99	9	(	(	-LRB-
cord-354168-omen8vvq	99	10	1.5	1.5	CD
cord-354168-omen8vvq	99	11	mg	mg	NNP
cord-354168-omen8vvq	99	12	/	/	SYM
cord-354168-omen8vvq	99	13	m	m	NNP
cord-354168-omen8vvq	99	14	2	2	CD
cord-354168-omen8vvq	99	15	s.c	s.c	NNP
cord-354168-omen8vvq	99	16	.	.	.
cord-354168-omen8vvq	100	1	on	on	IN
cord-354168-omen8vvq	100	2	days	day	NNS
cord-354168-omen8vvq	100	3	1	1	CD
cord-354168-omen8vvq	100	4	,	,	,
cord-354168-omen8vvq	100	5	8	8	CD
cord-354168-omen8vvq	100	6	,	,	,
cord-354168-omen8vvq	100	7	and15	and15	CD
cord-354168-omen8vvq	100	8	)	)	-RRB-
cord-354168-omen8vvq	100	9	,	,	,
cord-354168-omen8vvq	100	10	and	and	CC
cord-354168-omen8vvq	100	11	dexamethasone	dexamethasone	NN
cord-354168-omen8vvq	100	12	(	(	-LRB-
cord-354168-omen8vvq	100	13	20	20	CD
cord-354168-omen8vvq	100	14	mg	mg	NNP
cord-354168-omen8vvq	100	15	p.o	p.o	NNP
cord-354168-omen8vvq	100	16	.	.	NNP
cord-354168-omen8vvq	100	17	daily	daily	RB
cord-354168-omen8vvq	100	18	once	once	RB
cord-354168-omen8vvq	100	19	weekly	weekly	RB
cord-354168-omen8vvq	100	20	)	)	-RRB-
cord-354168-omen8vvq	100	21	.	.	.
cord-354168-omen8vvq	101	1	We	-PRON-	PRP
cord-354168-omen8vvq	101	2	want	want	VBP
cord-354168-omen8vvq	101	3	to	to	TO
cord-354168-omen8vvq	101	4	stress	stress	VB
cord-354168-omen8vvq	101	5	the	the	DT
cord-354168-omen8vvq	101	6	point	point	NN
cord-354168-omen8vvq	101	7	that	that	IN
cord-354168-omen8vvq	101	8	bortezomib	bortezomib	NNP
cord-354168-omen8vvq	101	9	should	should	MD
cord-354168-omen8vvq	101	10	be	be	VB
cord-354168-omen8vvq	101	11	given	give	VBN
cord-354168-omen8vvq	101	12	subcutaneously	subcutaneously	RB
cord-354168-omen8vvq	101	13	once	once	RB
cord-354168-omen8vvq	101	14	a	a	DT
cord-354168-omen8vvq	101	15	week	week	NN
cord-354168-omen8vvq	101	16	,	,	,
cord-354168-omen8vvq	101	17	rather	rather	RB
cord-354168-omen8vvq	101	18	than	than	IN
cord-354168-omen8vvq	101	19	intravenously	intravenously	RB
cord-354168-omen8vvq	101	20	or	or	CC
cord-354168-omen8vvq	101	21	twice	twice	RB
cord-354168-omen8vvq	101	22	weekly	weekly	JJ
cord-354168-omen8vvq	101	23	.	.	.
cord-354168-omen8vvq	102	1	In	in	IN
cord-354168-omen8vvq	102	2	some	some	DT
cord-354168-omen8vvq	102	3	countries	country	NNS
cord-354168-omen8vvq	102	4	,	,	,
cord-354168-omen8vvq	102	5	cyclophosphamide	cyclophosphamide	RB
cord-354168-omen8vvq	102	6	,	,	,
cord-354168-omen8vvq	102	7	bortezomib	bortezomib	NNP
cord-354168-omen8vvq	102	8	,	,	,
cord-354168-omen8vvq	102	9	and	and	CC
cord-354168-omen8vvq	102	10	dexamethasone	dexamethasone	NN
cord-354168-omen8vvq	102	11	(	(	-LRB-
cord-354168-omen8vvq	102	12	CyBorD	CyBorD	NNP
cord-354168-omen8vvq	102	13	)	)	-RRB-
cord-354168-omen8vvq	102	14	is	be	VBZ
cord-354168-omen8vvq	102	15	the	the	DT
cord-354168-omen8vvq	102	16	only	only	JJ
cord-354168-omen8vvq	102	17	approved	approve	VBN
cord-354168-omen8vvq	102	18	combination	combination	NN
cord-354168-omen8vvq	102	19	for	for	IN
cord-354168-omen8vvq	102	20	initial	initial	JJ
cord-354168-omen8vvq	102	21	therapy	therapy	NN
cord-354168-omen8vvq	102	22	.	.	.
cord-354168-omen8vvq	103	1	We	-PRON-	PRP
cord-354168-omen8vvq	103	2	again	again	RB
cord-354168-omen8vvq	103	3	would	would	MD
cord-354168-omen8vvq	103	4	recommend	recommend	VB
cord-354168-omen8vvq	103	5	bortezomib	bortezomib	NNP
cord-354168-omen8vvq	103	6	to	to	TO
cord-354168-omen8vvq	103	7	be	be	VB
cord-354168-omen8vvq	103	8	given	give	VBN
cord-354168-omen8vvq	103	9	subcutaneously	subcutaneously	RB
cord-354168-omen8vvq	103	10	once	once	RB
cord-354168-omen8vvq	103	11	a	a	DT
cord-354168-omen8vvq	103	12	week	week	NN
cord-354168-omen8vvq	103	13	and	and	CC
cord-354168-omen8vvq	103	14	the	the	DT
cord-354168-omen8vvq	103	15	dose	dose	NN
cord-354168-omen8vvq	103	16	of	of	IN
cord-354168-omen8vvq	103	17	dexamethasone	dexamethasone	NN
cord-354168-omen8vvq	103	18	reduced	reduce	VBN
cord-354168-omen8vvq	103	19	to	to	IN
cord-354168-omen8vvq	103	20	20	20	CD
cord-354168-omen8vvq	103	21	mg	mg	NN
cord-354168-omen8vvq	103	22	.	.	.
cord-354168-omen8vvq	104	1	For	for	IN
cord-354168-omen8vvq	104	2	High	high	JJ
cord-354168-omen8vvq	104	3	-	-	HYPH
cord-354168-omen8vvq	104	4	Risk	risk	NN
cord-354168-omen8vvq	104	5	Patients	patient	NNS
cord-354168-omen8vvq	104	6	Patients	patient	NNS
cord-354168-omen8vvq	104	7	with	with	IN
cord-354168-omen8vvq	104	8	high	high	JJ
cord-354168-omen8vvq	104	9	-	-	HYPH
cord-354168-omen8vvq	104	10	risk	risk	NN
cord-354168-omen8vvq	104	11	features	feature	NNS
cord-354168-omen8vvq	104	12	have	have	VBP
cord-354168-omen8vvq	104	13	a	a	DT
cord-354168-omen8vvq	104	14	different	different	JJ
cord-354168-omen8vvq	104	15	biology	biology	NN
cord-354168-omen8vvq	104	16	and	and	CC
cord-354168-omen8vvq	104	17	the	the	DT
cord-354168-omen8vvq	104	18	management	management	NN
cord-354168-omen8vvq	104	19	of	of	IN
cord-354168-omen8vvq	104	20	these	these	DT
cord-354168-omen8vvq	104	21	patients	patient	NNS
cord-354168-omen8vvq	104	22	can	can	MD
cord-354168-omen8vvq	104	23	be	be	VB
cord-354168-omen8vvq	104	24	very	very	RB
cord-354168-omen8vvq	104	25	challenging	challenging	JJ
cord-354168-omen8vvq	104	26	.	.	.
cord-354168-omen8vvq	105	1	We	-PRON-	PRP
cord-354168-omen8vvq	105	2	believe	believe	VBP
cord-354168-omen8vvq	105	3	these	these	DT
cord-354168-omen8vvq	105	4	patients	patient	NNS
cord-354168-omen8vvq	105	5	have	have	VBP
cord-354168-omen8vvq	105	6	a	a	DT
cord-354168-omen8vvq	105	7	greater	great	JJR
cord-354168-omen8vvq	105	8	risk	risk	NN
cord-354168-omen8vvq	105	9	of	of	IN
cord-354168-omen8vvq	105	10	morbidity	morbidity	NN
cord-354168-omen8vvq	105	11	from	from	IN
cord-354168-omen8vvq	105	12	myeloma	myeloma	NN
cord-354168-omen8vvq	105	13	than	than	IN
cord-354168-omen8vvq	105	14	COVID-19	covid-19	JJ
cord-354168-omen8vvq	105	15	infection	infection	NN
cord-354168-omen8vvq	105	16	justifying	justify	VBG
cord-354168-omen8vvq	105	17	weekly	weekly	JJ
cord-354168-omen8vvq	105	18	clinic	clinic	NN
cord-354168-omen8vvq	105	19	visits	visit	NNS
cord-354168-omen8vvq	105	20	for	for	IN
cord-354168-omen8vvq	105	21	therapy	therapy	NN
cord-354168-omen8vvq	105	22	,	,	,
cord-354168-omen8vvq	105	23	while	while	IN
cord-354168-omen8vvq	105	24	in	in	IN
cord-354168-omen8vvq	105	25	standard	standard	JJ
cord-354168-omen8vvq	105	26	-	-	HYPH
cord-354168-omen8vvq	105	27	risk	risk	NN
cord-354168-omen8vvq	105	28	patients	patient	NNS
cord-354168-omen8vvq	105	29	an	an	DT
cord-354168-omen8vvq	105	30	all	all	DT
cord-354168-omen8vvq	105	31	oral	oral	JJ
cord-354168-omen8vvq	105	32	regimen	regimen	NN
cord-354168-omen8vvq	105	33	allows	allow	VBZ
cord-354168-omen8vvq	105	34	for	for	IN
cord-354168-omen8vvq	105	35	therapy	therapy	NN
cord-354168-omen8vvq	105	36	visits	visit	NNS
cord-354168-omen8vvq	105	37	every	every	DT
cord-354168-omen8vvq	105	38	4	4	CD
cord-354168-omen8vvq	105	39	weeks	week	NNS
cord-354168-omen8vvq	105	40	.	.	.
cord-354168-omen8vvq	106	1	For	for	IN
cord-354168-omen8vvq	106	2	high	high	JJ
cord-354168-omen8vvq	106	3	-	-	HYPH
cord-354168-omen8vvq	106	4	risk	risk	NN
cord-354168-omen8vvq	106	5	patients	patient	NNS
cord-354168-omen8vvq	106	6	,	,	,
cord-354168-omen8vvq	106	7	we	-PRON-	PRP
cord-354168-omen8vvq	106	8	would	would	MD
cord-354168-omen8vvq	106	9	recommend	recommend	VB
cord-354168-omen8vvq	106	10	carfilzomib	carfilzomib	NNP
cord-354168-omen8vvq	106	11	,	,	,
cord-354168-omen8vvq	106	12	lenalidomide	lenalidomide	NN
cord-354168-omen8vvq	106	13	,	,	,
cord-354168-omen8vvq	106	14	and	and	CC
cord-354168-omen8vvq	106	15	dexamethasone	dexamethasone	NN
cord-354168-omen8vvq	106	16	(	(	-LRB-
cord-354168-omen8vvq	106	17	KRd	KRd	NNS
cord-354168-omen8vvq	106	18	)	)	-RRB-
cord-354168-omen8vvq	106	19	given	give	VBN
cord-354168-omen8vvq	106	20	over	over	IN
cord-354168-omen8vvq	106	21	28	28	CD
cord-354168-omen8vvq	106	22	days	day	NNS
cord-354168-omen8vvq	106	23	for	for	IN
cord-354168-omen8vvq	106	24	each	each	DT
cord-354168-omen8vvq	106	25	cycle	cycle	NN
cord-354168-omen8vvq	106	26	.	.	.
cord-354168-omen8vvq	107	1	We	-PRON-	PRP
cord-354168-omen8vvq	107	2	do	do	VBP
cord-354168-omen8vvq	107	3	not	not	RB
cord-354168-omen8vvq	107	4	believe	believe	VB
cord-354168-omen8vvq	107	5	there	there	EX
cord-354168-omen8vvq	107	6	is	be	VBZ
cord-354168-omen8vvq	107	7	a	a	DT
cord-354168-omen8vvq	107	8	high	high	JJ
cord-354168-omen8vvq	107	9	risk	risk	NN
cord-354168-omen8vvq	107	10	for	for	IN
cord-354168-omen8vvq	107	11	tumor	tumor	NN
cord-354168-omen8vvq	107	12	lysis	lysis	NN
cord-354168-omen8vvq	107	13	syndrome	syndrome	NN
cord-354168-omen8vvq	107	14	with	with	IN
cord-354168-omen8vvq	107	15	MM	MM	NNP
cord-354168-omen8vvq	108	1	and	and	CC
cord-354168-omen8vvq	108	2	we	-PRON-	PRP
cord-354168-omen8vvq	108	3	would	would	MD
cord-354168-omen8vvq	108	4	recommend	recommend	VB
cord-354168-omen8vvq	108	5	starting	start	VBG
cord-354168-omen8vvq	108	6	therapy	therapy	NN
cord-354168-omen8vvq	108	7	for	for	IN
cord-354168-omen8vvq	108	8	the	the	DT
cord-354168-omen8vvq	108	9	first	first	JJ
cord-354168-omen8vvq	108	10	cycle	cycle	NN
cord-354168-omen8vvq	108	11	with	with	IN
cord-354168-omen8vvq	108	12	once	once	RB
cord-354168-omen8vvq	108	13	-	-	HYPH
cord-354168-omen8vvq	108	14	weekly	weekly	NN
cord-354168-omen8vvq	108	15	dosing	dosing	NN
cord-354168-omen8vvq	108	16	,	,	,
cord-354168-omen8vvq	108	17	rather	rather	RB
cord-354168-omen8vvq	108	18	than	than	IN
cord-354168-omen8vvq	108	19	doing	do	VBG
cord-354168-omen8vvq	108	20	day	day	NN
cord-354168-omen8vvq	108	21	1	1	CD
cord-354168-omen8vvq	108	22	and	and	CC
cord-354168-omen8vvq	108	23	day	day	NN
cord-354168-omen8vvq	108	24	2	2	CD
cord-354168-omen8vvq	108	25	infusions	infusion	NNS
cord-354168-omen8vvq	108	26	.	.	.
cord-354168-omen8vvq	109	1	If	if	IN
cord-354168-omen8vvq	109	2	the	the	DT
cord-354168-omen8vvq	109	3	patient	patient	NN
cord-354168-omen8vvq	109	4	has	have	VBZ
cord-354168-omen8vvq	109	5	good	good	JJ
cord-354168-omen8vvq	109	6	bone	bone	NN
cord-354168-omen8vvq	109	7	marrow	marrow	NN
cord-354168-omen8vvq	109	8	reserve	reserve	NN
cord-354168-omen8vvq	109	9	,	,	,
cord-354168-omen8vvq	109	10	we	-PRON-	PRP
cord-354168-omen8vvq	109	11	would	would	MD
cord-354168-omen8vvq	109	12	recommend	recommend	VB
cord-354168-omen8vvq	109	13	carfilzomib	carfilzomib	NNP
cord-354168-omen8vvq	109	14	at	at	IN
cord-354168-omen8vvq	109	15	70	70	CD
cord-354168-omen8vvq	109	16	mg/	mg/	NN
cord-354168-omen8vvq	109	17	For	for	IN
cord-354168-omen8vvq	109	18	Pneumocystis	Pneumocystis	NNP
cord-354168-omen8vvq	109	19	jirovecii	jirovecii	NNP
cord-354168-omen8vvq	109	20	prophylaxis	prophylaxis	NN
cord-354168-omen8vvq	109	21	,	,	,
cord-354168-omen8vvq	109	22	we	-PRON-	PRP
cord-354168-omen8vvq	109	23	would	would	MD
cord-354168-omen8vvq	109	24	recommend	recommend	VB
cord-354168-omen8vvq	109	25	using	use	VBG
cord-354168-omen8vvq	109	26	single	single	JJ
cord-354168-omen8vvq	109	27	-	-	HYPH
cord-354168-omen8vvq	109	28	strength	strength	NN
cord-354168-omen8vvq	109	29	trimethoprim	trimethoprim	NNP
cord-354168-omen8vvq	109	30	-	-	HYPH
cord-354168-omen8vvq	109	31	sulfamethoxazole	sulfamethoxazole	NNP
cord-354168-omen8vvq	109	32	given	give	VBN
cord-354168-omen8vvq	109	33	daily	daily	JJ
cord-354168-omen8vvq	109	34	or	or	CC
cord-354168-omen8vvq	109	35	double	double	JJ
cord-354168-omen8vvq	109	36	strength	strength	NN
cord-354168-omen8vvq	109	37	given	give	VBN
cord-354168-omen8vvq	109	38	on	on	IN
cord-354168-omen8vvq	109	39	Monday	Monday	NNP
cord-354168-omen8vvq	109	40	,	,	,
cord-354168-omen8vvq	109	41	Wednesday	Wednesday	NNP
cord-354168-omen8vvq	109	42	,	,	,
cord-354168-omen8vvq	109	43	and	and	CC
cord-354168-omen8vvq	109	44	Friday	Friday	NNP
cord-354168-omen8vvq	109	45	.	.	.
cord-354168-omen8vvq	110	1	If	if	IN
cord-354168-omen8vvq	110	2	the	the	DT
cord-354168-omen8vvq	110	3	patient	patient	NN
cord-354168-omen8vvq	110	4	can	can	MD
cord-354168-omen8vvq	110	5	not	not	RB
cord-354168-omen8vvq	110	6	safely	safely	RB
cord-354168-omen8vvq	110	7	receive	receive	VB
cord-354168-omen8vvq	110	8	sulfa	sulfa	NN
cord-354168-omen8vvq	110	9	,	,	,
cord-354168-omen8vvq	110	10	we	-PRON-	PRP
cord-354168-omen8vvq	110	11	would	would	MD
cord-354168-omen8vvq	110	12	recommend	recommend	VB
cord-354168-omen8vvq	110	13	using	use	VBG
cord-354168-omen8vvq	110	14	prophylaxis	prophylaxis	NN
cord-354168-omen8vvq	110	15	other	other	JJ
cord-354168-omen8vvq	110	16	than	than	IN
cord-354168-omen8vvq	110	17	pentamidine	pentamidine	NNP
cord-354168-omen8vvq	110	18	,	,	,
cord-354168-omen8vvq	110	19	as	as	IN
cord-354168-omen8vvq	110	20	its	-PRON-	PRP$
cord-354168-omen8vvq	110	21	administration	administration	NN
cord-354168-omen8vvq	110	22	requires	require	VBZ
cord-354168-omen8vvq	110	23	a	a	DT
cord-354168-omen8vvq	110	24	clinic	clinic	NN
cord-354168-omen8vvq	110	25	visit	visit	NN
cord-354168-omen8vvq	110	26	and	and	CC
cord-354168-omen8vvq	110	27	the	the	DT
cord-354168-omen8vvq	110	28	fact	fact	NN
cord-354168-omen8vvq	110	29	that	that	IN
cord-354168-omen8vvq	110	30	it	-PRON-	PRP
cord-354168-omen8vvq	110	31	is	be	VBZ
cord-354168-omen8vvq	110	32	an	an	DT
cord-354168-omen8vvq	110	33	aerosolized	aerosolize	VBN
cord-354168-omen8vvq	110	34	therapy	therapy	NN
cord-354168-omen8vvq	110	35	could	could	MD
cord-354168-omen8vvq	110	36	be	be	VB
cord-354168-omen8vvq	110	37	a	a	DT
cord-354168-omen8vvq	110	38	concern	concern	NN
cord-354168-omen8vvq	110	39	with	with	IN
cord-354168-omen8vvq	110	40	the	the	DT
cord-354168-omen8vvq	110	41	current	current	JJ
cord-354168-omen8vvq	110	42	COVID-19	COVID-19	NNP
cord-354168-omen8vvq	110	43	pandemic	pandemic	NN
cord-354168-omen8vvq	110	44	.	.	.
cord-354168-omen8vvq	111	1	For	for	IN
cord-354168-omen8vvq	111	2	bone	bone	NN
cord-354168-omen8vvq	111	3	disease	disease	NN
cord-354168-omen8vvq	111	4	prophylaxis	prophylaxis	NN
cord-354168-omen8vvq	111	5	,	,	,
cord-354168-omen8vvq	111	6	we	-PRON-	PRP
cord-354168-omen8vvq	111	7	believe	believe	VBP
cord-354168-omen8vvq	111	8	that	that	IN
cord-354168-omen8vvq	111	9	it	-PRON-	PRP
cord-354168-omen8vvq	111	10	can	can	MD
cord-354168-omen8vvq	111	11	be	be	VB
cord-354168-omen8vvq	111	12	delayed	delay	VBN
cord-354168-omen8vvq	111	13	,	,	,
cord-354168-omen8vvq	111	14	especially	especially	RB
cord-354168-omen8vvq	111	15	in	in	IN
cord-354168-omen8vvq	111	16	patients	patient	NNS
cord-354168-omen8vvq	111	17	without	without	IN
cord-354168-omen8vvq	111	18	active	active	JJ
cord-354168-omen8vvq	111	19	bone	bone	NN
cord-354168-omen8vvq	111	20	disease	disease	NN
cord-354168-omen8vvq	111	21	.	.	.
cord-354168-omen8vvq	112	1	If	if	IN
cord-354168-omen8vvq	112	2	a	a	DT
cord-354168-omen8vvq	112	3	patient	patient	NN
cord-354168-omen8vvq	112	4	has	have	VBZ
cord-354168-omen8vvq	112	5	diffuse	diffuse	JJ
cord-354168-omen8vvq	112	6	bone	bone	NN
cord-354168-omen8vvq	112	7	disease	disease	NN
cord-354168-omen8vvq	112	8	or	or	CC
cord-354168-omen8vvq	112	9	has	have	VBZ
cord-354168-omen8vvq	112	10	hypercalcemia	hypercalcemia	NN
cord-354168-omen8vvq	112	11	,	,	,
cord-354168-omen8vvq	112	12	then	then	RB
cord-354168-omen8vvq	112	13	we	-PRON-	PRP
cord-354168-omen8vvq	112	14	would	would	MD
cord-354168-omen8vvq	112	15	recommend	recommend	VB
cord-354168-omen8vvq	112	16	using	use	VBG
cord-354168-omen8vvq	112	17	zoledronic	zoledronic	NNP
cord-354168-omen8vvq	112	18	acid	acid	NN
cord-354168-omen8vvq	112	19	.	.	.
cord-354168-omen8vvq	113	1	For	for	IN
cord-354168-omen8vvq	113	2	bone	bone	NN
cord-354168-omen8vvq	113	3	prophylaxis	prophylaxis	NN
cord-354168-omen8vvq	113	4	,	,	,
cord-354168-omen8vvq	113	5	this	this	DT
cord-354168-omen8vvq	113	6	can	can	MD
cord-354168-omen8vvq	113	7	be	be	VB
cord-354168-omen8vvq	113	8	given	give	VBN
cord-354168-omen8vvq	113	9	every	every	DT
cord-354168-omen8vvq	113	10	3	3	CD
cord-354168-omen8vvq	113	11	months	month	NNS
cord-354168-omen8vvq	113	12	,	,	,
cord-354168-omen8vvq	113	13	rather	rather	RB
cord-354168-omen8vvq	113	14	than	than	IN
cord-354168-omen8vvq	113	15	monthly	monthly	JJ
cord-354168-omen8vvq	113	16	.	.	.
cord-354168-omen8vvq	114	1	Patients	patient	NNS
cord-354168-omen8vvq	114	2	should	should	MD
cord-354168-omen8vvq	114	3	be	be	VB
cord-354168-omen8vvq	114	4	advised	advise	VBN
cord-354168-omen8vvq	114	5	to	to	TO
cord-354168-omen8vvq	114	6	take	take	VB
cord-354168-omen8vvq	114	7	calcium	calcium	NN
cord-354168-omen8vvq	114	8	and	and	CC
cord-354168-omen8vvq	114	9	vitamin	vitamin	NN
cord-354168-omen8vvq	114	10	D.	D.	NNP
cord-354168-omen8vvq	115	1	We	-PRON-	PRP
cord-354168-omen8vvq	115	2	do	do	VBP
cord-354168-omen8vvq	115	3	not	not	RB
cord-354168-omen8vvq	115	4	recommend	recommend	VB
cord-354168-omen8vvq	115	5	using	use	VBG
cord-354168-omen8vvq	115	6	growth	growth	NN
cord-354168-omen8vvq	115	7	factors	factor	NNS
cord-354168-omen8vvq	115	8	.	.	.
cord-354168-omen8vvq	116	1	If	if	IN
cord-354168-omen8vvq	116	2	a	a	DT
cord-354168-omen8vvq	116	3	patient	patient	NN
cord-354168-omen8vvq	116	4	requires	require	VBZ
cord-354168-omen8vvq	116	5	it	-PRON-	PRP
cord-354168-omen8vvq	116	6	,	,	,
cord-354168-omen8vvq	116	7	we	-PRON-	PRP
cord-354168-omen8vvq	116	8	would	would	MD
cord-354168-omen8vvq	116	9	recommend	recommend	VB
cord-354168-omen8vvq	116	10	using	use	VBG
cord-354168-omen8vvq	116	11	pegfilgrastim	pegfilgrastim	NNP
cord-354168-omen8vvq	116	12	,	,	,
cord-354168-omen8vvq	116	13	if	if	IN
cord-354168-omen8vvq	116	14	possible	possible	JJ
cord-354168-omen8vvq	116	15	.	.	.
cord-354168-omen8vvq	117	1	We	-PRON-	PRP
cord-354168-omen8vvq	117	2	would	would	MD
cord-354168-omen8vvq	117	3	recommend	recommend	VB
cord-354168-omen8vvq	117	4	decreasing	decrease	VBG
cord-354168-omen8vvq	117	5	the	the	DT
cord-354168-omen8vvq	117	6	frequency	frequency	NN
cord-354168-omen8vvq	117	7	of	of	IN
cord-354168-omen8vvq	117	8	blood	blood	NN
cord-354168-omen8vvq	117	9	work	work	NN
cord-354168-omen8vvq	117	10	during	during	IN
cord-354168-omen8vvq	117	11	each	each	DT
cord-354168-omen8vvq	117	12	cycle	cycle	NN
cord-354168-omen8vvq	117	13	as	as	RB
cord-354168-omen8vvq	117	14	much	much	RB
cord-354168-omen8vvq	117	15	as	as	IN
cord-354168-omen8vvq	117	16	possible	possible	JJ
cord-354168-omen8vvq	117	17	.	.	.
cord-354168-omen8vvq	118	1	If	if	IN
cord-354168-omen8vvq	118	2	the	the	DT
cord-354168-omen8vvq	118	3	patient	patient	NN
cord-354168-omen8vvq	118	4	has	have	VBZ
cord-354168-omen8vvq	118	5	good	good	JJ
cord-354168-omen8vvq	118	6	bone	bone	NN
cord-354168-omen8vvq	118	7	marrow	marrow	NN
cord-354168-omen8vvq	118	8	reserve	reserve	NN
cord-354168-omen8vvq	118	9	,	,	,
cord-354168-omen8vvq	118	10	blood	blood	NN
cord-354168-omen8vvq	118	11	work	work	NN
cord-354168-omen8vvq	118	12	can	can	MD
cord-354168-omen8vvq	118	13	be	be	VB
cord-354168-omen8vvq	118	14	done	do	VBN
cord-354168-omen8vvq	118	15	after	after	IN
cord-354168-omen8vvq	118	16	finishing	finish	VBG
cord-354168-omen8vvq	118	17	the	the	DT
cord-354168-omen8vvq	118	18	cycle	cycle	NN
cord-354168-omen8vvq	118	19	(	(	-LRB-
cord-354168-omen8vvq	118	20	before	before	IN
cord-354168-omen8vvq	118	21	starting	start	VBG
cord-354168-omen8vvq	118	22	the	the	DT
cord-354168-omen8vvq	118	23	next	next	JJ
cord-354168-omen8vvq	118	24	cycle	cycle	NN
cord-354168-omen8vvq	118	25	)	)	-RRB-
cord-354168-omen8vvq	118	26	,	,	,
cord-354168-omen8vvq	118	27	rather	rather	RB
cord-354168-omen8vvq	118	28	than	than	IN
cord-354168-omen8vvq	118	29	checking	check	VBG
cord-354168-omen8vvq	118	30	counts	count	NNS
cord-354168-omen8vvq	118	31	routinely	routinely	RB
cord-354168-omen8vvq	118	32	every	every	DT
cord-354168-omen8vvq	118	33	week	week	NN
cord-354168-omen8vvq	118	34	during	during	IN
cord-354168-omen8vvq	118	35	the	the	DT
cord-354168-omen8vvq	118	36	first	first	JJ
cord-354168-omen8vvq	118	37	cycle	cycle	NN
cord-354168-omen8vvq	118	38	.	.	.
cord-354168-omen8vvq	119	1	We	-PRON-	PRP
cord-354168-omen8vvq	119	2	also	also	RB
cord-354168-omen8vvq	119	3	recommend	recommend	VBP
cord-354168-omen8vvq	119	4	followup	followup	JJ
cord-354168-omen8vvq	119	5	using	use	VBG
cord-354168-omen8vvq	119	6	telehealth	telehealth	NN
cord-354168-omen8vvq	119	7	technologies	technology	NNS
cord-354168-omen8vvq	119	8	(	(	-LRB-
cord-354168-omen8vvq	119	9	telephone	telephone	NN
cord-354168-omen8vvq	119	10	calls	call	NNS
cord-354168-omen8vvq	119	11	,	,	,
cord-354168-omen8vvq	119	12	video	video	NN
cord-354168-omen8vvq	119	13	,	,	,
cord-354168-omen8vvq	119	14	etc	etc	FW
cord-354168-omen8vvq	119	15	.	.	.
cord-354168-omen8vvq	119	16	)	)	-RRB-
cord-354168-omen8vvq	119	17	.	.	.
cord-354168-omen8vvq	120	1	Drug	drug	NN
cord-354168-omen8vvq	120	2	companies	company	NNS
cord-354168-omen8vvq	120	3	have	have	VBP
cord-354168-omen8vvq	120	4	extended	extend	VBN
cord-354168-omen8vvq	120	5	the	the	DT
cord-354168-omen8vvq	120	6	supply	supply	NN
cord-354168-omen8vvq	120	7	of	of	IN
cord-354168-omen8vvq	120	8	lenalidomide	lenalidomide	NN
cord-354168-omen8vvq	120	9	and	and	CC
cord-354168-omen8vvq	120	10	pomalidomide	pomalidomide	NN
cord-354168-omen8vvq	120	11	to	to	IN
cord-354168-omen8vvq	120	12	8	8	CD
cord-354168-omen8vvq	120	13	weeks	week	NNS
cord-354168-omen8vvq	120	14	with	with	IN
cord-354168-omen8vvq	120	15	drugs	drug	NNS
cord-354168-omen8vvq	120	16	being	be	VBG
cord-354168-omen8vvq	120	17	shipped	ship	VBN
cord-354168-omen8vvq	120	18	home	home	RB
cord-354168-omen8vvq	120	19	,	,	,
cord-354168-omen8vvq	120	20	rather	rather	RB
cord-354168-omen8vvq	120	21	than	than	IN
cord-354168-omen8vvq	120	22	requiring	require	VBG
cord-354168-omen8vvq	120	23	a	a	DT
cord-354168-omen8vvq	120	24	visit	visit	NN
cord-354168-omen8vvq	120	25	to	to	IN
cord-354168-omen8vvq	120	26	a	a	DT
cord-354168-omen8vvq	120	27	specialized	specialized	JJ
cord-354168-omen8vvq	120	28	pharmacy	pharmacy	NN
cord-354168-omen8vvq	120	29	.	.	.
cord-354168-omen8vvq	121	1	This	this	DT
cord-354168-omen8vvq	121	2	will	will	MD
cord-354168-omen8vvq	121	3	help	help	VB
cord-354168-omen8vvq	121	4	reduce	reduce	VB
cord-354168-omen8vvq	121	5	potential	potential	JJ
cord-354168-omen8vvq	121	6	exposure	exposure	NN
cord-354168-omen8vvq	121	7	to	to	IN
cord-354168-omen8vvq	121	8	COVID-19	COVID-19	NNP
cord-354168-omen8vvq	121	9	.	.	.
cord-354168-omen8vvq	122	1	Autologous	autologous	JJ
cord-354168-omen8vvq	122	2	stem	stem	NN
cord-354168-omen8vvq	122	3	cell	cell	NN
cord-354168-omen8vvq	122	4	transplant	transplant	NN
cord-354168-omen8vvq	122	5	(	(	-LRB-
cord-354168-omen8vvq	122	6	ASCT	ASCT	NNP
cord-354168-omen8vvq	122	7	)	)	-RRB-
cord-354168-omen8vvq	122	8	clearly	clearly	RB
cord-354168-omen8vvq	122	9	improves	improve	VBZ
cord-354168-omen8vvq	122	10	outcomes	outcome	NNS
cord-354168-omen8vvq	122	11	in	in	IN
cord-354168-omen8vvq	122	12	newly	newly	RB
cord-354168-omen8vvq	122	13	diagnosed	diagnose	VBN
cord-354168-omen8vvq	122	14	MM	MM	NNP
cord-354168-omen8vvq	122	15	patients	patient	NNS
cord-354168-omen8vvq	122	16	.	.	.
cord-354168-omen8vvq	123	1	However	however	RB
cord-354168-omen8vvq	123	2	,	,	,
cord-354168-omen8vvq	123	3	during	during	IN
cord-354168-omen8vvq	123	4	this	this	DT
cord-354168-omen8vvq	123	5	challenging	challenging	JJ
cord-354168-omen8vvq	123	6	time	time	NN
cord-354168-omen8vvq	123	7	,	,	,
cord-354168-omen8vvq	123	8	each	each	DT
cord-354168-omen8vvq	123	9	patient	patient	NN
cord-354168-omen8vvq	123	10	should	should	MD
cord-354168-omen8vvq	123	11	be	be	VB
cord-354168-omen8vvq	123	12	evaluated	evaluate	VBN
cord-354168-omen8vvq	123	13	individually	individually	RB
cord-354168-omen8vvq	123	14	.	.	.
cord-354168-omen8vvq	124	1	Multiple	multiple	JJ
cord-354168-omen8vvq	124	2	trials	trial	NNS
cord-354168-omen8vvq	124	3	have	have	VBP
cord-354168-omen8vvq	124	4	evaluated	evaluate	VBN
cord-354168-omen8vvq	124	5	upfront	upfront	NN
cord-354168-omen8vvq	124	6	versus	versus	IN
cord-354168-omen8vvq	124	7	delayed	delay	VBN
cord-354168-omen8vvq	124	8	ASCT	ASCT	NNP
cord-354168-omen8vvq	124	9	and	and	CC
cord-354168-omen8vvq	124	10	overall	overall	JJ
cord-354168-omen8vvq	124	11	,	,	,
cord-354168-omen8vvq	124	12	upfront	upfront	JJ
cord-354168-omen8vvq	124	13	ASCT	ASCT	NNP
cord-354168-omen8vvq	124	14	improves	improve	VBZ
cord-354168-omen8vvq	124	15	PFS	PFS	NNP
cord-354168-omen8vvq	124	16	,	,	,
cord-354168-omen8vvq	124	17	but	but	CC
cord-354168-omen8vvq	124	18	not	not	RB
cord-354168-omen8vvq	124	19	OS	OS	NNP
cord-354168-omen8vvq	124	20	[	[	-LRB-
cord-354168-omen8vvq	124	21	27	27	CD
cord-354168-omen8vvq	124	22	]	]	-RRB-
cord-354168-omen8vvq	124	23	[	[	-LRB-
cord-354168-omen8vvq	124	24	28	28	CD
cord-354168-omen8vvq	124	25	]	]	-RRB-
cord-354168-omen8vvq	124	26	[	[	-LRB-
cord-354168-omen8vvq	124	27	29	29	CD
cord-354168-omen8vvq	124	28	]	]	-RRB-
cord-354168-omen8vvq	124	29	[	[	-LRB-
cord-354168-omen8vvq	124	30	30	30	CD
cord-354168-omen8vvq	124	31	]	]	-RRB-
cord-354168-omen8vvq	124	32	[	[	-LRB-
cord-354168-omen8vvq	124	33	31	31	CD
cord-354168-omen8vvq	124	34	]	]	-RRB-
cord-354168-omen8vvq	124	35	.	.	.
cord-354168-omen8vvq	125	1	The	the	DT
cord-354168-omen8vvq	125	2	two	two	CD
cord-354168-omen8vvq	125	3	main	main	JJ
cord-354168-omen8vvq	125	4	concerns	concern	NNS
cord-354168-omen8vvq	125	5	with	with	IN
cord-354168-omen8vvq	125	6	the	the	DT
cord-354168-omen8vvq	125	7	current	current	JJ
cord-354168-omen8vvq	125	8	COVID-19	COVID-19	NNP
cord-354168-omen8vvq	125	9	pandemic	pandemic	NN
cord-354168-omen8vvq	125	10	is	be	VBZ
cord-354168-omen8vvq	125	11	that	that	IN
cord-354168-omen8vvq	125	12	patients	patient	NNS
cord-354168-omen8vvq	125	13	need	need	VBP
cord-354168-omen8vvq	125	14	their	-PRON-	PRP$
cord-354168-omen8vvq	125	15	stem	stem	NN
cord-354168-omen8vvq	125	16	cells	cell	NNS
cord-354168-omen8vvq	125	17	collected	collect	VBN
cord-354168-omen8vvq	125	18	and	and	CC
cord-354168-omen8vvq	125	19	some	some	DT
cord-354168-omen8vvq	125	20	patients	patient	NNS
cord-354168-omen8vvq	125	21	require	require	VBP
cord-354168-omen8vvq	125	22	more	more	JJR
cord-354168-omen8vvq	125	23	than	than	IN
cord-354168-omen8vvq	125	24	one	one	CD
cord-354168-omen8vvq	125	25	apheresis	apheresis	NN
cord-354168-omen8vvq	125	26	.	.	.
cord-354168-omen8vvq	126	1	With	with	IN
cord-354168-omen8vvq	126	2	conditioning	conditioning	NN
cord-354168-omen8vvq	126	3	comes	come	VBZ
cord-354168-omen8vvq	126	4	the	the	DT
cord-354168-omen8vvq	126	5	increased	increase	VBN
cord-354168-omen8vvq	126	6	risk	risk	NN
cord-354168-omen8vvq	126	7	of	of	IN
cord-354168-omen8vvq	126	8	infection	infection	NN
cord-354168-omen8vvq	126	9	related	relate	VBN
cord-354168-omen8vvq	126	10	to	to	IN
cord-354168-omen8vvq	126	11	the	the	DT
cord-354168-omen8vvq	126	12	7	7	CD
cord-354168-omen8vvq	126	13	-	-	SYM
cord-354168-omen8vvq	126	14	9	9	CD
cord-354168-omen8vvq	126	15	days	day	NNS
cord-354168-omen8vvq	126	16	of	of	IN
cord-354168-omen8vvq	126	17	severe	severe	JJ
cord-354168-omen8vvq	126	18	neutropenia	neutropenia	NN
cord-354168-omen8vvq	126	19	.	.	.
cord-354168-omen8vvq	127	1	For	for	IN
cord-354168-omen8vvq	127	2	standard	standard	JJ
cord-354168-omen8vvq	127	3	-	-	HYPH
cord-354168-omen8vvq	127	4	risk	risk	NN
cord-354168-omen8vvq	127	5	patients	patient	NNS
cord-354168-omen8vvq	127	6	who	who	WP
cord-354168-omen8vvq	127	7	are	be	VBP
cord-354168-omen8vvq	127	8	responding	respond	VBG
cord-354168-omen8vvq	127	9	well	well	RB
cord-354168-omen8vvq	127	10	to	to	IN
cord-354168-omen8vvq	127	11	therapy	therapy	NN
cord-354168-omen8vvq	127	12	,	,	,
cord-354168-omen8vvq	127	13	we	-PRON-	PRP
cord-354168-omen8vvq	127	14	would	would	MD
cord-354168-omen8vvq	127	15	recommend	recommend	VB
cord-354168-omen8vvq	127	16	delaying	delay	VBG
cord-354168-omen8vvq	127	17	ASCT	ASCT	NNP
cord-354168-omen8vvq	127	18	until	until	IN
cord-354168-omen8vvq	127	19	the	the	DT
cord-354168-omen8vvq	127	20	current	current	JJ
cord-354168-omen8vvq	127	21	situation	situation	NN
cord-354168-omen8vvq	127	22	with	with	IN
cord-354168-omen8vvq	127	23	COVID-19	COVID-19	NNP
cord-354168-omen8vvq	127	24	improves	improve	NNS
cord-354168-omen8vvq	127	25	.	.	.
cord-354168-omen8vvq	128	1	Continued	continued	JJ
cord-354168-omen8vvq	128	2	induction	induction	NN
cord-354168-omen8vvq	128	3	therapy	therapy	NN
cord-354168-omen8vvq	128	4	can	can	MD
cord-354168-omen8vvq	128	5	safely	safely	RB
cord-354168-omen8vvq	128	6	be	be	VB
cord-354168-omen8vvq	128	7	used	use	VBN
cord-354168-omen8vvq	128	8	as	as	IN
cord-354168-omen8vvq	128	9	a	a	DT
cord-354168-omen8vvq	128	10	bridge	bridge	NN
cord-354168-omen8vvq	128	11	until	until	IN
cord-354168-omen8vvq	128	12	the	the	DT
cord-354168-omen8vvq	128	13	epidemic	epidemic	NN
cord-354168-omen8vvq	128	14	subsides	subside	VBZ
cord-354168-omen8vvq	128	15	[	[	-LRB-
cord-354168-omen8vvq	128	16	32	32	CD
cord-354168-omen8vvq	128	17	]	]	-RRB-
cord-354168-omen8vvq	128	18	.	.	.
cord-354168-omen8vvq	129	1	For	for	IN
cord-354168-omen8vvq	129	2	high	high	JJ
cord-354168-omen8vvq	129	3	-	-	HYPH
cord-354168-omen8vvq	129	4	risk	risk	NN
cord-354168-omen8vvq	129	5	patients	patient	NNS
cord-354168-omen8vvq	129	6	,	,	,
cord-354168-omen8vvq	129	7	if	if	IN
cord-354168-omen8vvq	129	8	they	-PRON-	PRP
cord-354168-omen8vvq	129	9	are	be	VBP
cord-354168-omen8vvq	129	10	responding	respond	VBG
cord-354168-omen8vvq	129	11	(	(	-LRB-
cord-354168-omen8vvq	129	12	at	at	IN
cord-354168-omen8vvq	129	13	least	least	JJS
cord-354168-omen8vvq	129	14	with	with	IN
cord-354168-omen8vvq	129	15	partial	partial	JJ
cord-354168-omen8vvq	129	16	response	response	NN
cord-354168-omen8vvq	129	17	)	)	-RRB-
cord-354168-omen8vvq	129	18	ASCT	ASCT	NNP
cord-354168-omen8vvq	129	19	can	can	MD
cord-354168-omen8vvq	129	20	be	be	VB
cord-354168-omen8vvq	129	21	delayed	delay	VBN
cord-354168-omen8vvq	129	22	.	.	.
cord-354168-omen8vvq	130	1	However	however	RB
cord-354168-omen8vvq	130	2	,	,	,
cord-354168-omen8vvq	130	3	patients	patient	NNS
cord-354168-omen8vvq	130	4	who	who	WP
cord-354168-omen8vvq	130	5	are	be	VBP
cord-354168-omen8vvq	130	6	not	not	RB
cord-354168-omen8vvq	130	7	responding	respond	VBG
cord-354168-omen8vvq	130	8	or	or	CC
cord-354168-omen8vvq	130	9	progressing	progress	VBG
cord-354168-omen8vvq	130	10	quickly	quickly	RB
cord-354168-omen8vvq	130	11	,	,	,
cord-354168-omen8vvq	130	12	ASCT	ASCT	NNP
cord-354168-omen8vvq	130	13	can	can	MD
cord-354168-omen8vvq	130	14	be	be	VB
cord-354168-omen8vvq	130	15	considered	consider	VBN
cord-354168-omen8vvq	130	16	as	as	IN
cord-354168-omen8vvq	130	17	salvage	salvage	NN
cord-354168-omen8vvq	130	18	therapy	therapy	NN
cord-354168-omen8vvq	130	19	.	.	.
cord-354168-omen8vvq	131	1	Testing	test	VBG
cord-354168-omen8vvq	131	2	for	for	IN
cord-354168-omen8vvq	131	3	COV	COV	NNP
cord-354168-omen8vvq	131	4	-	-	HYPH
cord-354168-omen8vvq	131	5	ID-19	ID-19	NNP
cord-354168-omen8vvq	131	6	should	should	MD
cord-354168-omen8vvq	131	7	be	be	VB
cord-354168-omen8vvq	131	8	done	do	VBN
cord-354168-omen8vvq	131	9	before	before	IN
cord-354168-omen8vvq	131	10	ASCT	ASCT	NNP
cord-354168-omen8vvq	131	11	.	.	.
cord-354168-omen8vvq	132	1	Balancing	balance	VBG
cord-354168-omen8vvq	132	2	the	the	DT
cord-354168-omen8vvq	132	3	risks	risk	NNS
cord-354168-omen8vvq	132	4	of	of	IN
cord-354168-omen8vvq	132	5	COVID-19	covid-19	JJ
cord-354168-omen8vvq	132	6	infection	infection	NN
cord-354168-omen8vvq	132	7	and	and	CC
cord-354168-omen8vvq	132	8	MM	mm	NN
cord-354168-omen8vvq	132	9	-	-	HYPH
cord-354168-omen8vvq	132	10	related	relate	VBN
cord-354168-omen8vvq	132	11	mortality	mortality	NN
cord-354168-omen8vvq	132	12	is	be	VBZ
cord-354168-omen8vvq	132	13	difficult	difficult	JJ
cord-354168-omen8vvq	132	14	.	.	.
cord-354168-omen8vvq	133	1	Consultation	consultation	NN
cord-354168-omen8vvq	133	2	with	with	IN
cord-354168-omen8vvq	133	3	a	a	DT
cord-354168-omen8vvq	133	4	MM	MM	NNP
cord-354168-omen8vvq	133	5	expert	expert	NN
cord-354168-omen8vvq	133	6	is	be	VBZ
cord-354168-omen8vvq	133	7	recommended	recommend	VBN
cord-354168-omen8vvq	133	8	.	.	.
cord-354168-omen8vvq	134	1	These	these	DT
cord-354168-omen8vvq	134	2	are	be	VBP
cord-354168-omen8vvq	134	3	the	the	DT
cord-354168-omen8vvq	134	4	most	most	RBS
cord-354168-omen8vvq	134	5	challenging	challenging	JJ
cord-354168-omen8vvq	134	6	patients	patient	NNS
cord-354168-omen8vvq	134	7	during	during	IN
cord-354168-omen8vvq	134	8	the	the	DT
cord-354168-omen8vvq	134	9	current	current	JJ
cord-354168-omen8vvq	134	10	pandemic	pandemic	NN
cord-354168-omen8vvq	134	11	.	.	.
cord-354168-omen8vvq	135	1	The	the	DT
cord-354168-omen8vvq	135	2	median	median	JJ
cord-354168-omen8vvq	135	3	OS	os	NN
cord-354168-omen8vvq	135	4	in	in	IN
cord-354168-omen8vvq	135	5	these	these	DT
cord-354168-omen8vvq	135	6	patients	patient	NNS
cord-354168-omen8vvq	135	7	is	be	VBZ
cord-354168-omen8vvq	135	8	less	less	JJR
cord-354168-omen8vvq	135	9	than	than	IN
cord-354168-omen8vvq	135	10	a	a	DT
cord-354168-omen8vvq	135	11	year	year	NN
cord-354168-omen8vvq	135	12	with	with	IN
cord-354168-omen8vvq	135	13	current	current	JJ
cord-354168-omen8vvq	135	14	treatment	treatment	NN
cord-354168-omen8vvq	135	15	approaches	approach	NNS
cord-354168-omen8vvq	135	16	[	[	-LRB-
cord-354168-omen8vvq	135	17	33	33	CD
cord-354168-omen8vvq	135	18	]	]	-RRB-
cord-354168-omen8vvq	135	19	.	.	.
cord-354168-omen8vvq	136	1	We	-PRON-	PRP
cord-354168-omen8vvq	136	2	believe	believe	VBP
cord-354168-omen8vvq	136	3	that	that	IN
cord-354168-omen8vvq	136	4	induction	induction	NN
cord-354168-omen8vvq	136	5	chemotherapy	chemotherapy	NN
cord-354168-omen8vvq	136	6	followed	follow	VBN
cord-354168-omen8vvq	136	7	by	by	IN
cord-354168-omen8vvq	136	8	ASCT	ASCT	NNP
cord-354168-omen8vvq	136	9	should	should	MD
cord-354168-omen8vvq	136	10	be	be	VB
cord-354168-omen8vvq	136	11	done	do	VBN
cord-354168-omen8vvq	136	12	for	for	IN
cord-354168-omen8vvq	136	13	these	these	DT
cord-354168-omen8vvq	136	14	patients	patient	NNS
cord-354168-omen8vvq	136	15	,	,	,
cord-354168-omen8vvq	136	16	as	as	IN
cord-354168-omen8vvq	136	17	the	the	DT
cord-354168-omen8vvq	136	18	risk	risk	NN
cord-354168-omen8vvq	136	19	of	of	IN
cord-354168-omen8vvq	136	20	progressive	progressive	JJ
cord-354168-omen8vvq	136	21	disease	disease	NN
cord-354168-omen8vvq	136	22	is	be	VBZ
cord-354168-omen8vvq	136	23	high	high	JJ
cord-354168-omen8vvq	136	24	.	.	.
cord-354168-omen8vvq	137	1	Testing	test	VBG
cord-354168-omen8vvq	137	2	for	for	IN
cord-354168-omen8vvq	137	3	COVID-19	COVID-19	NNP
cord-354168-omen8vvq	137	4	should	should	MD
cord-354168-omen8vvq	137	5	be	be	VB
cord-354168-omen8vvq	137	6	done	do	VBN
cord-354168-omen8vvq	137	7	before	before	IN
cord-354168-omen8vvq	137	8	ASCT	ASCT	NNP
cord-354168-omen8vvq	137	9	.	.	.
cord-354168-omen8vvq	138	1	There	there	EX
cord-354168-omen8vvq	138	2	are	be	VBP
cord-354168-omen8vvq	138	3	no	no	DT
cord-354168-omen8vvq	138	4	major	major	JJ
cord-354168-omen8vvq	138	5	concerns	concern	NNS
cord-354168-omen8vvq	138	6	for	for	IN
cord-354168-omen8vvq	138	7	collection	collection	NN
cord-354168-omen8vvq	138	8	,	,	,
cord-354168-omen8vvq	138	9	as	as	IN
cord-354168-omen8vvq	138	10	patients	patient	NNS
cord-354168-omen8vvq	138	11	receiving	receive	VBG
cord-354168-omen8vvq	138	12	IMiD	imid	NN
cord-354168-omen8vvq	138	13	-	-	HYPH
cord-354168-omen8vvq	138	14	based	base	VBN
cord-354168-omen8vvq	138	15	therapy	therapy	NN
cord-354168-omen8vvq	138	16	can	can	MD
cord-354168-omen8vvq	138	17	successfully	successfully	RB
cord-354168-omen8vvq	138	18	undergo	undergo	VB
cord-354168-omen8vvq	138	19	stem	stem	NN
cord-354168-omen8vvq	138	20	cell	cell	NN
cord-354168-omen8vvq	138	21	collection	collection	NN
cord-354168-omen8vvq	138	22	after	after	IN
cord-354168-omen8vvq	138	23	6	6	CD
cord-354168-omen8vvq	138	24	cycles	cycle	NNS
cord-354168-omen8vvq	138	25	[	[	-LRB-
cord-354168-omen8vvq	138	26	34	34	CD
cord-354168-omen8vvq	138	27	]	]	-RRB-
cord-354168-omen8vvq	138	28	using	use	VBG
cord-354168-omen8vvq	138	29	granulocyte	granulocyte	NN
cord-354168-omen8vvq	138	30	colony	colony	NN
cord-354168-omen8vvq	138	31	-	-	HYPH
cord-354168-omen8vvq	138	32	stimulating	stimulate	VBG
cord-354168-omen8vvq	138	33	factor	factor	NN
cord-354168-omen8vvq	138	34	(	(	-LRB-
cord-354168-omen8vvq	138	35	G	G	NNP
cord-354168-omen8vvq	138	36	-	-	HYPH
cord-354168-omen8vvq	138	37	CSF	CSF	NNP
cord-354168-omen8vvq	138	38	)	)	-RRB-
cord-354168-omen8vvq	138	39	.	.	.
cord-354168-omen8vvq	139	1	For	for	IN
cord-354168-omen8vvq	139	2	patients	patient	NNS
cord-354168-omen8vvq	139	3	who	who	WP
cord-354168-omen8vvq	139	4	fail	fail	VBP
cord-354168-omen8vvq	139	5	to	to	TO
cord-354168-omen8vvq	139	6	collect	collect	VB
cord-354168-omen8vvq	139	7	using	use	VBG
cord-354168-omen8vvq	139	8	G	G	NNP
cord-354168-omen8vvq	139	9	-	-	HYPH
cord-354168-omen8vvq	139	10	CSF	CSF	NNP
cord-354168-omen8vvq	139	11	,	,	,
cord-354168-omen8vvq	139	12	plerixafor	plerixafor	NN
cord-354168-omen8vvq	139	13	can	can	MD
cord-354168-omen8vvq	139	14	be	be	VB
cord-354168-omen8vvq	139	15	used	use	VBN
cord-354168-omen8vvq	139	16	.	.	.
cord-354168-omen8vvq	140	1	Delaying	delay	VBG
cord-354168-omen8vvq	140	2	stem	stem	NN
cord-354168-omen8vvq	140	3	cell	cell	NN
cord-354168-omen8vvq	140	4	collection	collection	NN
cord-354168-omen8vvq	140	5	is	be	VBZ
cord-354168-omen8vvq	140	6	wise	wise	JJ
cord-354168-omen8vvq	140	7	,	,	,
cord-354168-omen8vvq	140	8	especially	especially	RB
cord-354168-omen8vvq	140	9	in	in	IN
cord-354168-omen8vvq	140	10	patients	patient	NNS
cord-354168-omen8vvq	140	11	who	who	WP
cord-354168-omen8vvq	140	12	had	have	VBD
cord-354168-omen8vvq	140	13	a	a	DT
cord-354168-omen8vvq	140	14	recent	recent	JJ
cord-354168-omen8vvq	140	15	COVID-19	covid-19	CD
cord-354168-omen8vvq	140	16	infection	infection	NN
cord-354168-omen8vvq	140	17	.	.	.
cord-354168-omen8vvq	141	1	Hyperimmunity	Hyperimmunity	NNP
cord-354168-omen8vvq	141	2	with	with	IN
cord-354168-omen8vvq	141	3	cytokine	cytokine	NN
cord-354168-omen8vvq	141	4	storms	storm	NNS
cord-354168-omen8vvq	141	5	and	and	CC
cord-354168-omen8vvq	141	6	acute	acute	JJ
cord-354168-omen8vvq	141	7	respiratory	respiratory	JJ
cord-354168-omen8vvq	141	8	distress	distress	NN
cord-354168-omen8vvq	141	9	syndrome	syndrome	NN
cord-354168-omen8vvq	141	10	from	from	IN
cord-354168-omen8vvq	141	11	the	the	DT
cord-354168-omen8vvq	141	12	infection	infection	NN
cord-354168-omen8vvq	141	13	has	have	VBZ
cord-354168-omen8vvq	141	14	been	be	VBN
cord-354168-omen8vvq	141	15	described	describe	VBN
cord-354168-omen8vvq	141	16	[	[	-LRB-
cord-354168-omen8vvq	141	17	35	35	CD
cord-354168-omen8vvq	141	18	,	,	,
cord-354168-omen8vvq	141	19	36	36	CD
cord-354168-omen8vvq	141	20	]	]	-RRB-
cord-354168-omen8vvq	141	21	.	.	.
cord-354168-omen8vvq	142	1	In	in	IN
cord-354168-omen8vvq	142	2	theory	theory	NN
cord-354168-omen8vvq	142	3	G	G	NNP
cord-354168-omen8vvq	142	4	-	-	HYPH
cord-354168-omen8vvq	142	5	CSF	CSF	NNP
cord-354168-omen8vvq	142	6	can	can	MD
cord-354168-omen8vvq	142	7	reinitiate	reinitiate	VB
cord-354168-omen8vvq	142	8	the	the	DT
cord-354168-omen8vvq	142	9	immune	immune	JJ
cord-354168-omen8vvq	142	10	stimulus	stimulus	NN
cord-354168-omen8vvq	142	11	leading	lead	VBG
cord-354168-omen8vvq	142	12	to	to	IN
cord-354168-omen8vvq	142	13	complications	complication	NNS
cord-354168-omen8vvq	142	14	.	.	.
cord-354168-omen8vvq	143	1	Acta	Acta	NNP
cord-354168-omen8vvq	143	2	Haematol	Haematol	NNP
cord-354168-omen8vvq	143	3	DOI	DOI	NNP
cord-354168-omen8vvq	143	4	:	:	:
cord-354168-omen8vvq	143	5	10.1159/000507690	10.1159/000507690	CD
cord-354168-omen8vvq	144	1	In	in	IN
cord-354168-omen8vvq	144	2	general	general	JJ
cord-354168-omen8vvq	144	3	,	,	,
cord-354168-omen8vvq	144	4	we	-PRON-	PRP
cord-354168-omen8vvq	144	5	would	would	MD
cord-354168-omen8vvq	144	6	recommend	recommend	VB
cord-354168-omen8vvq	144	7	continuing	continue	VBG
cord-354168-omen8vvq	144	8	with	with	IN
cord-354168-omen8vvq	144	9	treatment	treatment	NN
cord-354168-omen8vvq	144	10	until	until	IN
cord-354168-omen8vvq	144	11	the	the	DT
cord-354168-omen8vvq	144	12	current	current	JJ
cord-354168-omen8vvq	144	13	epidemic	epidemic	NN
cord-354168-omen8vvq	144	14	with	with	IN
cord-354168-omen8vvq	144	15	COVID-19	COVID-19	NNP
cord-354168-omen8vvq	144	16	improves	improve	NNS
cord-354168-omen8vvq	144	17	and	and	CC
cord-354168-omen8vvq	144	18	ASCT	ASCT	NNP
cord-354168-omen8vvq	144	19	is	be	VBZ
cord-354168-omen8vvq	144	20	safer	safe	JJR
cord-354168-omen8vvq	144	21	.	.	.
cord-354168-omen8vvq	145	1	Patients	patient	NNS
cord-354168-omen8vvq	145	2	who	who	WP
cord-354168-omen8vvq	145	3	achieve	achieve	VBP
cord-354168-omen8vvq	145	4	sustained	sustain	VBN
cord-354168-omen8vvq	145	5	very	very	RB
cord-354168-omen8vvq	145	6	good	good	JJ
cord-354168-omen8vvq	145	7	partial	partial	JJ
cord-354168-omen8vvq	145	8	response	response	NN
cord-354168-omen8vvq	145	9	or	or	CC
cord-354168-omen8vvq	145	10	better	well	JJR
cord-354168-omen8vvq	145	11	(	(	-LRB-
cord-354168-omen8vvq	145	12	≥VGPR	≥vgpr	NN
cord-354168-omen8vvq	145	13	)	)	-RRB-
cord-354168-omen8vvq	145	14	after	after	IN
cord-354168-omen8vvq	145	15	3	3	CD
cord-354168-omen8vvq	145	16	-	-	SYM
cord-354168-omen8vvq	145	17	4	4	CD
cord-354168-omen8vvq	145	18	cycles	cycle	NNS
cord-354168-omen8vvq	145	19	,	,	,
cord-354168-omen8vvq	145	20	the	the	DT
cord-354168-omen8vvq	145	21	doses	dose	NNS
cord-354168-omen8vvq	145	22	of	of	IN
cord-354168-omen8vvq	145	23	dexamethasone	dexamethasone	NN
cord-354168-omen8vvq	145	24	should	should	MD
cord-354168-omen8vvq	145	25	be	be	VB
cord-354168-omen8vvq	145	26	decreased	decrease	VBN
cord-354168-omen8vvq	145	27	further	further	RB
cord-354168-omen8vvq	145	28	to	to	IN
cord-354168-omen8vvq	145	29	12	12	CD
cord-354168-omen8vvq	145	30	mg	mg	NN
cord-354168-omen8vvq	145	31	with	with	IN
cord-354168-omen8vvq	145	32	monitoring	monitoring	NN
cord-354168-omen8vvq	145	33	of	of	IN
cord-354168-omen8vvq	145	34	response	response	NN
cord-354168-omen8vvq	145	35	.	.	.
cord-354168-omen8vvq	146	1	If	if	IN
cord-354168-omen8vvq	146	2	the	the	DT
cord-354168-omen8vvq	146	3	concerns	concern	NNS
cord-354168-omen8vvq	146	4	regarding	regard	VBG
cord-354168-omen8vvq	146	5	COVID-19	covid-19	CD
cord-354168-omen8vvq	146	6	continue	continue	VB
cord-354168-omen8vvq	146	7	,	,	,
cord-354168-omen8vvq	146	8	and	and	CC
cord-354168-omen8vvq	146	9	the	the	DT
cord-354168-omen8vvq	146	10	patient	patient	NN
cord-354168-omen8vvq	146	11	is	be	VBZ
cord-354168-omen8vvq	146	12	on	on	IN
cord-354168-omen8vvq	146	13	bortezomib	bortezomib	NNP
cord-354168-omen8vvq	146	14	,	,	,
cord-354168-omen8vvq	146	15	the	the	DT
cord-354168-omen8vvq	146	16	frequency	frequency	NN
cord-354168-omen8vvq	146	17	of	of	IN
cord-354168-omen8vvq	146	18	administration	administration	NN
cord-354168-omen8vvq	146	19	can	can	MD
cord-354168-omen8vvq	146	20	be	be	VB
cord-354168-omen8vvq	146	21	decreased	decrease	VBN
cord-354168-omen8vvq	146	22	to	to	IN
cord-354168-omen8vvq	146	23	every	every	DT
cord-354168-omen8vvq	146	24	other	other	JJ
cord-354168-omen8vvq	146	25	week	week	NN
cord-354168-omen8vvq	146	26	after	after	IN
cord-354168-omen8vvq	146	27	6	6	CD
cord-354168-omen8vvq	146	28	-	-	SYM
cord-354168-omen8vvq	146	29	8	8	CD
cord-354168-omen8vvq	146	30	cycles	cycle	NNS
cord-354168-omen8vvq	146	31	(	(	-LRB-
cord-354168-omen8vvq	146	32	if	if	IN
cord-354168-omen8vvq	146	33	response	response	NN
cord-354168-omen8vvq	146	34	is	be	VBZ
cord-354168-omen8vvq	146	35	≥VGPR	≥vgpr	NN
cord-354168-omen8vvq	146	36	and	and	CC
cord-354168-omen8vvq	146	37	is	be	VBZ
cord-354168-omen8vvq	146	38	sustained	sustain	VBN
cord-354168-omen8vvq	146	39	)	)	-RRB-
cord-354168-omen8vvq	146	40	.	.	.
cord-354168-omen8vvq	147	1	If	if	IN
cord-354168-omen8vvq	147	2	the	the	DT
cord-354168-omen8vvq	147	3	patient	patient	NN
cord-354168-omen8vvq	147	4	is	be	VBZ
cord-354168-omen8vvq	147	5	on	on	IN
cord-354168-omen8vvq	147	6	daratumumabbased	daratumumabbase	VBN
cord-354168-omen8vvq	147	7	therapy	therapy	NN
cord-354168-omen8vvq	147	8	(	(	-LRB-
cord-354168-omen8vvq	147	9	DRd	DRd	NNS
cord-354168-omen8vvq	147	10	)	)	-RRB-
cord-354168-omen8vvq	147	11	and	and	CC
cord-354168-omen8vvq	147	12	has	have	VBZ
cord-354168-omen8vvq	147	13	achieved	achieve	VBN
cord-354168-omen8vvq	147	14	≥VGPR	≥vgpr	NN
cord-354168-omen8vvq	147	15	after	after	IN
cord-354168-omen8vvq	147	16	the	the	DT
cord-354168-omen8vvq	147	17	second	second	JJ
cord-354168-omen8vvq	147	18	cycle	cycle	NN
cord-354168-omen8vvq	147	19	,	,	,
cord-354168-omen8vvq	147	20	we	-PRON-	PRP
cord-354168-omen8vvq	147	21	would	would	MD
cord-354168-omen8vvq	147	22	recommend	recommend	VB
cord-354168-omen8vvq	147	23	continuing	continue	VBG
cord-354168-omen8vvq	147	24	the	the	DT
cord-354168-omen8vvq	147	25	cycle	cycle	NN
cord-354168-omen8vvq	147	26	every	every	DT
cord-354168-omen8vvq	147	27	28	28	CD
cord-354168-omen8vvq	147	28	days	day	NNS
cord-354168-omen8vvq	147	29	,	,	,
cord-354168-omen8vvq	147	30	but	but	CC
cord-354168-omen8vvq	147	31	change	change	VB
cord-354168-omen8vvq	147	32	the	the	DT
cord-354168-omen8vvq	147	33	daratumumab	daratumumab	NN
cord-354168-omen8vvq	147	34	to	to	IN
cord-354168-omen8vvq	147	35	every	every	DT
cord-354168-omen8vvq	147	36	4	4	CD
cord-354168-omen8vvq	147	37	weeks	week	NNS
cord-354168-omen8vvq	147	38	rather	rather	RB
cord-354168-omen8vvq	147	39	than	than	IN
cord-354168-omen8vvq	147	40	every	every	DT
cord-354168-omen8vvq	147	41	2	2	CD
cord-354168-omen8vvq	147	42	weeks	week	NNS
cord-354168-omen8vvq	147	43	.	.	.
cord-354168-omen8vvq	148	1	After	after	IN
cord-354168-omen8vvq	148	2	10	10	CD
cord-354168-omen8vvq	148	3	-	-	SYM
cord-354168-omen8vvq	148	4	12	12	CD
cord-354168-omen8vvq	148	5	cycles	cycle	NNS
cord-354168-omen8vvq	148	6	and	and	CC
cord-354168-omen8vvq	148	7	if	if	IN
cord-354168-omen8vvq	148	8	the	the	DT
cord-354168-omen8vvq	148	9	goals	goal	NNS
cord-354168-omen8vvq	148	10	of	of	IN
cord-354168-omen8vvq	148	11	therapy	therapy	NN
cord-354168-omen8vvq	148	12	are	be	VBP
cord-354168-omen8vvq	148	13	achieved	achieve	VBN
cord-354168-omen8vvq	148	14	,	,	,
cord-354168-omen8vvq	148	15	switching	switch	VBG
cord-354168-omen8vvq	148	16	to	to	IN
cord-354168-omen8vvq	148	17	maintenance	maintenance	NN
cord-354168-omen8vvq	148	18	therapy	therapy	NN
cord-354168-omen8vvq	148	19	with	with	IN
cord-354168-omen8vvq	148	20	lenalidomide	lenalidomide	NN
cord-354168-omen8vvq	148	21	can	can	MD
cord-354168-omen8vvq	148	22	be	be	VB
cord-354168-omen8vvq	148	23	considered	consider	VBN
cord-354168-omen8vvq	148	24	.	.	.
cord-354168-omen8vvq	149	1	Overall	overall	RB
cord-354168-omen8vvq	149	2	,	,	,
cord-354168-omen8vvq	149	3	we	-PRON-	PRP
cord-354168-omen8vvq	149	4	believe	believe	VBP
cord-354168-omen8vvq	149	5	that	that	IN
cord-354168-omen8vvq	149	6	these	these	DT
cord-354168-omen8vvq	149	7	patients	patient	NNS
cord-354168-omen8vvq	149	8	should	should	MD
cord-354168-omen8vvq	149	9	continue	continue	VB
cord-354168-omen8vvq	149	10	on	on	IN
cord-354168-omen8vvq	149	11	their	-PRON-	PRP$
cord-354168-omen8vvq	149	12	triplet	triplet	NN
cord-354168-omen8vvq	149	13	therapy	therapy	NN
cord-354168-omen8vvq	149	14	for	for	IN
cord-354168-omen8vvq	149	15	10	10	CD
cord-354168-omen8vvq	149	16	-	-	SYM
cord-354168-omen8vvq	149	17	12	12	CD
cord-354168-omen8vvq	149	18	months	month	NNS
cord-354168-omen8vvq	149	19	.	.	.
cord-354168-omen8vvq	150	1	The	the	DT
cord-354168-omen8vvq	150	2	dose	dose	NN
cord-354168-omen8vvq	150	3	of	of	IN
cord-354168-omen8vvq	150	4	dexamethasone	dexamethasone	NN
cord-354168-omen8vvq	150	5	can	can	MD
cord-354168-omen8vvq	150	6	be	be	VB
cord-354168-omen8vvq	150	7	decreased	decrease	VBN
cord-354168-omen8vvq	150	8	after	after	IN
cord-354168-omen8vvq	150	9	4	4	CD
cord-354168-omen8vvq	150	10	-	-	SYM
cord-354168-omen8vvq	150	11	6	6	CD
cord-354168-omen8vvq	150	12	cycles	cycle	NNS
cord-354168-omen8vvq	150	13	if	if	IN
cord-354168-omen8vvq	150	14	sustained	sustain	VBD
cord-354168-omen8vvq	150	15	deep	deep	JJ
cord-354168-omen8vvq	150	16	responses	response	NNS
cord-354168-omen8vvq	150	17	(	(	-LRB-
cord-354168-omen8vvq	150	18	≥VGPR	≥vgpr	NN
cord-354168-omen8vvq	150	19	)	)	-RRB-
cord-354168-omen8vvq	150	20	are	be	VBP
cord-354168-omen8vvq	150	21	achieved	achieve	VBN
cord-354168-omen8vvq	150	22	.	.	.
cord-354168-omen8vvq	151	1	The	the	DT
cord-354168-omen8vvq	151	2	frequency	frequency	NN
cord-354168-omen8vvq	151	3	of	of	IN
cord-354168-omen8vvq	151	4	PIs	pi	NNS
cord-354168-omen8vvq	151	5	can	can	MD
cord-354168-omen8vvq	151	6	be	be	VB
cord-354168-omen8vvq	151	7	reduced	reduce	VBN
cord-354168-omen8vvq	151	8	to	to	IN
cord-354168-omen8vvq	151	9	every	every	DT
cord-354168-omen8vvq	151	10	2	2	CD
cord-354168-omen8vvq	151	11	weeks	week	NNS
cord-354168-omen8vvq	151	12	,	,	,
cord-354168-omen8vvq	151	13	if	if	IN
cord-354168-omen8vvq	151	14	the	the	DT
cord-354168-omen8vvq	151	15	response	response	NN
cord-354168-omen8vvq	151	16	is	be	VBZ
cord-354168-omen8vvq	151	17	sustained	sustain	VBN
cord-354168-omen8vvq	151	18	.	.	.
cord-354168-omen8vvq	152	1	After	after	IN
cord-354168-omen8vvq	152	2	10	10	CD
cord-354168-omen8vvq	152	3	-	-	SYM
cord-354168-omen8vvq	152	4	12	12	CD
cord-354168-omen8vvq	152	5	cycles	cycle	NNS
cord-354168-omen8vvq	152	6	,	,	,
cord-354168-omen8vvq	152	7	we	-PRON-	PRP
cord-354168-omen8vvq	152	8	would	would	MD
cord-354168-omen8vvq	152	9	recommend	recommend	VB
cord-354168-omen8vvq	152	10	PI	PI	NNP
cord-354168-omen8vvq	152	11	-	-	HYPH
cord-354168-omen8vvq	152	12	based	base	VBN
cord-354168-omen8vvq	152	13	maintenance	maintenance	NN
cord-354168-omen8vvq	152	14	with	with	IN
cord-354168-omen8vvq	152	15	bortezomib	bortezomib	NNP
cord-354168-omen8vvq	152	16	subcutaneously	subcutaneously	RB
cord-354168-omen8vvq	152	17	every	every	DT
cord-354168-omen8vvq	152	18	2	2	CD
cord-354168-omen8vvq	152	19	weeks	week	NNS
cord-354168-omen8vvq	152	20	or	or	CC
cord-354168-omen8vvq	152	21	weekly	weekly	JJ
cord-354168-omen8vvq	152	22	ixazomib	ixazomib	NNS
cord-354168-omen8vvq	152	23	.	.	.
cord-354168-omen8vvq	153	1	Those	those	DT
cord-354168-omen8vvq	153	2	patients	patient	NNS
cord-354168-omen8vvq	153	3	should	should	MD
cord-354168-omen8vvq	153	4	undergo	undergo	VB
cord-354168-omen8vvq	153	5	ASCT	ASCT	NNP
cord-354168-omen8vvq	153	6	as	as	RB
cord-354168-omen8vvq	153	7	soon	soon	RB
cord-354168-omen8vvq	153	8	as	as	IN
cord-354168-omen8vvq	153	9	the	the	DT
cord-354168-omen8vvq	153	10	pandemic	pandemic	NN
cord-354168-omen8vvq	153	11	resolves	resolve	VBZ
cord-354168-omen8vvq	153	12	.	.	.
cord-354168-omen8vvq	154	1	If	if	IN
cord-354168-omen8vvq	154	2	DRd	DRd	NNS
cord-354168-omen8vvq	154	3	is	be	VBZ
cord-354168-omen8vvq	154	4	available	available	JJ
cord-354168-omen8vvq	154	5	,	,	,
cord-354168-omen8vvq	154	6	we	-PRON-	PRP
cord-354168-omen8vvq	154	7	would	would	MD
cord-354168-omen8vvq	154	8	recommend	recommend	VB
cord-354168-omen8vvq	154	9	it	-PRON-	PRP
cord-354168-omen8vvq	154	10	for	for	IN
cord-354168-omen8vvq	154	11	these	these	DT
cord-354168-omen8vvq	154	12	patients	patient	NNS
cord-354168-omen8vvq	154	13	if	if	IN
cord-354168-omen8vvq	154	14	weekly	weekly	JJ
cord-354168-omen8vvq	154	15	clinic	clinic	NN
cord-354168-omen8vvq	154	16	visits	visit	NNS
cord-354168-omen8vvq	154	17	are	be	VBP
cord-354168-omen8vvq	154	18	feasible	feasible	JJ
cord-354168-omen8vvq	154	19	and	and	CC
cord-354168-omen8vvq	154	20	safe	safe	JJ
cord-354168-omen8vvq	154	21	.	.	.
cord-354168-omen8vvq	155	1	If	if	IN
cord-354168-omen8vvq	155	2	not	not	RB
cord-354168-omen8vvq	155	3	,	,	,
cord-354168-omen8vvq	155	4	using	use	VBG
cord-354168-omen8vvq	155	5	a	a	DT
cord-354168-omen8vvq	155	6	triplet	triplet	NN
cord-354168-omen8vvq	155	7	,	,	,
cord-354168-omen8vvq	155	8	such	such	JJ
cord-354168-omen8vvq	155	9	as	as	IN
cord-354168-omen8vvq	155	10	IRd	IRd	NNP
cord-354168-omen8vvq	155	11	(	(	-LRB-
cord-354168-omen8vvq	155	12	preferred	prefer	VBN
cord-354168-omen8vvq	155	13	)	)	-RRB-
cord-354168-omen8vvq	155	14	,	,	,
cord-354168-omen8vvq	155	15	CRd	CRd	NNS
cord-354168-omen8vvq	155	16	,	,	,
cord-354168-omen8vvq	155	17	RVd	rvd	NN
cord-354168-omen8vvq	155	18	,	,	,
cord-354168-omen8vvq	155	19	or	or	CC
cord-354168-omen8vvq	155	20	CyBorD	CyBorD	NNP
cord-354168-omen8vvq	155	21	can	can	MD
cord-354168-omen8vvq	155	22	also	also	RB
cord-354168-omen8vvq	155	23	be	be	VB
cord-354168-omen8vvq	155	24	considered	consider	VBN
cord-354168-omen8vvq	155	25	,	,	,
cord-354168-omen8vvq	155	26	depending	depend	VBG
cord-354168-omen8vvq	155	27	on	on	IN
cord-354168-omen8vvq	155	28	availability	availability	NN
cord-354168-omen8vvq	155	29	.	.	.
cord-354168-omen8vvq	156	1	These	these	DT
cord-354168-omen8vvq	156	2	patients	patient	NNS
cord-354168-omen8vvq	156	3	frequently	frequently	RB
cord-354168-omen8vvq	156	4	require	require	VBP
cord-354168-omen8vvq	156	5	dose	dose	JJ
cord-354168-omen8vvq	156	6	adjustments	adjustment	NNS
cord-354168-omen8vvq	156	7	and	and	CC
cord-354168-omen8vvq	156	8	close	close	JJ
cord-354168-omen8vvq	156	9	monitoring	monitoring	NN
cord-354168-omen8vvq	156	10	is	be	VBZ
cord-354168-omen8vvq	156	11	recommended	recommend	VBN
cord-354168-omen8vvq	156	12	.	.	.
cord-354168-omen8vvq	157	1	Most	Most	JJS
cord-354168-omen8vvq	157	2	patients	patient	NNS
cord-354168-omen8vvq	157	3	with	with	IN
cord-354168-omen8vvq	157	4	MM	MM	NNP
cord-354168-omen8vvq	157	5	will	will	MD
cord-354168-omen8vvq	157	6	relapse	relapse	VB
cord-354168-omen8vvq	157	7	and	and	CC
cord-354168-omen8vvq	157	8	the	the	DT
cord-354168-omen8vvq	157	9	management	management	NN
cord-354168-omen8vvq	157	10	of	of	IN
cord-354168-omen8vvq	157	11	relapse	relapse	NN
cord-354168-omen8vvq	157	12	should	should	MD
cord-354168-omen8vvq	157	13	be	be	VB
cord-354168-omen8vvq	157	14	individualized	individualize	VBN
cord-354168-omen8vvq	157	15	depending	depend	VBG
cord-354168-omen8vvq	157	16	on	on	IN
cord-354168-omen8vvq	157	17	the	the	DT
cord-354168-omen8vvq	157	18	patient	patient	NN
cord-354168-omen8vvq	157	19	,	,	,
cord-354168-omen8vvq	157	20	as	as	IN
cord-354168-omen8vvq	157	21	not	not	RB
cord-354168-omen8vvq	157	22	all	all	DT
cord-354168-omen8vvq	157	23	relapses	relapse	NNS
cord-354168-omen8vvq	157	24	biologically	biologically	RB
cord-354168-omen8vvq	157	25	behave	behave	VBP
cord-354168-omen8vvq	157	26	the	the	DT
cord-354168-omen8vvq	157	27	same	same	JJ
cord-354168-omen8vvq	157	28	.	.	.
cord-354168-omen8vvq	158	1	A	a	DT
cord-354168-omen8vvq	158	2	discussion	discussion	NN
cord-354168-omen8vvq	158	3	regarding	regard	VBG
cord-354168-omen8vvq	158	4	the	the	DT
cord-354168-omen8vvq	158	5	management	management	NN
cord-354168-omen8vvq	158	6	of	of	IN
cord-354168-omen8vvq	158	7	relapsed	relapse	VBN
cord-354168-omen8vvq	158	8	MM	MM	NNP
cord-354168-omen8vvq	158	9	patients	patient	NNS
cord-354168-omen8vvq	158	10	is	be	VBZ
cord-354168-omen8vvq	158	11	beyond	beyond	IN
cord-354168-omen8vvq	158	12	the	the	DT
cord-354168-omen8vvq	158	13	scope	scope	NN
cord-354168-omen8vvq	158	14	of	of	IN
cord-354168-omen8vvq	158	15	this	this	DT
cord-354168-omen8vvq	158	16	review	review	NN
cord-354168-omen8vvq	158	17	.	.	.
cord-354168-omen8vvq	159	1	We	-PRON-	PRP
cord-354168-omen8vvq	159	2	recommend	recommend	VBP
cord-354168-omen8vvq	159	3	viewing	view	VBG
cord-354168-omen8vvq	159	4	the	the	DT
cord-354168-omen8vvq	159	5	mSMART	mSMART	NNP
cord-354168-omen8vvq	159	6	guidelines	guideline	NNS
cord-354168-omen8vvq	159	7	from	from	IN
cord-354168-omen8vvq	159	8	our	-PRON-	PRP$
cord-354168-omen8vvq	159	9	institution	institution	NN
cord-354168-omen8vvq	159	10	[	[	-LRB-
cord-354168-omen8vvq	159	11	37	37	CD
cord-354168-omen8vvq	159	12	]	]	-RRB-
cord-354168-omen8vvq	159	13	.	.	.
cord-354168-omen8vvq	160	1	Key	key	JJ
cord-354168-omen8vvq	160	2	points	point	NNS
cord-354168-omen8vvq	160	3	are	be	VBP
cord-354168-omen8vvq	160	4	described	describe	VBN
cord-354168-omen8vvq	160	5	below	below	RB
cord-354168-omen8vvq	160	6	:	:	:
cord-354168-omen8vvq	160	7	For	for	IN
cord-354168-omen8vvq	160	8	those	those	DT
cord-354168-omen8vvq	160	9	patients	patient	NNS
cord-354168-omen8vvq	160	10	who	who	WP
cord-354168-omen8vvq	160	11	relapse	relapse	VBP
cord-354168-omen8vvq	160	12	late	late	RB
cord-354168-omen8vvq	160	13	from	from	IN
cord-354168-omen8vvq	160	14	diagnosis	diagnosis	NN
cord-354168-omen8vvq	160	15	with	with	IN
cord-354168-omen8vvq	160	16	no	no	DT
cord-354168-omen8vvq	160	17	high	high	JJ
cord-354168-omen8vvq	160	18	-	-	HYPH
cord-354168-omen8vvq	160	19	risk	risk	NN
cord-354168-omen8vvq	160	20	genetic	genetic	JJ
cord-354168-omen8vvq	160	21	features	feature	NNS
cord-354168-omen8vvq	160	22	and	and	CC
cord-354168-omen8vvq	160	23	who	who	WP
cord-354168-omen8vvq	160	24	did	do	VBD
cord-354168-omen8vvq	160	25	not	not	RB
cord-354168-omen8vvq	160	26	receive	receive	VB
cord-354168-omen8vvq	160	27	daratumumab	daratumumab	NNP
cord-354168-omen8vvq	160	28	as	as	IN
cord-354168-omen8vvq	160	29	part	part	NN
cord-354168-omen8vvq	160	30	of	of	IN
cord-354168-omen8vvq	160	31	the	the	DT
cord-354168-omen8vvq	160	32	induction	induction	NN
cord-354168-omen8vvq	160	33	,	,	,
cord-354168-omen8vvq	160	34	we	-PRON-	PRP
cord-354168-omen8vvq	160	35	would	would	MD
cord-354168-omen8vvq	160	36	recommend	recommend	VB
cord-354168-omen8vvq	160	37	daratumumab	daratumumab	NNP
cord-354168-omen8vvq	160	38	-	-	HYPH
cord-354168-omen8vvq	160	39	based	base	VBN
cord-354168-omen8vvq	160	40	regimens	regimen	NNS
cord-354168-omen8vvq	160	41	.	.	.
cord-354168-omen8vvq	161	1	If	if	IN
cord-354168-omen8vvq	161	2	the	the	DT
cord-354168-omen8vvq	161	3	patient	patient	NN
cord-354168-omen8vvq	161	4	responds	respond	VBZ
cord-354168-omen8vvq	161	5	well	well	RB
cord-354168-omen8vvq	161	6	and	and	CC
cord-354168-omen8vvq	161	7	is	be	VBZ
cord-354168-omen8vvq	161	8	stable	stable	JJ
cord-354168-omen8vvq	161	9	,	,	,
cord-354168-omen8vvq	161	10	recommendations	recommendation	NNS
cord-354168-omen8vvq	161	11	regarding	regard	VBG
cord-354168-omen8vvq	161	12	dose	dose	JJ
cord-354168-omen8vvq	161	13	adjustment	adjustment	NN
cord-354168-omen8vvq	161	14	can	can	MD
cord-354168-omen8vvq	161	15	be	be	VB
cord-354168-omen8vvq	161	16	followed	follow	VBN
cord-354168-omen8vvq	161	17	as	as	IN
cord-354168-omen8vvq	161	18	for	for	IN
cord-354168-omen8vvq	161	19	newly	newly	RB
cord-354168-omen8vvq	161	20	diagnosed	diagnose	VBN
cord-354168-omen8vvq	161	21	patients	patient	NNS
cord-354168-omen8vvq	161	22	(	(	-LRB-
cord-354168-omen8vvq	161	23	above	above	RB
cord-354168-omen8vvq	161	24	)	)	-RRB-
cord-354168-omen8vvq	161	25	.	.	.
cord-354168-omen8vvq	162	1	We	-PRON-	PRP
cord-354168-omen8vvq	162	2	would	would	MD
cord-354168-omen8vvq	162	3	not	not	RB
cord-354168-omen8vvq	162	4	recommend	recommend	VB
cord-354168-omen8vvq	162	5	proceeding	proceed	VBG
cord-354168-omen8vvq	162	6	directly	directly	RB
cord-354168-omen8vvq	162	7	with	with	IN
cord-354168-omen8vvq	162	8	ASCT	ASCT	NNP
cord-354168-omen8vvq	163	1	(	(	-LRB-
cord-354168-omen8vvq	163	2	if	if	IN
cord-354168-omen8vvq	163	3	it	-PRON-	PRP
cord-354168-omen8vvq	163	4	was	be	VBD
cord-354168-omen8vvq	163	5	part	part	NN
cord-354168-omen8vvq	163	6	of	of	IN
cord-354168-omen8vvq	163	7	the	the	DT
cord-354168-omen8vvq	163	8	treatment	treatment	NN
cord-354168-omen8vvq	163	9	plan	plan	NN
cord-354168-omen8vvq	163	10	)	)	-RRB-
cord-354168-omen8vvq	163	11	until	until	IN
cord-354168-omen8vvq	163	12	the	the	DT
cord-354168-omen8vvq	163	13	current	current	JJ
cord-354168-omen8vvq	163	14	pandemic	pandemic	NN
cord-354168-omen8vvq	163	15	resolves	resolve	VBZ
cord-354168-omen8vvq	163	16	.	.	.
cord-354168-omen8vvq	164	1	If	if	IN
cord-354168-omen8vvq	164	2	daratumumab	daratumumab	NNP
cord-354168-omen8vvq	164	3	is	be	VBZ
cord-354168-omen8vvq	164	4	not	not	RB
cord-354168-omen8vvq	164	5	available	available	JJ
cord-354168-omen8vvq	164	6	,	,	,
cord-354168-omen8vvq	164	7	other	other	JJ
cord-354168-omen8vvq	164	8	triplet	triplet	NN
cord-354168-omen8vvq	164	9	combinations	combination	NNS
cord-354168-omen8vvq	164	10	should	should	MD
cord-354168-omen8vvq	164	11	be	be	VB
cord-354168-omen8vvq	164	12	used	use	VBN
cord-354168-omen8vvq	164	13	depending	depend	VBG
cord-354168-omen8vvq	164	14	on	on	IN
cord-354168-omen8vvq	164	15	availability	availability	NN
cord-354168-omen8vvq	164	16	,	,	,
cord-354168-omen8vvq	164	17	fitness	fitness	NN
cord-354168-omen8vvq	164	18	of	of	IN
cord-354168-omen8vvq	164	19	the	the	DT
cord-354168-omen8vvq	164	20	patient	patient	NN
cord-354168-omen8vvq	164	21	,	,	,
cord-354168-omen8vvq	164	22	and	and	CC
cord-354168-omen8vvq	164	23	type	type	NN
cord-354168-omen8vvq	164	24	of	of	IN
cord-354168-omen8vvq	164	25	maintenance	maintenance	NN
cord-354168-omen8vvq	164	26	therapy	therapy	NN
cord-354168-omen8vvq	164	27	.	.	.
cord-354168-omen8vvq	165	1	If	if	IN
cord-354168-omen8vvq	165	2	the	the	DT
cord-354168-omen8vvq	165	3	patient	patient	NN
cord-354168-omen8vvq	165	4	is	be	VBZ
cord-354168-omen8vvq	165	5	not	not	RB
cord-354168-omen8vvq	165	6	responding	respond	VBG
cord-354168-omen8vvq	165	7	well	well	RB
cord-354168-omen8vvq	165	8	and	and	CC
cord-354168-omen8vvq	165	9	is	be	VBZ
cord-354168-omen8vvq	165	10	failing	fail	VBG
cord-354168-omen8vvq	165	11	conventional	conventional	JJ
cord-354168-omen8vvq	165	12	therapy	therapy	NN
cord-354168-omen8vvq	165	13	,	,	,
cord-354168-omen8vvq	165	14	ASCT	ASCT	NNP
cord-354168-omen8vvq	165	15	can	can	MD
cord-354168-omen8vvq	165	16	be	be	VB
cord-354168-omen8vvq	165	17	considered	consider	VBN
cord-354168-omen8vvq	165	18	as	as	IN
cord-354168-omen8vvq	165	19	salvage	salvage	NN
cord-354168-omen8vvq	165	20	.	.	.
cord-354168-omen8vvq	166	1	A	a	DT
cord-354168-omen8vvq	166	2	reminder	reminder	NN
cord-354168-omen8vvq	166	3	:	:	:
cord-354168-omen8vvq	166	4	these	these	DT
cord-354168-omen8vvq	166	5	patients	patient	NNS
cord-354168-omen8vvq	166	6	should	should	MD
cord-354168-omen8vvq	166	7	be	be	VB
cord-354168-omen8vvq	166	8	screened	screen	VBN
cord-354168-omen8vvq	166	9	for	for	IN
cord-354168-omen8vvq	166	10	COV	COV	NNP
cord-354168-omen8vvq	166	11	-	-	HYPH
cord-354168-omen8vvq	166	12	ID-19	ID-19	NNP
cord-354168-omen8vvq	166	13	before	before	IN
cord-354168-omen8vvq	166	14	ASCT	ASCT	NNP
cord-354168-omen8vvq	166	15	.	.	.
cord-354168-omen8vvq	167	1	These	these	DT
cord-354168-omen8vvq	167	2	patients	patient	NNS
cord-354168-omen8vvq	167	3	are	be	VBP
cord-354168-omen8vvq	167	4	the	the	DT
cord-354168-omen8vvq	167	5	most	most	RBS
cord-354168-omen8vvq	167	6	difficult	difficult	JJ
cord-354168-omen8vvq	167	7	to	to	TO
cord-354168-omen8vvq	167	8	manage	manage	VB
cord-354168-omen8vvq	167	9	with	with	IN
cord-354168-omen8vvq	167	10	the	the	DT
cord-354168-omen8vvq	167	11	current	current	JJ
cord-354168-omen8vvq	167	12	situation	situation	NN
cord-354168-omen8vvq	167	13	.	.	.
cord-354168-omen8vvq	168	1	The	the	DT
cord-354168-omen8vvq	168	2	management	management	NN
cord-354168-omen8vvq	168	3	will	will	MD
cord-354168-omen8vvq	168	4	depend	depend	VB
cord-354168-omen8vvq	168	5	on	on	IN
cord-354168-omen8vvq	168	6	the	the	DT
cord-354168-omen8vvq	168	7	nature	nature	NN
cord-354168-omen8vvq	168	8	of	of	IN
cord-354168-omen8vvq	168	9	relapse	relapse	NN
cord-354168-omen8vvq	168	10	and	and	CC
cord-354168-omen8vvq	168	11	how	how	WRB
cord-354168-omen8vvq	168	12	aggressive	aggressive	JJ
cord-354168-omen8vvq	168	13	it	-PRON-	PRP
cord-354168-omen8vvq	168	14	is	be	VBZ
cord-354168-omen8vvq	168	15	.	.	.
cord-354168-omen8vvq	169	1	Again	again	RB
cord-354168-omen8vvq	169	2	,	,	,
cord-354168-omen8vvq	169	3	if	if	IN
cord-354168-omen8vvq	169	4	patients	patient	NNS
cord-354168-omen8vvq	169	5	did	do	VBD
cord-354168-omen8vvq	169	6	not	not	RB
cord-354168-omen8vvq	169	7	receive	receive	VB
cord-354168-omen8vvq	169	8	daratumumab	daratumumab	NNP
cord-354168-omen8vvq	169	9	,	,	,
cord-354168-omen8vvq	169	10	daratumumabbased	daratumumabbased	JJ
cord-354168-omen8vvq	169	11	treatment	treatment	NN
cord-354168-omen8vvq	169	12	should	should	MD
cord-354168-omen8vvq	169	13	be	be	VB
cord-354168-omen8vvq	169	14	used	use	VBN
cord-354168-omen8vvq	169	15	.	.	.
cord-354168-omen8vvq	170	1	If	if	IN
cord-354168-omen8vvq	170	2	daratumumab	daratumumab	NNP
cord-354168-omen8vvq	170	3	is	be	VBZ
cord-354168-omen8vvq	170	4	not	not	RB
cord-354168-omen8vvq	170	5	available	available	JJ
cord-354168-omen8vvq	170	6	,	,	,
cord-354168-omen8vvq	170	7	other	other	JJ
cord-354168-omen8vvq	170	8	triplet	triplet	NN
cord-354168-omen8vvq	170	9	combinations	combination	NNS
cord-354168-omen8vvq	170	10	should	should	MD
cord-354168-omen8vvq	170	11	be	be	VB
cord-354168-omen8vvq	170	12	considered	consider	VBN
cord-354168-omen8vvq	170	13	depending	depend	VBG
cord-354168-omen8vvq	170	14	on	on	IN
cord-354168-omen8vvq	170	15	availability	availability	NN
cord-354168-omen8vvq	170	16	,	,	,
cord-354168-omen8vvq	170	17	fitness	fitness	NN
cord-354168-omen8vvq	170	18	of	of	IN
cord-354168-omen8vvq	170	19	the	the	DT
cord-354168-omen8vvq	170	20	patient	patient	NN
cord-354168-omen8vvq	170	21	,	,	,
cord-354168-omen8vvq	170	22	and	and	CC
cord-354168-omen8vvq	170	23	type	type	NN
cord-354168-omen8vvq	170	24	of	of	IN
cord-354168-omen8vvq	170	25	maintenance	maintenance	NN
cord-354168-omen8vvq	170	26	therapy	therapy	NN
cord-354168-omen8vvq	170	27	.	.	.
cord-354168-omen8vvq	171	1	The	the	DT
cord-354168-omen8vvq	171	2	decision	decision	NN
cord-354168-omen8vvq	171	3	regarding	regard	VBG
cord-354168-omen8vvq	171	4	ASCT	ASCT	NNP
cord-354168-omen8vvq	171	5	should	should	MD
cord-354168-omen8vvq	171	6	be	be	VB
cord-354168-omen8vvq	171	7	individualized	individualize	VBN
cord-354168-omen8vvq	171	8	.	.	.
cord-354168-omen8vvq	172	1	For	for	IN
cord-354168-omen8vvq	172	2	patients	patient	NNS
cord-354168-omen8vvq	172	3	with	with	IN
cord-354168-omen8vvq	172	4	aggressive	aggressive	JJ
cord-354168-omen8vvq	172	5	relapse	relapse	NN
cord-354168-omen8vvq	172	6	(	(	-LRB-
cord-354168-omen8vvq	172	7	especially	especially	RB
cord-354168-omen8vvq	172	8	with	with	IN
cord-354168-omen8vvq	172	9	suboptimal	suboptimal	JJ
cord-354168-omen8vvq	172	10	responses	response	NNS
cord-354168-omen8vvq	172	11	to	to	TO
cord-354168-omen8vvq	172	12	salvage	salvage	VB
cord-354168-omen8vvq	172	13	therapy	therapy	NN
cord-354168-omen8vvq	172	14	)	)	-RRB-
cord-354168-omen8vvq	172	15	,	,	,
cord-354168-omen8vvq	172	16	ASCT	ASCT	NNP
cord-354168-omen8vvq	172	17	should	should	MD
cord-354168-omen8vvq	172	18	be	be	VB
cord-354168-omen8vvq	172	19	considered	consider	VBN
cord-354168-omen8vvq	172	20	as	as	IN
cord-354168-omen8vvq	172	21	salvage	salvage	NN
cord-354168-omen8vvq	172	22	.	.	.
cord-354168-omen8vvq	173	1	These	these	DT
cord-354168-omen8vvq	173	2	patients	patient	NNS
cord-354168-omen8vvq	173	3	should	should	MD
cord-354168-omen8vvq	173	4	be	be	VB
cord-354168-omen8vvq	173	5	screened	screen	VBN
cord-354168-omen8vvq	173	6	for	for	IN
cord-354168-omen8vvq	173	7	COVID-19	COVID-19	NNP
cord-354168-omen8vvq	173	8	before	before	IN
cord-354168-omen8vvq	173	9	ASCT	ASCT	NNP
cord-354168-omen8vvq	173	10	.	.	.
cord-354168-omen8vvq	174	1	For	for	IN
cord-354168-omen8vvq	174	2	patients	patient	NNS
cord-354168-omen8vvq	174	3	who	who	WP
cord-354168-omen8vvq	174	4	relapse	relapse	VBP
cord-354168-omen8vvq	174	5	slowly	slowly	RB
cord-354168-omen8vvq	174	6	and	and	CC
cord-354168-omen8vvq	174	7	achieve	achieve	VB
cord-354168-omen8vvq	174	8	deep	deep	JJ
cord-354168-omen8vvq	174	9	responses	response	NNS
cord-354168-omen8vvq	174	10	(	(	-LRB-
cord-354168-omen8vvq	174	11	≥VGPR	≥vgpr	NN
cord-354168-omen8vvq	174	12	)	)	-RRB-
cord-354168-omen8vvq	174	13	after	after	IN
cord-354168-omen8vvq	174	14	therapy	therapy	NN
cord-354168-omen8vvq	174	15	,	,	,
cord-354168-omen8vvq	174	16	ASCT	ASCT	NNP
cord-354168-omen8vvq	174	17	should	should	MD
cord-354168-omen8vvq	174	18	be	be	VB
cord-354168-omen8vvq	174	19	delayed	delay	VBN
cord-354168-omen8vvq	174	20	.	.	.
cord-354168-omen8vvq	175	1	Patients	patient	NNS
cord-354168-omen8vvq	175	2	with	with	IN
cord-354168-omen8vvq	175	3	secondary	secondary	JJ
cord-354168-omen8vvq	175	4	PCL	PCL	NNP
cord-354168-omen8vvq	175	5	(	(	-LRB-
cord-354168-omen8vvq	175	6	in	in	IN
cord-354168-omen8vvq	175	7	the	the	DT
cord-354168-omen8vvq	175	8	setting	setting	NN
cord-354168-omen8vvq	175	9	of	of	IN
cord-354168-omen8vvq	175	10	refractory	refractory	JJ
cord-354168-omen8vvq	175	11	/	/	SYM
cord-354168-omen8vvq	175	12	relapsed	relapse	VBN
cord-354168-omen8vvq	175	13	MM	MM	NNP
cord-354168-omen8vvq	175	14	)	)	-RRB-
cord-354168-omen8vvq	175	15	have	have	VBP
cord-354168-omen8vvq	175	16	a	a	DT
cord-354168-omen8vvq	175	17	grim	grim	JJ
cord-354168-omen8vvq	175	18	prognosis	prognosis	NN
cord-354168-omen8vvq	175	19	[	[	-LRB-
cord-354168-omen8vvq	175	20	38	38	CD
cord-354168-omen8vvq	175	21	]	]	-RRB-
cord-354168-omen8vvq	175	22	.	.	.
cord-354168-omen8vvq	176	1	These	these	DT
cord-354168-omen8vvq	176	2	patients	patient	NNS
cord-354168-omen8vvq	176	3	should	should	MD
cord-354168-omen8vvq	176	4	receive	receive	VB
cord-354168-omen8vvq	176	5	myeloma	myeloma	NN
cord-354168-omen8vvq	176	6	-	-	HYPH
cord-354168-omen8vvq	176	7	directed	direct	VBN
cord-354168-omen8vvq	176	8	therapy	therapy	NN
cord-354168-omen8vvq	176	9	followed	follow	VBN
cord-354168-omen8vvq	176	10	by	by	IN
cord-354168-omen8vvq	176	11	ASCT	ASCT	NNP
cord-354168-omen8vvq	176	12	.	.	.
cord-354168-omen8vvq	177	1	Testing	test	VBG
cord-354168-omen8vvq	177	2	for	for	IN
cord-354168-omen8vvq	177	3	COVID-19	COVID-19	NNP
cord-354168-omen8vvq	177	4	should	should	MD
cord-354168-omen8vvq	177	5	be	be	VB
cord-354168-omen8vvq	177	6	done	do	VBN
cord-354168-omen8vvq	177	7	before	before	IN
cord-354168-omen8vvq	177	8	ASCT	ASCT	NNP
cord-354168-omen8vvq	177	9	.	.	.
cord-354168-omen8vvq	178	1	We	-PRON-	PRP
cord-354168-omen8vvq	178	2	believe	believe	VBP
cord-354168-omen8vvq	178	3	that	that	IN
cord-354168-omen8vvq	178	4	patients	patient	NNS
cord-354168-omen8vvq	178	5	who	who	WP
cord-354168-omen8vvq	178	6	are	be	VBP
cord-354168-omen8vvq	178	7	stable	stable	JJ
cord-354168-omen8vvq	178	8	on	on	IN
cord-354168-omen8vvq	178	9	maintenance	maintenance	NN
cord-354168-omen8vvq	178	10	with	with	IN
cord-354168-omen8vvq	178	11	no	no	DT
cord-354168-omen8vvq	178	12	major	major	JJ
cord-354168-omen8vvq	178	13	side	side	NN
cord-354168-omen8vvq	178	14	effects	effect	NNS
cord-354168-omen8vvq	178	15	should	should	MD
cord-354168-omen8vvq	178	16	continue	continue	VB
cord-354168-omen8vvq	178	17	on	on	IN
cord-354168-omen8vvq	178	18	their	-PRON-	PRP$
cord-354168-omen8vvq	178	19	maintenance	maintenance	NN
cord-354168-omen8vvq	178	20	.	.	.
cord-354168-omen8vvq	179	1	If	if	IN
cord-354168-omen8vvq	179	2	the	the	DT
cord-354168-omen8vvq	179	3	patient	patient	NN
cord-354168-omen8vvq	179	4	is	be	VBZ
cord-354168-omen8vvq	179	5	on	on	IN
cord-354168-omen8vvq	179	6	dexamethasone	dexamethasone	NN
cord-354168-omen8vvq	179	7	during	during	IN
cord-354168-omen8vvq	179	8	their	-PRON-	PRP$
cord-354168-omen8vvq	179	9	maintenance	maintenance	NN
cord-354168-omen8vvq	179	10	,	,	,
cord-354168-omen8vvq	179	11	we	-PRON-	PRP
cord-354168-omen8vvq	179	12	recommend	recommend	VBP
cord-354168-omen8vvq	179	13	tapering	taper	VBG
cord-354168-omen8vvq	179	14	it	-PRON-	PRP
cord-354168-omen8vvq	179	15	down	down	RP
cord-354168-omen8vvq	179	16	with	with	IN
cord-354168-omen8vvq	179	17	the	the	DT
cord-354168-omen8vvq	179	18	goal	goal	NN
cord-354168-omen8vvq	179	19	of	of	IN
cord-354168-omen8vvq	179	20	discontinuing	discontinue	VBG
cord-354168-omen8vvq	179	21	it	-PRON-	PRP
cord-354168-omen8vvq	179	22	.	.	.
cord-354168-omen8vvq	180	1	These	these	DT
cord-354168-omen8vvq	180	2	patients	patient	NNS
cord-354168-omen8vvq	180	3	do	do	VBP
cord-354168-omen8vvq	180	4	not	not	RB
cord-354168-omen8vvq	180	5	need	need	VB
cord-354168-omen8vvq	180	6	to	to	TO
cord-354168-omen8vvq	180	7	be	be	VB
cord-354168-omen8vvq	180	8	seen	see	VBN
cord-354168-omen8vvq	180	9	in	in	IN
cord-354168-omen8vvq	180	10	clinic	clinic	NN
cord-354168-omen8vvq	180	11	for	for	IN
cord-354168-omen8vvq	180	12	3	3	CD
cord-354168-omen8vvq	180	13	months	month	NNS
cord-354168-omen8vvq	180	14	.	.	.
cord-354168-omen8vvq	181	1	Monitoring	monitoring	NN
cord-354168-omen8vvq	181	2	should	should	MD
cord-354168-omen8vvq	181	3	occur	occur	VB
cord-354168-omen8vvq	181	4	in	in	IN
cord-354168-omen8vvq	181	5	the	the	DT
cord-354168-omen8vvq	181	6	closest	close	JJS
cord-354168-omen8vvq	181	7	laboratory	laboratory	NN
cord-354168-omen8vvq	181	8	and	and	CC
cord-354168-omen8vvq	181	9	phone	phone	NN
cord-354168-omen8vvq	181	10	visits	visit	NNS
cord-354168-omen8vvq	181	11	may	may	MD
cord-354168-omen8vvq	181	12	be	be	VB
cord-354168-omen8vvq	181	13	used	use	VBN
cord-354168-omen8vvq	181	14	for	for	IN
cord-354168-omen8vvq	181	15	toxicity	toxicity	NN
cord-354168-omen8vvq	181	16	checks	check	NNS
cord-354168-omen8vvq	181	17	.	.	.
cord-354168-omen8vvq	182	1	In	in	IN
cord-354168-omen8vvq	182	2	many	many	JJ
cord-354168-omen8vvq	182	3	centers	center	NNS
cord-354168-omen8vvq	182	4	clinical	clinical	JJ
cord-354168-omen8vvq	182	5	trials	trial	NNS
cord-354168-omen8vvq	182	6	have	have	VBP
cord-354168-omen8vvq	182	7	been	be	VBN
cord-354168-omen8vvq	182	8	suspended	suspend	VBN
cord-354168-omen8vvq	182	9	for	for	IN
cord-354168-omen8vvq	182	10	new	new	JJ
cord-354168-omen8vvq	182	11	patients	patient	NNS
cord-354168-omen8vvq	182	12	because	because	IN
cord-354168-omen8vvq	182	13	the	the	DT
cord-354168-omen8vvq	182	14	requirements	requirement	NNS
cord-354168-omen8vvq	182	15	for	for	IN
cord-354168-omen8vvq	182	16	testing	testing	NN
cord-354168-omen8vvq	182	17	lead	lead	NN
cord-354168-omen8vvq	182	18	to	to	IN
cord-354168-omen8vvq	182	19	frequent	frequent	JJ
cord-354168-omen8vvq	182	20	protocol	protocol	NN
cord-354168-omen8vvq	182	21	violations	violation	NNS
cord-354168-omen8vvq	182	22	.	.	.
cord-354168-omen8vvq	183	1	Some	some	DT
cord-354168-omen8vvq	183	2	clinical	clinical	JJ
cord-354168-omen8vvq	183	3	trials	trial	NNS
cord-354168-omen8vvq	183	4	are	be	VBP
cord-354168-omen8vvq	183	5	modifying	modify	VBG
cord-354168-omen8vvq	183	6	their	-PRON-	PRP$
cord-354168-omen8vvq	183	7	protocols	protocol	NNS
cord-354168-omen8vvq	183	8	,	,	,
cord-354168-omen8vvq	183	9	allowing	allow	VBG
cord-354168-omen8vvq	183	10	blood	blood	NN
cord-354168-omen8vvq	183	11	draws	draw	VBZ
cord-354168-omen8vvq	183	12	to	to	TO
cord-354168-omen8vvq	183	13	be	be	VB
cord-354168-omen8vvq	183	14	done	do	VBN
cord-354168-omen8vvq	183	15	locally	locally	RB
cord-354168-omen8vvq	183	16	,	,	,
cord-354168-omen8vvq	183	17	telemedicine	telemedicine	NN
cord-354168-omen8vvq	183	18	evaluation	evaluation	NN
cord-354168-omen8vvq	183	19	,	,	,
cord-354168-omen8vvq	183	20	and	and	CC
cord-354168-omen8vvq	183	21	oral	oral	JJ
cord-354168-omen8vvq	183	22	drugs	drug	NNS
cord-354168-omen8vvq	183	23	to	to	TO
cord-354168-omen8vvq	183	24	be	be	VB
cord-354168-omen8vvq	183	25	shipped	ship	VBN
cord-354168-omen8vvq	183	26	home	home	RB
cord-354168-omen8vvq	183	27	.	.	.
cord-354168-omen8vvq	184	1	The	the	DT
cord-354168-omen8vvq	184	2	management	management	NN
cord-354168-omen8vvq	184	3	of	of	IN
cord-354168-omen8vvq	184	4	patients	patient	NNS
cord-354168-omen8vvq	184	5	with	with	IN
cord-354168-omen8vvq	184	6	MM	MM	NNP
cord-354168-omen8vvq	184	7	during	during	IN
cord-354168-omen8vvq	184	8	the	the	DT
cord-354168-omen8vvq	184	9	current	current	JJ
cord-354168-omen8vvq	184	10	pandemic	pandemic	NN
cord-354168-omen8vvq	184	11	of	of	IN
cord-354168-omen8vvq	184	12	COVID-19	COVID-19	NNP
cord-354168-omen8vvq	184	13	is	be	VBZ
cord-354168-omen8vvq	184	14	challenging	challenging	JJ
cord-354168-omen8vvq	184	15	.	.	.
cord-354168-omen8vvq	185	1	We	-PRON-	PRP
cord-354168-omen8vvq	185	2	do	do	VBP
cord-354168-omen8vvq	185	3	not	not	RB
cord-354168-omen8vvq	185	4	recommend	recommend	VB
cord-354168-omen8vvq	185	5	any	any	DT
cord-354168-omen8vvq	185	6	active	active	JJ
cord-354168-omen8vvq	185	7	therapy	therapy	NN
cord-354168-omen8vvq	185	8	for	for	IN
cord-354168-omen8vvq	185	9	SMM	SMM	NNP
cord-354168-omen8vvq	185	10	patients	patient	NNS
cord-354168-omen8vvq	185	11	,	,	,
cord-354168-omen8vvq	185	12	standard	standard	JJ
cord-354168-omen8vvq	185	13	or	or	CC
cord-354168-omen8vvq	185	14	high	high	JJ
cord-354168-omen8vvq	185	15	risk	risk	NN
cord-354168-omen8vvq	185	16	.	.	.
cord-354168-omen8vvq	186	1	Patients	patient	NNS
cord-354168-omen8vvq	186	2	with	with	IN
cord-354168-omen8vvq	186	3	active	active	JJ
cord-354168-omen8vvq	186	4	MM	MM	NNP
cord-354168-omen8vvq	186	5	should	should	MD
cord-354168-omen8vvq	186	6	be	be	VB
cord-354168-omen8vvq	186	7	risk	risk	NN
cord-354168-omen8vvq	186	8	stratified	stratify	VBN
cord-354168-omen8vvq	186	9	before	before	IN
cord-354168-omen8vvq	186	10	treatment	treatment	NN
cord-354168-omen8vvq	186	11	.	.	.
cord-354168-omen8vvq	187	1	Screening	screen	VBG
cord-354168-omen8vvq	187	2	for	for	IN
cord-354168-omen8vvq	187	3	COVID-19	COVID-19	NNP
cord-354168-omen8vvq	187	4	should	should	MD
cord-354168-omen8vvq	187	5	be	be	VB
cord-354168-omen8vvq	187	6	done	do	VBN
cord-354168-omen8vvq	187	7	for	for	IN
cord-354168-omen8vvq	187	8	all	all	DT
cord-354168-omen8vvq	187	9	patients	patient	NNS
cord-354168-omen8vvq	187	10	(	(	-LRB-
cord-354168-omen8vvq	187	11	in	in	IN
cord-354168-omen8vvq	187	12	patients	patient	NNS
cord-354168-omen8vvq	187	13	and	and	CC
cord-354168-omen8vvq	187	14	outpatients	outpatient	NNS
cord-354168-omen8vvq	187	15	)	)	-RRB-
cord-354168-omen8vvq	187	16	before	before	IN
cord-354168-omen8vvq	187	17	starting	start	VBG
cord-354168-omen8vvq	187	18	therapy	therapy	NN
cord-354168-omen8vvq	187	19	.	.	.
cord-354168-omen8vvq	188	1	For	for	IN
cord-354168-omen8vvq	188	2	standard	standard	JJ
cord-354168-omen8vvq	188	3	-	-	HYPH
cord-354168-omen8vvq	188	4	risk	risk	NN
cord-354168-omen8vvq	188	5	patients	patient	NNS
cord-354168-omen8vvq	188	6	options	option	NNS
cord-354168-omen8vvq	188	7	include	include	VBP
cord-354168-omen8vvq	188	8	:	:	:
cord-354168-omen8vvq	188	9	IRd	IRd	NNP
cord-354168-omen8vvq	188	10	(	(	-LRB-
cord-354168-omen8vvq	188	11	preferred	prefer	VBN
cord-354168-omen8vvq	188	12	)	)	-RRB-
cord-354168-omen8vvq	188	13	,	,	,
cord-354168-omen8vvq	188	14	CRd	CRd	NNS
cord-354168-omen8vvq	188	15	,	,	,
cord-354168-omen8vvq	188	16	DRd	DRd	NNS
cord-354168-omen8vvq	188	17	,	,	,
cord-354168-omen8vvq	188	18	RVd	rvd	WDT
cord-354168-omen8vvq	188	19	,	,	,
cord-354168-omen8vvq	188	20	or	or	CC
cord-354168-omen8vvq	188	21	CyBorD.	CyBorD.	NNP
cord-354168-omen8vvq	189	1	For	for	IN
cord-354168-omen8vvq	189	2	high	high	JJ
cord-354168-omen8vvq	189	3	-	-	HYPH
cord-354168-omen8vvq	189	4	risk	risk	NN
cord-354168-omen8vvq	189	5	patients	patient	NNS
cord-354168-omen8vvq	189	6	KRd	KRd	NNS
cord-354168-omen8vvq	189	7	(	(	-LRB-
cord-354168-omen8vvq	189	8	preferred	prefer	VBN
cord-354168-omen8vvq	189	9	)	)	-RRB-
cord-354168-omen8vvq	189	10	or	or	CC
cord-354168-omen8vvq	189	11	RVd	rvd	WDT
cord-354168-omen8vvq	189	12	are	be	VBP
cord-354168-omen8vvq	189	13	options	option	NNS
cord-354168-omen8vvq	189	14	.	.	.
cord-354168-omen8vvq	190	1	We	-PRON-	PRP
cord-354168-omen8vvq	190	2	recommend	recommend	VBP
cord-354168-omen8vvq	190	3	decreasing	decrease	VBG
cord-354168-omen8vvq	190	4	the	the	DT
cord-354168-omen8vvq	190	5	dose	dose	NN
cord-354168-omen8vvq	190	6	of	of	IN
cord-354168-omen8vvq	190	7	dexamethasone	dexamethasone	NN
cord-354168-omen8vvq	190	8	to	to	IN
cord-354168-omen8vvq	190	9	20	20	CD
cord-354168-omen8vvq	190	10	mg	mg	NNP
cord-354168-omen8vvq	190	11	p.o	p.o	NNP
cord-354168-omen8vvq	190	12	.	.	.
cord-354168-omen8vvq	191	1	once	once	RB
cord-354168-omen8vvq	191	2	weekly	weekly	RB
cord-354168-omen8vvq	191	3	and	and	CC
cord-354168-omen8vvq	191	4	the	the	DT
cord-354168-omen8vvq	191	5	PIs	pi	NNS
cord-354168-omen8vvq	191	6	should	should	MD
cord-354168-omen8vvq	191	7	be	be	VB
cord-354168-omen8vvq	191	8	given	give	VBN
cord-354168-omen8vvq	191	9	once	once	RB
cord-354168-omen8vvq	191	10	weekly	weekly	RB
cord-354168-omen8vvq	191	11	with	with	IN
cord-354168-omen8vvq	191	12	bortezomib	bortezomib	NNP
cord-354168-omen8vvq	191	13	being	be	VBG
cord-354168-omen8vvq	191	14	given	give	VBN
cord-354168-omen8vvq	191	15	subcutaneously	subcutaneously	RB
cord-354168-omen8vvq	191	16	.	.	.
cord-354168-omen8vvq	192	1	Supportive	supportive	JJ
cord-354168-omen8vvq	192	2	management	management	NN
cord-354168-omen8vvq	192	3	with	with	IN
cord-354168-omen8vvq	192	4	antibiotics	antibiotic	NNS
cord-354168-omen8vvq	192	5	and	and	CC
cord-354168-omen8vvq	192	6	anticoagulants	anticoagulant	NNS
cord-354168-omen8vvq	192	7	(	(	-LRB-
cord-354168-omen8vvq	192	8	as	as	IN
cord-354168-omen8vvq	192	9	needed	need	VBN
cord-354168-omen8vvq	192	10	)	)	-RRB-
cord-354168-omen8vvq	192	11	is	be	VBZ
cord-354168-omen8vvq	192	12	critical	critical	JJ
cord-354168-omen8vvq	192	13	.	.	.
cord-354168-omen8vvq	193	1	We	-PRON-	PRP
cord-354168-omen8vvq	193	2	recommend	recommend	VBP
cord-354168-omen8vvq	193	3	delaying	delay	VBG
cord-354168-omen8vvq	193	4	ASCT	ASCT	NNP
cord-354168-omen8vvq	193	5	,	,	,
cord-354168-omen8vvq	193	6	un	un	NNP
cord-354168-omen8vvq	193	7	-	-	NN
cord-354168-omen8vvq	193	8	less	less	JJR
cord-354168-omen8vvq	194	1	the	the	DT
cord-354168-omen8vvq	194	2	patient	patient	NN
cord-354168-omen8vvq	194	3	has	have	VBZ
cord-354168-omen8vvq	194	4	high	high	JJ
cord-354168-omen8vvq	194	5	-	-	HYPH
cord-354168-omen8vvq	194	6	risk	risk	NN
cord-354168-omen8vvq	194	7	disease	disease	NN
cord-354168-omen8vvq	194	8	that	that	WDT
cord-354168-omen8vvq	194	9	is	be	VBZ
cord-354168-omen8vvq	194	10	not	not	RB
cord-354168-omen8vvq	194	11	responding	respond	VBG
cord-354168-omen8vvq	194	12	well	well	RB
cord-354168-omen8vvq	194	13	,	,	,
cord-354168-omen8vvq	194	14	or	or	CC
cord-354168-omen8vvq	194	15	if	if	IN
cord-354168-omen8vvq	194	16	the	the	DT
cord-354168-omen8vvq	194	17	patient	patient	NN
cord-354168-omen8vvq	194	18	has	have	VBZ
cord-354168-omen8vvq	194	19	PCL	PCL	NNP
cord-354168-omen8vvq	194	20	.	.	.
cord-354168-omen8vvq	195	1	Testing	test	VBG
cord-354168-omen8vvq	195	2	for	for	IN
cord-354168-omen8vvq	195	3	COVID-19	COVID-19	NNP
cord-354168-omen8vvq	195	4	should	should	MD
cord-354168-omen8vvq	195	5	be	be	VB
cord-354168-omen8vvq	195	6	done	do	VBN
cord-354168-omen8vvq	195	7	before	before	IN
cord-354168-omen8vvq	195	8	any	any	DT
cord-354168-omen8vvq	195	9	ASCT	ASCT	NNP
cord-354168-omen8vvq	195	10	or	or	CC
cord-354168-omen8vvq	195	11	new	new	JJ
cord-354168-omen8vvq	195	12	chemotherapy	chemotherapy	NN
cord-354168-omen8vvq	195	13	regimen	regimen	NN
cord-354168-omen8vvq	195	14	.	.	.
cord-354168-omen8vvq	196	1	Doses	dose	NNS
cord-354168-omen8vvq	196	2	and	and	CC
cord-354168-omen8vvq	196	3	frequency	frequency	NN
cord-354168-omen8vvq	196	4	of	of	IN
cord-354168-omen8vvq	196	5	drug	drug	NN
cord-354168-omen8vvq	196	6	administration	administration	NN
cord-354168-omen8vvq	196	7	can	can	MD
cord-354168-omen8vvq	196	8	be	be	VB
cord-354168-omen8vvq	196	9	modified	modify	VBN
cord-354168-omen8vvq	196	10	,	,	,
cord-354168-omen8vvq	196	11	especially	especially	RB
cord-354168-omen8vvq	196	12	in	in	IN
cord-354168-omen8vvq	196	13	patients	patient	NNS
cord-354168-omen8vvq	196	14	with	with	IN
cord-354168-omen8vvq	196	15	≥VGPR	≥VGPR	NNS
cord-354168-omen8vvq	196	16	that	that	WDT
cord-354168-omen8vvq	196	17	is	be	VBZ
cord-354168-omen8vvq	196	18	sustained	sustain	VBN
cord-354168-omen8vvq	196	19	.	.	.
cord-354168-omen8vvq	197	1	After	after	IN
cord-354168-omen8vvq	197	2	10	10	CD
cord-354168-omen8vvq	197	3	-	-	SYM
cord-354168-omen8vvq	197	4	12	12	CD
cord-354168-omen8vvq	197	5	cycles	cycle	NNS
cord-354168-omen8vvq	197	6	,	,	,
cord-354168-omen8vvq	197	7	maintenance	maintenance	NN
cord-354168-omen8vvq	197	8	can	can	MD
cord-354168-omen8vvq	197	9	be	be	VB
cord-354168-omen8vvq	197	10	started	start	VBN
cord-354168-omen8vvq	197	11	with	with	IN
cord-354168-omen8vvq	197	12	lenalidomide	lenalidomide	NN
cord-354168-omen8vvq	197	13	for	for	IN
cord-354168-omen8vvq	197	14	standard	standard	JJ
cord-354168-omen8vvq	197	15	-	-	HYPH
cord-354168-omen8vvq	197	16	risk	risk	NN
cord-354168-omen8vvq	197	17	patients	patient	NNS
cord-354168-omen8vvq	197	18	and	and	CC
cord-354168-omen8vvq	197	19	bortezomib	bortezomib	NNP
cord-354168-omen8vvq	197	20	or	or	CC
cord-354168-omen8vvq	197	21	ixazomib	ixazomib	JJ
cord-354168-omen8vvq	197	22	for	for	IN
cord-354168-omen8vvq	197	23	high	high	JJ
cord-354168-omen8vvq	197	24	-	-	HYPH
cord-354168-omen8vvq	197	25	risk	risk	NN
cord-354168-omen8vvq	197	26	patients	patient	NNS
cord-354168-omen8vvq	197	27	.	.	.
cord-354168-omen8vvq	198	1	For	for	IN
cord-354168-omen8vvq	198	2	relapsed	relapsed	JJ
cord-354168-omen8vvq	198	3	patients	patient	NNS
cord-354168-omen8vvq	198	4	,	,	,
cord-354168-omen8vvq	198	5	daratumumab	daratumumab	VBN
cord-354168-omen8vvq	198	6	-	-	HYPH
cord-354168-omen8vvq	198	7	based	base	VBN
cord-354168-omen8vvq	198	8	regimens	regimen	NNS
cord-354168-omen8vvq	198	9	should	should	MD
cord-354168-omen8vvq	198	10	be	be	VB
cord-354168-omen8vvq	198	11	considered	consider	VBN
cord-354168-omen8vvq	198	12	.	.	.
cord-354168-omen8vvq	199	1	We	-PRON-	PRP
cord-354168-omen8vvq	199	2	would	would	MD
cord-354168-omen8vvq	199	3	recommend	recommend	VB
cord-354168-omen8vvq	199	4	ASCT	ASCT	NNP
cord-354168-omen8vvq	199	5	for	for	IN
cord-354168-omen8vvq	199	6	patients	patient	NNS
cord-354168-omen8vvq	199	7	with	with	IN
cord-354168-omen8vvq	199	8	aggressive	aggressive	JJ
cord-354168-omen8vvq	199	9	relapse	relapse	NN
cord-354168-omen8vvq	199	10	,	,	,
cord-354168-omen8vvq	199	11	as	as	RB
cord-354168-omen8vvq	199	12	well	well	RB
cord-354168-omen8vvq	199	13	for	for	IN
cord-354168-omen8vvq	199	14	patients	patient	NNS
cord-354168-omen8vvq	199	15	with	with	IN
cord-354168-omen8vvq	199	16	secondary	secondary	JJ
cord-354168-omen8vvq	199	17	PCL	PCL	NNP
cord-354168-omen8vvq	199	18	.	.	.
cord-354168-omen8vvq	200	1	Patients	patient	NNS
cord-354168-omen8vvq	200	2	on	on	IN
cord-354168-omen8vvq	200	3	maintenance	maintenance	NN
cord-354168-omen8vvq	200	4	should	should	MD
cord-354168-omen8vvq	200	5	continue	continue	VB
cord-354168-omen8vvq	200	6	their	-PRON-	PRP$
cord-354168-omen8vvq	200	7	therapy	therapy	NN
cord-354168-omen8vvq	200	8	.	.	.
cord-354168-omen8vvq	201	1	In	in	IN
cord-354168-omen8vvq	201	2	many	many	JJ
cord-354168-omen8vvq	201	3	centers	center	NNS
cord-354168-omen8vvq	201	4	clinical	clinical	JJ
cord-354168-omen8vvq	201	5	trials	trial	NNS
cord-354168-omen8vvq	201	6	have	have	VBP
cord-354168-omen8vvq	201	7	been	be	VBN
cord-354168-omen8vvq	201	8	suspended	suspend	VBN
cord-354168-omen8vvq	201	9	as	as	IN
cord-354168-omen8vvq	201	10	a	a	DT
cord-354168-omen8vvq	201	11	result	result	NN
cord-354168-omen8vvq	201	12	of	of	IN
cord-354168-omen8vvq	201	13	the	the	DT
cord-354168-omen8vvq	201	14	current	current	JJ
cord-354168-omen8vvq	201	15	pandemic	pandemic	NN
cord-354168-omen8vvq	201	16	with	with	IN
cord-354168-omen8vvq	201	17	COVID-19	COVID-19	NNP
cord-354168-omen8vvq	201	18	.	.	.
cord-354168-omen8vvq	202	1	World	World	NNP
cord-354168-omen8vvq	202	2	Health	Health	NNP
cord-354168-omen8vvq	202	3	Organization	Organization	NNP
cord-354168-omen8vvq	202	4	Coronavirus	Coronavirus	NNP
cord-354168-omen8vvq	202	5	disease	disease	NN
cord-354168-omen8vvq	203	1	(	(	-LRB-
cord-354168-omen8vvq	203	2	COVID-2019	COVID-2019	NNP
cord-354168-omen8vvq	203	3	)	)	-RRB-
cord-354168-omen8vvq	203	4	situation	situation	NN
cord-354168-omen8vvq	203	5	reports	report	VBZ
cord-354168-omen8vvq	203	6	How	how	WRB
cord-354168-omen8vvq	203	7	COVID-19	COVID-19	NNP
cord-354168-omen8vvq	203	8	Outbreak	Outbreak	NNP
cord-354168-omen8vvq	203	9	is	be	VBZ
cord-354168-omen8vvq	203	10	impacting	impact	VBG
cord-354168-omen8vvq	203	11	colorectal	colorectal	JJ
cord-354168-omen8vvq	203	12	cancer	cancer	NN
cord-354168-omen8vvq	203	13	patients	patient	NNS
cord-354168-omen8vvq	203	14	in	in	IN
cord-354168-omen8vvq	203	15	Italy	Italy	NNP
cord-354168-omen8vvq	203	16	:	:	:
cord-354168-omen8vvq	203	17	a	a	DT
cord-354168-omen8vvq	203	18	long	long	JJ
cord-354168-omen8vvq	203	19	shadow	shadow	NN
cord-354168-omen8vvq	203	20	beyond	beyond	IN
cord-354168-omen8vvq	203	21	infection	infection	NN
cord-354168-omen8vvq	203	22	.	.	.
cord-354168-omen8vvq	204	1	Dis	Dis	NNP
cord-354168-omen8vvq	204	2	Colon	colon	NN
cord-354168-omen8vvq	204	3	Rectum	rectum	NN
cord-354168-omen8vvq	204	4	.	.	.
cord-354168-omen8vvq	205	1	2020	2020	CD
cord-354168-omen8vvq	205	2	Mar	Mar	NNP
cord-354168-omen8vvq	205	3	;	;	:
cord-354168-omen8vvq	205	4	1	1	CD
cord-354168-omen8vvq	205	5	.	.	.
cord-354168-omen8vvq	206	1	Epub	Epub	NNP
cord-354168-omen8vvq	206	2	ahead	ahead	RB
cord-354168-omen8vvq	206	3	of	of	IN
cord-354168-omen8vvq	206	4	print	print	NN
cord-354168-omen8vvq	206	5	Individualized	individualized	JJ
cord-354168-omen8vvq	206	6	treatment	treatment	NN
cord-354168-omen8vvq	206	7	recommendations	recommendation	NNS
cord-354168-omen8vvq	206	8	for	for	IN
cord-354168-omen8vvq	206	9	lung	lung	NN
cord-354168-omen8vvq	206	10	cancer	cancer	NN
cord-354168-omen8vvq	206	11	patients	patient	NNS
cord-354168-omen8vvq	206	12	at	at	IN
cord-354168-omen8vvq	206	13	different	different	JJ
cord-354168-omen8vvq	206	14	stages	stage	NNS
cord-354168-omen8vvq	206	15	of	of	IN
cord-354168-omen8vvq	206	16	treatment	treatment	NN
cord-354168-omen8vvq	206	17	during	during	IN
cord-354168-omen8vvq	206	18	the	the	DT
cord-354168-omen8vvq	206	19	outbreak	outbreak	NN
cord-354168-omen8vvq	206	20	of	of	IN
cord-354168-omen8vvq	206	21	Cancer	Cancer	NNP
cord-354168-omen8vvq	206	22	patients	patient	NNS
cord-354168-omen8vvq	206	23	in	in	IN
cord-354168-omen8vvq	206	24	SARS	SARS	NNP
cord-354168-omen8vvq	206	25	-	-	HYPH
cord-354168-omen8vvq	206	26	CoV-2	CoV-2	NNP
cord-354168-omen8vvq	206	27	infection	infection	NN
cord-354168-omen8vvq	206	28	:	:	:
cord-354168-omen8vvq	206	29	a	a	DT
cord-354168-omen8vvq	206	30	nationwide	nationwide	JJ
cord-354168-omen8vvq	206	31	analysis	analysis	NN
cord-354168-omen8vvq	206	32	in	in	IN
cord-354168-omen8vvq	206	33	China	China	NNP
cord-354168-omen8vvq	206	34	.	.	.
cord-354168-omen8vvq	207	1	Lancet	Lancet	NNP
cord-354168-omen8vvq	207	2	Oncol	Oncol	NNP
cord-354168-omen8vvq	207	3	Multiple	multiple	JJ
cord-354168-omen8vvq	207	4	myeloma	myeloma	NN
cord-354168-omen8vvq	207	5	and	and	CC
cord-354168-omen8vvq	207	6	infections	infection	NNS
cord-354168-omen8vvq	207	7	:	:	:
cord-354168-omen8vvq	207	8	a	a	DT
cord-354168-omen8vvq	207	9	population	population	NN
cord-354168-omen8vvq	207	10	-	-	HYPH
cord-354168-omen8vvq	207	11	based	base	VBN
cord-354168-omen8vvq	207	12	study	study	NN
cord-354168-omen8vvq	207	13	on	on	IN
cord-354168-omen8vvq	207	14	9253	9253	CD
cord-354168-omen8vvq	207	15	multiple	multiple	JJ
cord-354168-omen8vvq	207	16	myeloma	myeloma	NN
cord-354168-omen8vvq	207	17	patients	patient	NNS
cord-354168-omen8vvq	207	18	Nadir	Nadir	NNP
cord-354168-omen8vvq	207	19	lymphocytopenia	lymphocytopenia	NNP
cord-354168-omen8vvq	207	20	as	as	IN
cord-354168-omen8vvq	207	21	a	a	DT
cord-354168-omen8vvq	207	22	risk	risk	NN
cord-354168-omen8vvq	207	23	factor	factor	NN
cord-354168-omen8vvq	207	24	of	of	IN
cord-354168-omen8vvq	207	25	bloodstream	bloodstream	NN
cord-354168-omen8vvq	207	26	infection	infection	NN
cord-354168-omen8vvq	207	27	during	during	IN
cord-354168-omen8vvq	207	28	molecular	molecular	JJ
cord-354168-omen8vvq	207	29	targeting	target	VBG
cord-354168-omen8vvq	207	30	pharmacotherapy	pharmacotherapy	NN
cord-354168-omen8vvq	207	31	in	in	IN
cord-354168-omen8vvq	207	32	multiple	multiple	JJ
cord-354168-omen8vvq	207	33	myeloma	myeloma	NN
cord-354168-omen8vvq	207	34	Pretreatment	Pretreatment	NNP
cord-354168-omen8vvq	207	35	lymphopenia	lymphopenia	NNP
cord-354168-omen8vvq	207	36	,	,	,
cord-354168-omen8vvq	207	37	poor	poor	JJ
cord-354168-omen8vvq	207	38	performance	performance	NN
cord-354168-omen8vvq	207	39	status	status	NN
cord-354168-omen8vvq	207	40	,	,	,
cord-354168-omen8vvq	207	41	and	and	CC
cord-354168-omen8vvq	207	42	early	early	JJ
cord-354168-omen8vvq	207	43	courses	course	NNS
cord-354168-omen8vvq	207	44	of	of	IN
cord-354168-omen8vvq	207	45	therapy	therapy	NN
cord-354168-omen8vvq	207	46	are	be	VBP
cord-354168-omen8vvq	207	47	risk	risk	NN
cord-354168-omen8vvq	207	48	factors	factor	NNS
cord-354168-omen8vvq	207	49	for	for	IN
cord-354168-omen8vvq	207	50	severe	severe	JJ
cord-354168-omen8vvq	207	51	bacterial	bacterial	JJ
cord-354168-omen8vvq	207	52	infection	infection	NN
cord-354168-omen8vvq	207	53	in	in	IN
cord-354168-omen8vvq	207	54	patients	patient	NNS
cord-354168-omen8vvq	207	55	with	with	IN
cord-354168-omen8vvq	207	56	multiple	multiple	JJ
cord-354168-omen8vvq	207	57	myeloma	myeloma	NN
cord-354168-omen8vvq	207	58	during	during	IN
cord-354168-omen8vvq	207	59	treatment	treatment	NN
cord-354168-omen8vvq	207	60	with	with	IN
cord-354168-omen8vvq	207	61	bortezomib	bortezomib	NNP
cord-354168-omen8vvq	207	62	-	-	HYPH
cord-354168-omen8vvq	207	63	based	base	VBN
cord-354168-omen8vvq	207	64	regimens	regimen	NNS
cord-354168-omen8vvq	208	1	Lymphocytopenia	Lymphocytopenia	NNP
cord-354168-omen8vvq	208	2	is	be	VBZ
cord-354168-omen8vvq	208	3	associated	associate	VBN
cord-354168-omen8vvq	208	4	with	with	IN
cord-354168-omen8vvq	208	5	an	an	DT
cord-354168-omen8vvq	208	6	increased	increase	VBN
cord-354168-omen8vvq	208	7	risk	risk	NN
cord-354168-omen8vvq	208	8	of	of	IN
cord-354168-omen8vvq	208	9	severe	severe	JJ
cord-354168-omen8vvq	208	10	infections	infection	NNS
cord-354168-omen8vvq	208	11	in	in	IN
cord-354168-omen8vvq	208	12	patients	patient	NNS
cord-354168-omen8vvq	208	13	with	with	IN
cord-354168-omen8vvq	208	14	multiple	multiple	JJ
cord-354168-omen8vvq	208	15	myeloma	myeloma	NN
cord-354168-omen8vvq	208	16	treated	treat	VBN
cord-354168-omen8vvq	208	17	with	with	IN
cord-354168-omen8vvq	208	18	bortezomib	bortezomib	NNP
cord-354168-omen8vvq	208	19	-	-	HYPH
cord-354168-omen8vvq	208	20	based	base	VBN
cord-354168-omen8vvq	208	21	regimens	regimen	NNS
cord-354168-omen8vvq	208	22	Immune	immune	JJ
cord-354168-omen8vvq	208	23	parameters	parameter	NNS
cord-354168-omen8vvq	208	24	in	in	IN
cord-354168-omen8vvq	208	25	multiple	multiple	JJ
cord-354168-omen8vvq	208	26	myeloma	myeloma	NN
cord-354168-omen8vvq	208	27	patients	patient	NNS
cord-354168-omen8vvq	208	28	:	:	:
cord-354168-omen8vvq	208	29	influence	influence	NN
cord-354168-omen8vvq	208	30	of	of	IN
cord-354168-omen8vvq	208	31	treatment	treatment	NN
cord-354168-omen8vvq	208	32	and	and	CC
cord-354168-omen8vvq	208	33	correlation	correlation	NN
cord-354168-omen8vvq	208	34	with	with	IN
cord-354168-omen8vvq	208	35	opportunistic	opportunistic	JJ
cord-354168-omen8vvq	208	36	infections	infection	NNS
cord-354168-omen8vvq	208	37	Low	low	JJ
cord-354168-omen8vvq	208	38	frequency	frequency	NN
cord-354168-omen8vvq	208	39	of	of	IN
cord-354168-omen8vvq	208	40	CD3+CD4+CD161	CD3+CD4+CD161	NNP
cord-354168-omen8vvq	209	1	+	+	CC
cord-354168-omen8vvq	209	2	T	t	NN
cord-354168-omen8vvq	209	3	cells	cell	NNS
cord-354168-omen8vvq	209	4	correlates	correlate	VBZ
cord-354168-omen8vvq	209	5	with	with	IN
cord-354168-omen8vvq	209	6	the	the	DT
cord-354168-omen8vvq	209	7	occurrence	occurrence	NN
cord-354168-omen8vvq	209	8	of	of	IN
cord-354168-omen8vvq	209	9	infections	infection	NNS
cord-354168-omen8vvq	209	10	in	in	IN
cord-354168-omen8vvq	209	11	refractory	refractory	JJ
cord-354168-omen8vvq	209	12	/	/	SYM
cord-354168-omen8vvq	209	13	relapsed	relapse	VBD
cord-354168-omen8vvq	209	14	multiple	multiple	JJ
cord-354168-omen8vvq	209	15	myeloma	myeloma	NN
cord-354168-omen8vvq	209	16	patients	patient	NNS
cord-354168-omen8vvq	209	17	receiving	receive	VBG
cord-354168-omen8vvq	209	18	lenalidomide	lenalidomide	JJ
cord-354168-omen8vvq	209	19	plus	plus	CC
cord-354168-omen8vvq	209	20	low	low	JJ
cord-354168-omen8vvq	209	21	-	-	HYPH
cord-354168-omen8vvq	209	22	dose	dose	NN
cord-354168-omen8vvq	209	23	dexamethasone	dexamethasone	NN
cord-354168-omen8vvq	209	24	treatment	treatment	NN
cord-354168-omen8vvq	209	25	Infection	Infection	NNP
cord-354168-omen8vvq	209	26	risk	risk	NN
cord-354168-omen8vvq	209	27	with	with	IN
cord-354168-omen8vvq	209	28	immunomodulatory	immunomodulatory	NNP
cord-354168-omen8vvq	209	29	and	and	CC
cord-354168-omen8vvq	209	30	proteasome	proteasome	JJ
cord-354168-omen8vvq	209	31	inhibitor	inhibitor	NN
cord-354168-omen8vvq	209	32	-	-	HYPH
cord-354168-omen8vvq	209	33	based	base	VBN
cord-354168-omen8vvq	209	34	therapies	therapy	NNS
cord-354168-omen8vvq	209	35	across	across	IN
cord-354168-omen8vvq	209	36	treatment	treatment	NN
cord-354168-omen8vvq	209	37	phases	phase	NNS
cord-354168-omen8vvq	209	38	for	for	IN
cord-354168-omen8vvq	209	39	multiple	multiple	JJ
cord-354168-omen8vvq	209	40	myeloma	myeloma	NN
cord-354168-omen8vvq	209	41	:	:	:
cord-354168-omen8vvq	209	42	a	a	DT
cord-354168-omen8vvq	209	43	systematic	systematic	JJ
cord-354168-omen8vvq	209	44	review	review	NN
cord-354168-omen8vvq	209	45	and	and	CC
cord-354168-omen8vvq	209	46	meta	meta	NNP
cord-354168-omen8vvq	209	47	-	-	HYPH
cord-354168-omen8vvq	209	48	analysis	analysis	NN
cord-354168-omen8vvq	209	49	Decrease	decrease	NN
cord-354168-omen8vvq	209	50	in	in	IN
cord-354168-omen8vvq	209	51	CD4	CD4	NNP
cord-354168-omen8vvq	209	52	+	+	CC
cord-354168-omen8vvq	209	53	T	t	NN
cord-354168-omen8vvq	209	54	-	-	HYPH
cord-354168-omen8vvq	209	55	cell	cell	NN
cord-354168-omen8vvq	209	56	counts	count	NNS
cord-354168-omen8vvq	209	57	in	in	IN
cord-354168-omen8vvq	209	58	patients	patient	NNS
cord-354168-omen8vvq	209	59	with	with	IN
cord-354168-omen8vvq	209	60	multiple	multiple	JJ
cord-354168-omen8vvq	209	61	myeloma	myeloma	NN
cord-354168-omen8vvq	209	62	treated	treat	VBN
cord-354168-omen8vvq	209	63	with	with	IN
cord-354168-omen8vvq	209	64	bortezomib	bortezomib	NNP
cord-354168-omen8vvq	209	65	Analysis	Analysis	NNP
cord-354168-omen8vvq	209	66	of	of	IN
cord-354168-omen8vvq	209	67	herpes	herpes	NNP
cord-354168-omen8vvq	209	68	zoster	zoster	NN
cord-354168-omen8vvq	209	69	events	event	NNS
cord-354168-omen8vvq	209	70	among	among	IN
cord-354168-omen8vvq	209	71	bortezomib	bortezomib	NNP
cord-354168-omen8vvq	209	72	-	-	HYPH
cord-354168-omen8vvq	209	73	treated	treat	VBN
cord-354168-omen8vvq	209	74	patients	patient	NNS
cord-354168-omen8vvq	209	75	in	in	IN
cord-354168-omen8vvq	209	76	the	the	DT
cord-354168-omen8vvq	209	77	phase	phase	NN
cord-354168-omen8vvq	209	78	III	iii	CD
cord-354168-omen8vvq	209	79	APEX	APEX	NNP
cord-354168-omen8vvq	209	80	study	study	NN
cord-354168-omen8vvq	209	81	Levofloxacin	Levofloxacin	NNP
cord-354168-omen8vvq	209	82	prophylaxis	prophylaxis	NN
cord-354168-omen8vvq	209	83	in	in	IN
cord-354168-omen8vvq	209	84	patients	patient	NNS
cord-354168-omen8vvq	209	85	with	with	IN
cord-354168-omen8vvq	209	86	newly	newly	RB
cord-354168-omen8vvq	209	87	diagnosed	diagnose	VBN
cord-354168-omen8vvq	209	88	myeloma	myeloma	NN
cord-354168-omen8vvq	209	89	(	(	-LRB-
cord-354168-omen8vvq	209	90	TEAMM	TEAMM	NNP
cord-354168-omen8vvq	209	91	)	)	-RRB-
cord-354168-omen8vvq	209	92	:	:	:
cord-354168-omen8vvq	209	93	a	a	DT
cord-354168-omen8vvq	209	94	multicentre	multicentre	NN
cord-354168-omen8vvq	209	95	,	,	,
cord-354168-omen8vvq	209	96	double	double	JJ
cord-354168-omen8vvq	209	97	-	-	HYPH
cord-354168-omen8vvq	209	98	blind	blind	JJ
cord-354168-omen8vvq	209	99	,	,	,
cord-354168-omen8vvq	209	100	placebo	placebo	NN
cord-354168-omen8vvq	209	101	-	-	HYPH
cord-354168-omen8vvq	209	102	controlled	control	VBN
cord-354168-omen8vvq	209	103	,	,	,
cord-354168-omen8vvq	209	104	randomised	randomised	JJ
cord-354168-omen8vvq	209	105	,	,	,
cord-354168-omen8vvq	209	106	phase	phase	NN
cord-354168-omen8vvq	209	107	3	3	CD
cord-354168-omen8vvq	209	108	trial	trial	NN
cord-354168-omen8vvq	209	109	Clinical	clinical	JJ
cord-354168-omen8vvq	209	110	features	feature	NNS
cord-354168-omen8vvq	209	111	of	of	IN
cord-354168-omen8vvq	209	112	patients	patient	NNS
cord-354168-omen8vvq	209	113	infected	infect	VBN
cord-354168-omen8vvq	209	114	with	with	IN
cord-354168-omen8vvq	209	115	2019	2019	CD
cord-354168-omen8vvq	209	116	novel	novel	JJ
cord-354168-omen8vvq	209	117	coronavirus	coronavirus	NN
cord-354168-omen8vvq	209	118	in	in	IN
cord-354168-omen8vvq	209	119	Wuhan	Wuhan	NNP
cord-354168-omen8vvq	209	120	Risk	Risk	NNP
cord-354168-omen8vvq	209	121	stratification	stratification	NN
cord-354168-omen8vvq	209	122	of	of	IN
cord-354168-omen8vvq	209	123	smoldering	smolder	VBG
cord-354168-omen8vvq	209	124	multiple	multiple	JJ
cord-354168-omen8vvq	209	125	myeloma	myeloma	NN
cord-354168-omen8vvq	209	126	incorporating	incorporate	VBG
cord-354168-omen8vvq	209	127	revised	revise	VBN
cord-354168-omen8vvq	209	128	IMWG	IMWG	NNP
cord-354168-omen8vvq	209	129	diagnostic	diagnostic	JJ
cord-354168-omen8vvq	209	130	criteria	criterion	NNS
cord-354168-omen8vvq	209	131	Lenalidomide	Lenalidomide	NNP
cord-354168-omen8vvq	209	132	plus	plus	CC
cord-354168-omen8vvq	209	133	dexamethasone	dexamethasone	NN
cord-354168-omen8vvq	209	134	for	for	IN
cord-354168-omen8vvq	209	135	high	high	JJ
cord-354168-omen8vvq	209	136	-	-	HYPH
cord-354168-omen8vvq	209	137	risk	risk	NN
cord-354168-omen8vvq	209	138	smoldering	smolder	VBG
cord-354168-omen8vvq	209	139	multiple	multiple	JJ
cord-354168-omen8vvq	209	140	myeloma	myeloma	NN
cord-354168-omen8vvq	210	1	Randomized	randomized	JJ
cord-354168-omen8vvq	210	2	trial	trial	NN
cord-354168-omen8vvq	210	3	of	of	IN
cord-354168-omen8vvq	210	4	lenalidomide	lenalidomide	NN
cord-354168-omen8vvq	210	5	versus	versus	IN
cord-354168-omen8vvq	210	6	observation	observation	NN
cord-354168-omen8vvq	210	7	in	in	IN
cord-354168-omen8vvq	210	8	smoldering	smolder	VBG
cord-354168-omen8vvq	210	9	multiple	multiple	JJ
cord-354168-omen8vvq	210	10	myeloma	myeloma	NN
cord-354168-omen8vvq	210	11	Revised	revise	VBN
cord-354168-omen8vvq	210	12	international	international	JJ
cord-354168-omen8vvq	210	13	staging	staging	NN
cord-354168-omen8vvq	210	14	system	system	NN
cord-354168-omen8vvq	210	15	for	for	IN
cord-354168-omen8vvq	210	16	multiple	multiple	JJ
cord-354168-omen8vvq	210	17	myeloma	myeloma	NN
cord-354168-omen8vvq	210	18	:	:	:
cord-354168-omen8vvq	210	19	a	a	DT
cord-354168-omen8vvq	210	20	report	report	NN
cord-354168-omen8vvq	210	21	from	from	IN
cord-354168-omen8vvq	210	22	International	International	NNP
cord-354168-omen8vvq	210	23	Myeloma	Myeloma	NNP
cord-354168-omen8vvq	210	24	Working	Working	NNP
cord-354168-omen8vvq	210	25	Group	Group	NNP
cord-354168-omen8vvq	210	26	get-your-household-ready-for-COVID-19.html?CDC_AA	get-your-household-ready-for-COVID-19.html?CDC_AA	NNP
cord-354168-omen8vvq	210	27	_	_	NNP
cord-354168-omen8vvq	210	28	r	r	NN
cord-354168-omen8vvq	210	29	e	e	NN
cord-354168-omen8vvq	210	30	f	f	NN
cord-354168-omen8vvq	210	31	V	V	NNP
cord-354168-omen8vvq	210	32	a	a	DT
cord-354168-omen8vvq	211	1	l	l	NN
cord-354168-omen8vvq	211	2	=	=	SYM
cord-354168-omen8vvq	211	3	h	h	NN
cord-354168-omen8vvq	211	4	t	t	NN
cord-354168-omen8vvq	211	5	t	t	NN
cord-354168-omen8vvq	211	6	p	p	NN
cord-354168-omen8vvq	211	7	s	s	NN
cord-354168-omen8vvq	211	8	%	%	NN
cord-354168-omen8vvq	211	9	3	3	CD
cord-354168-omen8vvq	211	10	A	a	DT
cord-354168-omen8vvq	211	11	%	%	NN
cord-354168-omen8vvq	211	12	2	2	CD
cord-354168-omen8vvq	211	13	F	f	NN
cord-354168-omen8vvq	211	14	%	%	NN
cord-354168-omen8vvq	211	15	2	2	CD
cord-354168-omen8vvq	211	16	F	F	NNP
cord-354168-omen8vvq	211	17	w	w	NNP
cord-354168-omen8vvq	211	18	w	w	NNP
cord-354168-omen8vvq	211	19	w	w	NNP
cord-354168-omen8vvq	211	20	Suicide	Suicide	NNP
cord-354168-omen8vvq	211	21	Prevention	Prevention	NNP
cord-354168-omen8vvq	211	22	Lifeline	Lifeline	NNP
cord-354168-omen8vvq	211	23	Emotional	emotional	JJ
cord-354168-omen8vvq	211	24	wellbeing	wellbeing	NN
cord-354168-omen8vvq	211	25	during	during	IN
cord-354168-omen8vvq	211	26	the	the	DT
cord-354168-omen8vvq	211	27	COVID-19	covid-19	JJ
cord-354168-omen8vvq	211	28	outbreak	outbreak	NN
cord-354168-omen8vvq	211	29	lenalidomide	lenalidomide	NN
cord-354168-omen8vvq	211	30	,	,	,
cord-354168-omen8vvq	211	31	and	and	CC
cord-354168-omen8vvq	211	32	dexamethasone	dexamethasone	NN
cord-354168-omen8vvq	211	33	in	in	IN
cord-354168-omen8vvq	211	34	patients	patient	NNS
cord-354168-omen8vvq	211	35	with	with	IN
cord-354168-omen8vvq	211	36	newly	newly	RB
cord-354168-omen8vvq	211	37	diagnosed	diagnose	VBN
cord-354168-omen8vvq	211	38	multiple	multiple	JJ
cord-354168-omen8vvq	211	39	myeloma	myeloma	NN
cord-354168-omen8vvq	211	40	:	:	:
cord-354168-omen8vvq	211	41	long	long	JJ
cord-354168-omen8vvq	211	42	-	-	HYPH
cord-354168-omen8vvq	211	43	term	term	NN
cord-354168-omen8vvq	211	44	follow	follow	NN
cord-354168-omen8vvq	211	45	-	-	HYPH
cord-354168-omen8vvq	211	46	up	up	NN
cord-354168-omen8vvq	211	47	including	include	VBG
cord-354168-omen8vvq	211	48	ixazomib	ixazomib	JJ
cord-354168-omen8vvq	211	49	maintenance	maintenance	NN
cord-354168-omen8vvq	211	50	cyclophosphamide	cyclophosphamide	RB
cord-354168-omen8vvq	211	51	and	and	CC
cord-354168-omen8vvq	211	52	dexamethasone	dexamethasone	NN
cord-354168-omen8vvq	211	53	(	(	-LRB-
cord-354168-omen8vvq	211	54	CRd	CRd	NNP
cord-354168-omen8vvq	211	55	)	)	-RRB-
cord-354168-omen8vvq	211	56	for	for	IN
cord-354168-omen8vvq	211	57	newly	newly	RB
cord-354168-omen8vvq	211	58	diagnosed	diagnose	VBN
cord-354168-omen8vvq	211	59	multiple	multiple	JJ
cord-354168-omen8vvq	211	60	myeloma	myeloma	NN
cord-354168-omen8vvq	211	61	:	:	:
cord-354168-omen8vvq	211	62	results	result	NNS
cord-354168-omen8vvq	211	63	from	from	IN
cord-354168-omen8vvq	211	64	a	a	DT
cord-354168-omen8vvq	211	65	phase	phase	NN
cord-354168-omen8vvq	211	66	2	2	CD
cord-354168-omen8vvq	211	67	trial	trial	NN
cord-354168-omen8vvq	211	68	MAIA	MAIA	NNP
cord-354168-omen8vvq	211	69	Trial	Trial	NNP
cord-354168-omen8vvq	211	70	Investigators	Investigators	NNPS
cord-354168-omen8vvq	211	71	.	.	.
cord-354168-omen8vvq	212	1	Daratumumab	Daratumumab	NNP
cord-354168-omen8vvq	212	2	plus	plus	CC
cord-354168-omen8vvq	212	3	lenalidomide	lenalidomide	NN
cord-354168-omen8vvq	212	4	and	and	CC
cord-354168-omen8vvq	212	5	dexamethasone	dexamethasone	NN
cord-354168-omen8vvq	212	6	for	for	IN
cord-354168-omen8vvq	212	7	untreated	untreated	JJ
cord-354168-omen8vvq	212	8	myeloma	myeloma	NN
cord-354168-omen8vvq	212	9	High	high	JJ
cord-354168-omen8vvq	212	10	-	-	HYPH
cord-354168-omen8vvq	212	11	dose	dose	NN
cord-354168-omen8vvq	212	12	therapy	therapy	NN
cord-354168-omen8vvq	212	13	and	and	CC
cord-354168-omen8vvq	212	14	autologous	autologous	JJ
cord-354168-omen8vvq	212	15	peripheral	peripheral	JJ
cord-354168-omen8vvq	212	16	blood	blood	NN
cord-354168-omen8vvq	212	17	stem	stem	NN
cord-354168-omen8vvq	212	18	cell	cell	NN
cord-354168-omen8vvq	212	19	transplantation	transplantation	NN
cord-354168-omen8vvq	212	20	in	in	IN
cord-354168-omen8vvq	212	21	multiple	multiple	JJ
cord-354168-omen8vvq	212	22	myeloma	myeloma	NN
cord-354168-omen8vvq	212	23	:	:	:
cord-354168-omen8vvq	212	24	upfront	upfront	NN
cord-354168-omen8vvq	212	25	or	or	CC
cord-354168-omen8vvq	212	26	rescue	rescue	NN
cord-354168-omen8vvq	212	27	treatment	treatment	NN
cord-354168-omen8vvq	212	28	?	?	.
cord-354168-omen8vvq	213	1	Results	result	NNS
cord-354168-omen8vvq	213	2	of	of	IN
cord-354168-omen8vvq	213	3	a	a	DT
cord-354168-omen8vvq	213	4	multicenter	multicenter	JJ
cord-354168-omen8vvq	213	5	sequential	sequential	JJ
cord-354168-omen8vvq	213	6	randomized	randomized	JJ
cord-354168-omen8vvq	213	7	clinical	clinical	JJ
cord-354168-omen8vvq	213	8	trial	trial	NN
cord-354168-omen8vvq	213	9	IFM	IFM	NNP
cord-354168-omen8vvq	213	10	2009	2009	CD
cord-354168-omen8vvq	213	11	Study	Study	NNP
cord-354168-omen8vvq	213	12	.	.	.
cord-354168-omen8vvq	214	1	Lenalidomide	Lenalidomide	NNP
cord-354168-omen8vvq	214	2	,	,	,
cord-354168-omen8vvq	214	3	Bortezomib	Bortezomib	NNP
cord-354168-omen8vvq	214	4	,	,	,
cord-354168-omen8vvq	214	5	and	and	CC
cord-354168-omen8vvq	214	6	Dexamethasone	Dexamethasone	NNP
cord-354168-omen8vvq	214	7	with	with	IN
cord-354168-omen8vvq	214	8	Transplantation	transplantation	NN
cord-354168-omen8vvq	214	9	for	for	IN
cord-354168-omen8vvq	214	10	Myeloma	Myeloma	NNP
cord-354168-omen8vvq	214	11	Early	early	RB
cord-354168-omen8vvq	214	12	versus	versus	IN
cord-354168-omen8vvq	214	13	delayed	delay	VBN
cord-354168-omen8vvq	214	14	autologous	autologous	JJ
cord-354168-omen8vvq	214	15	transplantation	transplantation	NN
cord-354168-omen8vvq	214	16	after	after	IN
cord-354168-omen8vvq	214	17	immunomodulatory	immunomodulatory	JJ
cord-354168-omen8vvq	214	18	agents	agent	NNS
cord-354168-omen8vvq	214	19	-	-	HYPH
cord-354168-omen8vvq	214	20	based	base	VBN
cord-354168-omen8vvq	214	21	induction	induction	NN
cord-354168-omen8vvq	214	22	therapy	therapy	NN
cord-354168-omen8vvq	214	23	in	in	IN
cord-354168-omen8vvq	214	24	patients	patient	NNS
cord-354168-omen8vvq	214	25	with	with	IN
cord-354168-omen8vvq	214	26	newly	newly	RB
cord-354168-omen8vvq	214	27	diagnosed	diagnose	VBN
cord-354168-omen8vvq	214	28	multiple	multiple	JJ
cord-354168-omen8vvq	214	29	myeloma	myeloma	NN
cord-354168-omen8vvq	214	30	Early	early	RB
cord-354168-omen8vvq	214	31	versus	versus	IN
cord-354168-omen8vvq	214	32	delayed	delay	VBN
cord-354168-omen8vvq	214	33	autologous	autologous	JJ
cord-354168-omen8vvq	214	34	stem	stem	NN
cord-354168-omen8vvq	214	35	cell	cell	NN
cord-354168-omen8vvq	214	36	transplantation	transplantation	NN
cord-354168-omen8vvq	214	37	and	and	CC
cord-354168-omen8vvq	214	38	interferon	interferon	NN
cord-354168-omen8vvq	214	39	maintenance	maintenance	NN
cord-354168-omen8vvq	214	40	in	in	IN
cord-354168-omen8vvq	214	41	multiple	multiple	JJ
cord-354168-omen8vvq	214	42	myeloma	myeloma	NN
cord-354168-omen8vvq	214	43	:	:	:
cord-354168-omen8vvq	214	44	single	single	JJ
cord-354168-omen8vvq	214	45	-	-	HYPH
cord-354168-omen8vvq	214	46	center	center	NN
cord-354168-omen8vvq	214	47	experience	experience	NN
cord-354168-omen8vvq	214	48	of	of	IN
cord-354168-omen8vvq	214	49	18	18	CD
cord-354168-omen8vvq	214	50	Years	year	NNS
cord-354168-omen8vvq	215	1	Early	early	RB
cord-354168-omen8vvq	215	2	versus	versus	IN
cord-354168-omen8vvq	215	3	delayed	delay	VBN
cord-354168-omen8vvq	215	4	autologous	autologous	JJ
cord-354168-omen8vvq	215	5	stem	stem	NN
cord-354168-omen8vvq	215	6	cell	cell	NN
cord-354168-omen8vvq	215	7	transplant	transplant	NN
cord-354168-omen8vvq	215	8	in	in	IN
cord-354168-omen8vvq	215	9	patients	patient	NNS
cord-354168-omen8vvq	215	10	receiving	receive	VBG
cord-354168-omen8vvq	215	11	novel	novel	JJ
cord-354168-omen8vvq	215	12	therapies	therapy	NNS
cord-354168-omen8vvq	215	13	for	for	IN
cord-354168-omen8vvq	215	14	multiple	multiple	JJ
cord-354168-omen8vvq	215	15	myeloma	myeloma	NN
cord-354168-omen8vvq	215	16	Impact	impact	NN
cord-354168-omen8vvq	215	17	of	of	IN
cord-354168-omen8vvq	215	18	duration	duration	NN
cord-354168-omen8vvq	215	19	of	of	IN
cord-354168-omen8vvq	215	20	induction	induction	NN
cord-354168-omen8vvq	215	21	therapy	therapy	NN
cord-354168-omen8vvq	215	22	on	on	IN
cord-354168-omen8vvq	215	23	survival	survival	NN
cord-354168-omen8vvq	215	24	in	in	IN
cord-354168-omen8vvq	215	25	newly	newly	RB
cord-354168-omen8vvq	215	26	diagnosed	diagnose	VBN
cord-354168-omen8vvq	215	27	multiple	multiple	JJ
cord-354168-omen8vvq	215	28	myeloma	myeloma	NN
cord-354168-omen8vvq	215	29	patients	patient	NNS
cord-354168-omen8vvq	215	30	undergoing	undergo	VBG
cord-354168-omen8vvq	215	31	upfront	upfront	JJ
cord-354168-omen8vvq	215	32	autologous	autologous	JJ
cord-354168-omen8vvq	215	33	stem	stem	NN
cord-354168-omen8vvq	215	34	cell	cell	NN
cord-354168-omen8vvq	215	35	transplantation	transplantation	NN
cord-354168-omen8vvq	215	36	Revised	revise	VBD
cord-354168-omen8vvq	215	37	diagnostic	diagnostic	JJ
cord-354168-omen8vvq	215	38	criteria	criterion	NNS
cord-354168-omen8vvq	215	39	for	for	IN
cord-354168-omen8vvq	215	40	plasma	plasma	NN
cord-354168-omen8vvq	215	41	cell	cell	NN
cord-354168-omen8vvq	215	42	leukemia	leukemia	NN
cord-354168-omen8vvq	215	43	:	:	:
cord-354168-omen8vvq	216	1	results	result	NNS
cord-354168-omen8vvq	216	2	of	of	IN
cord-354168-omen8vvq	216	3	a	a	DT
cord-354168-omen8vvq	216	4	Mayo	Mayo	NNP
cord-354168-omen8vvq	216	5	Clinic	Clinic	NNP
cord-354168-omen8vvq	216	6	study	study	NN
cord-354168-omen8vvq	216	7	with	with	IN
cord-354168-omen8vvq	216	8	comparison	comparison	NN
cord-354168-omen8vvq	216	9	of	of	IN
cord-354168-omen8vvq	216	10	outcomes	outcome	NNS
cord-354168-omen8vvq	216	11	to	to	IN
cord-354168-omen8vvq	216	12	multiple	multiple	JJ
cord-354168-omen8vvq	216	13	myeloma	myeloma	NN
cord-354168-omen8vvq	216	14	Impact	Impact	NNP
cord-354168-omen8vvq	216	15	of	of	IN
cord-354168-omen8vvq	216	16	lenalidomide	lenalidomide	JJ
cord-354168-omen8vvq	216	17	therapy	therapy	NN
cord-354168-omen8vvq	216	18	on	on	IN
cord-354168-omen8vvq	216	19	stem	stem	NN
cord-354168-omen8vvq	216	20	cell	cell	NN
cord-354168-omen8vvq	216	21	mobilization	mobilization	NN
cord-354168-omen8vvq	216	22	and	and	CC
cord-354168-omen8vvq	216	23	engraftment	engraftment	NN
cord-354168-omen8vvq	216	24	post	post	JJ
cord-354168-omen8vvq	216	25	-	-	JJ
cord-354168-omen8vvq	216	26	peripheral	peripheral	JJ
cord-354168-omen8vvq	216	27	blood	blood	NN
cord-354168-omen8vvq	216	28	stem	stem	NN
cord-354168-omen8vvq	216	29	cell	cell	NN
cord-354168-omen8vvq	216	30	transplantation	transplantation	NN
cord-354168-omen8vvq	216	31	in	in	IN
cord-354168-omen8vvq	216	32	patients	patient	NNS
cord-354168-omen8vvq	216	33	with	with	IN
cord-354168-omen8vvq	216	34	newly	newly	RB
cord-354168-omen8vvq	216	35	diagnosed	diagnose	VBN
cord-354168-omen8vvq	216	36	myeloma	myeloma	NN
cord-354168-omen8vvq	216	37	Advances	advance	NNS
cord-354168-omen8vvq	216	38	in	in	IN
cord-354168-omen8vvq	216	39	the	the	DT
cord-354168-omen8vvq	216	40	research	research	NN
cord-354168-omen8vvq	216	41	of	of	IN
cord-354168-omen8vvq	216	42	cytokine	cytokine	NN
cord-354168-omen8vvq	216	43	storm	storm	NN
cord-354168-omen8vvq	216	44	mechanism	mechanism	NN
cord-354168-omen8vvq	216	45	induced	induce	VBN
cord-354168-omen8vvq	216	46	by	by	IN
cord-354168-omen8vvq	216	47	Corona	Corona	NNP
cord-354168-omen8vvq	216	48	Virus	Virus	NNP
cord-354168-omen8vvq	216	49	Disease	Disease	NNP
cord-354168-omen8vvq	216	50	2019	2019	CD
cord-354168-omen8vvq	216	51	and	and	CC
cord-354168-omen8vvq	216	52	the	the	DT
cord-354168-omen8vvq	216	53	corresponding	correspond	VBG
cord-354168-omen8vvq	216	54	immunotherapies	immunotherapy	NNS
cord-354168-omen8vvq	216	55	]	]	-RRB-
cord-354168-omen8vvq	216	56	.	.	.
cord-354168-omen8vvq	217	1	Zhonghua	Zhonghua	NNP
cord-354168-omen8vvq	217	2	Shao	Shao	NNP
cord-354168-omen8vvq	217	3	Shang	Shang	NNP
cord-354168-omen8vvq	217	4	Za	Za	NNP
cord-354168-omen8vvq	217	5	Zhi	Zhi	NNP
cord-354168-omen8vvq	217	6	Pathological	pathological	JJ
cord-354168-omen8vvq	217	7	findings	finding	NNS
cord-354168-omen8vvq	217	8	of	of	IN
cord-354168-omen8vvq	217	9	CO	co	NN
cord-354168-omen8vvq	217	10	-	-	HYPH
cord-354168-omen8vvq	217	11	VID-19	VID-19	NNP
cord-354168-omen8vvq	217	12	associated	associate	VBN
cord-354168-omen8vvq	217	13	with	with	IN
cord-354168-omen8vvq	217	14	acute	acute	JJ
cord-354168-omen8vvq	217	15	respiratory	respiratory	JJ
cord-354168-omen8vvq	217	16	distress	distress	NN
cord-354168-omen8vvq	217	17	syndrome	syndrome	NN
cord-354168-omen8vvq	217	18	Treatment	Treatment	NNP
cord-354168-omen8vvq	217	19	guidelines	guideline	NNS
cord-354168-omen8vvq	217	20	:	:	:
cord-354168-omen8vvq	217	21	multiple	multiple	JJ
cord-354168-omen8vvq	217	22	myeloma	myeloma	NN
cord-354168-omen8vvq	217	23	Genetic	genetic	JJ
cord-354168-omen8vvq	217	24	aberrations	aberration	NNS
cord-354168-omen8vvq	217	25	and	and	CC
cord-354168-omen8vvq	217	26	survival	survival	NN
cord-354168-omen8vvq	217	27	in	in	IN
cord-354168-omen8vvq	217	28	plasma	plasma	NN
cord-354168-omen8vvq	217	29	cell	cell	NN
cord-354168-omen8vvq	217	30	leukemia	leukemia	NN
cord-354168-omen8vvq	218	1	The	the	DT
cord-354168-omen8vvq	218	2	authors	author	NNS
cord-354168-omen8vvq	218	3	have	have	VBP
cord-354168-omen8vvq	218	4	no	no	DT
cord-354168-omen8vvq	218	5	conflicts	conflict	NNS
cord-354168-omen8vvq	218	6	of	of	IN
cord-354168-omen8vvq	218	7	interest	interest	NN
cord-354168-omen8vvq	218	8	to	to	TO
cord-354168-omen8vvq	218	9	declare	declare	VB
cord-354168-omen8vvq	218	10	related	relate	VBN
cord-354168-omen8vvq	218	11	to	to	IN
cord-354168-omen8vvq	218	12	this	this	DT
cord-354168-omen8vvq	218	13	paper	paper	NN
cord-354168-omen8vvq	218	14	.	.	.
cord-354168-omen8vvq	219	1	A	a	DT
cord-354168-omen8vvq	219	2	 	 	_SP
cord-354168-omen8vvq	220	1	The	the	DT
cord-354168-omen8vvq	220	2	authors	author	NNS
cord-354168-omen8vvq	220	3	have	have	VBP
cord-354168-omen8vvq	220	4	no	no	DT
cord-354168-omen8vvq	220	5	funding	funding	NN
cord-354168-omen8vvq	220	6	sources	source	NNS
cord-354168-omen8vvq	220	7	to	to	TO
cord-354168-omen8vvq	220	8	declare	declare	VB
cord-354168-omen8vvq	220	9	.	.	.
cord-354168-omen8vvq	220	10	 	 	_SP